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Abstract 
Safety of tattoos and permanent make-up (PMU) 
• 12% of Europeans have tattoos 
• Tattoo/PMU ink contains chemicals which stay in the body for life 
• Adverse health effects like infections and allergies are increasingly reported 
• Little is known about the long-term effects of these chemicals 
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Executive summary 
Quick guide Nowadays, tattoos are considered body art and are largely spread. They 
are applied by injecting coloured inks into the dermis and are meant to stay life long, 
thus resulting in long term exposure to the chemicals injected including their 
degradation products. Permanent Make-up (PMU) consists in (semi)permanent tattoos 
used to resemble make-up.  
Policy context This report addresses the issue of the safety of tattoo/PMU products and 
practices with a view to contribute to consumers' health protection. It has been prepared 
on behalf of the Directorate General Justice and Consumers (DG JUST), however it might 
also be of interest to other stakeholders dealing with health, internal market and 
environment, as well as to the European Chemicals Agency (ECHA). The conclusions of 
this project aim to provide the European Commission (EC) with the scientific evidences 
needed to decide if European Union (EU) measures are necessary to ensure the safety of 
tattoo/PMU inks and processes. In fact, apart from the general safety requirements by 
the General Product Safety Directive (GPSD) currently there is no specific EU legislation 
on tattoos/PMU products. In particular with regards to chemical requirements, there are 
chemicals which are banned in consumer products that get into direct contact with the 
skin under different EU legislations, like the Cosmetic Product Regulation or REACH, but 
not in tattoo inks. 
The report presents an updated review of the national legislative framework, ink 
ingredients in use and reported adverse health effects, as well as new data on analytical 
methods, statistics, market surveillance and RAPEX (Rapid alert system for non-food 
dangerous products) notifications, risk perception and communication and experience 
with the implementation of the Council of Europe (CoE) Resolutions (ResAP).  
Main findings Specific legislation, based on the CoE ResAPs (either of 2003 or 2008), 
exists in 7 Member States (MS) and 3 EFTA (European Free Trade Association) countries. 
3 MS notified their draft legal acts (currently on-hold). 
Statistics show that 12% of Europeans and up to 24% of United States' citizens are 
estimated to be tattooed, including teenagers. Tattoo prevalence in young adults may 
represent more than the double and is sometimes higher in women than in men, in 
particular in young generations.  
Tattoo/PMU inks contain several ingredients, plus impurities. More than 100 colorants 
and 100 additives are in use. Most tattoo inks on the EU market are imported from the 
US, while PMU inks are generally manufactured in Europe. The pigments used are not 
specifically produced for tattoo/PMU applications and generally show low purity. The 
majority of them is not authorised for the use in cosmetic products and several should 
not be present according to the CoE ResAP(2008)1. Over 80% of the colorants in use are 
organic and more than 60% of them are azo-pigments, some of which can release 
carcinogenic aromatic amines. This degradation may happen in the skin, particularly 
under solar/Ultra Violet radiation exposure or laser irradiation.  
Harmonised analytical methods for the analysis of tattoo/PMU inks are missing and need 
to be developed. For market surveillance purposes test methods developed for other 
products are used with some modifications. 
Tattoo/PMU products containing hazardous chemicals have been found on the European 
market. Polycyclic Aromatic Hydrocarbons (PAH) (43%), Primary Aromatic Amines (PAA) 
(14%), heavy metals (9%) and preservatives (6%), as well as microbiological 
contamination (11%) were detected in the indicated percentages of the analysed 
samples. 
In the absence of systematic data gathering, the actual prevalence of tattoo 
complications (mainly of dermatological nature) is currently unknown. Most complaints 
are transient and inherent to the wound healing process, but in some cases, up to 5% of 
the tattooed persons, bacterial infections may occur, especially in unhygienic settings. 
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Acute allergy and delayed hypersensitivity prompted by i.e. the inks ingredients and 
tattoo/removal trauma represent the bulk of tattoo/PMU complications, affecting mostly 
the red or black parts of the tattoos. Such nonspecific reactions, frequently exacerbated 
by sun exposure, are unpredictable and may sometimes appear after a long latency 
(decades), giving rise to chronic sequels in connection with underlying auto-immune 
pathologies. Additional adverse health effects, like skin pigmentation disorders may be 
encountered in 5-15% of patients having laser therapy, which is not always effective in 
removing completely the undesired tattoos. (Skin) cancer risk from tattoo procedures 
has been neither proved nor excluded. 
Based on the experience gained from implementing national laws and the CoE ResAPs, 
experts agreed that an update of the chemical and labelling requirements would be 
desirable. 
Risk perception is mainly based on the information given by tattooists, parents or 
friends, or read in mass media and internet. Among students, awareness about 
infectious risks seems to be higher that on non-infectious ones, but that knowledge is 
often only superficial. 
Many data gaps and research needs were identified. 
Key conclusions This report provides an up-to-date snapshot of the tattoo/PMU 
phenomenon. Due to the wide variety of legislative frameworks across Member States, 
some products can be sold in some MSs but not in others, because of different chemical 
or authorisation requirements, thus resulting in a fragmentation of the internal market. 
This might also have an impact on the protection of consumers' health. 
Tattooing is an increasing fashion phenomenon which already involves over 60 million 
Europeans. In parallel, removal procedures are becoming more frequent. Adverse health 
effects linked to the application and removal of tattoos are reported in the literature; in 
addition the potential long term effects of exposure to the chemicals in the inks are still 
unknown and might become critical with time due to the high number of tattooed 
people. To bring light into this unknown area, even if costly, epidemiological studies and 
research on the fate of ingredients in the whole body are needed. In particular, 
prospective cohort studies should be conducted to investigate the correlation between 
tattoos and possible carcinogenesis. 
Good Manufacturing Practices for manufacturing tattoo/PMU inks, as well as guidelines 
for their risk assessment should be developed. A full risk assessment of the ingredients, 
in particular colorants, used in tattoo/PMU inks is needed, including their phototoxicity, 
absorption level, distribution, metabolism and excretion, as well as Derived No Effect 
Level (DNEL), data which are largely missing so far. Further to this, it needs to be 
assessed whether the risks arising from the use of certain chemicals in tattoo/PMU inks 
are adequately controlled or need to be addressed by an EU measure. In the absence of 
this risk assessment, for azo pigments a precautionary approach would consist in not 
using those that contain in their structure aromatic amines classified as Carcinogenic, 
Mutagenic or Reprotoxic (CMR).  
Harmonised analytical methods should be developed to ensure reproducible results and 
allow a correct implementation of the chemical requirements of legislation in place. 
Market surveillance activities should be continued to identify hazardous products and be 
carried out also on products sold on-line.  
Additional information campaigns on risks for potential clients, particular targeted to 
teenagers and young people should be undertaken, allowing an informed choice. The 
training of tattooists should be compulsory and cover at least some key topics. The 
preparation of harmonised hygiene guidelines is highly recommended and inspections of 
studios required. The phenomenon of clandestine backyard tattooing should be stopped. 
Related and future JRC work Three detailed reports on specific part of this project 
were published in 2015 and 2016 [1-3]. 
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1. Introduction 
The growing popularity of tattoos and permanent make-up (PMU) over the last years, 
confirmed also by the large availability of products on-line, has given rise to increasing 
concerns about the safety of tattoo inks, which may entail infectious and non-infectious 
risks, since they might contain hazardous chemical ingredients and/or microbiological 
agents, or be applied under poor hygiene conditions. 
Tattooing is as old as humanity, but has rarely been addressed by regulators in a 
comprehensive and coordinated way. Tattoos are applied by injecting coloured inks into 
the dermis, are meant to stay lifelong. There are different types of tattoos which are 
classified as amateur or professional, according to the practitioner, "home" tattooist, or 
registered and trained professional. Cosmetic tattoos, also known as PMU, are used to 
resemble make-up and, probably due to the different ingredients and to the exposure to 
sunlight, might fade over years. Iatrogenic or medical tattoos are mainly carried out by 
physicians for diagnosis or therapeutic purposes, such as in nipple reconstruction; in 
Italy they can also be carried out by experienced beautician and/or tattooist with 
advanced training [4]. Finally traumatic tattoos may be provoked by accidents and 
explosions, where exogenous elements enter the human skin and colour it in an indelible 
way. 
There is no specific EU legislation on tattoos/PMU products. They fall, together with any 
other. consumer products, under Directive 2001/95/EC on General Product Safety 
(GPSD) [5] requiring that only safe products may be placed on the market. In 2003, the 
Directorate General Health and Consumers (DG SANCO) requested the DG Joint 
Research Centre (JRC) to collect and analyse all available relevant data needed for 
considering common EU initiative on tattoo/PMU inks. The outcome of that study was 
published in 2003 as "Recommendations for European Union (EU) regulatory action on 
the safety of tattoos, body piercing and related practices in the EU" [6]. That report 
pointed out the microbiological risk of tattooing, together with inks' toxic and allergenic 
properties, stressing that the colorants used for tattoo purposes were just the same as 
those utilised by industry for car painting, printing inks, plastics coloration, etc. 
The Council of Europe (CoE) adopted, also in 2003, a non-binding Resolution (ResAP) on 
the safety of tattoos and PMU, recommending inter alia some chemical, labelling and 
hygienic requirements [7]. These criteria were subsequently imbedded by several 
European countries into their domestic legislative framework, banning so the use of 
certain chemicals in tattoos and PMU inks The 2003 Resolution was overhauled in 2008 
[8] by a revised one. 
More than ten years after the first JRC Report, updated information was requested in 
order to take stock of significant modification of the state of play. 
• Candidates for tattoo/PMU applications and removals are ever more numerous, 
especially among the young generation, and products can be increasingly 
purchased online. 
• Some EU/EFTA (European Free Trade Association) countries have taken 
regulatory action in line with the CoE ResAP recommendations of 2003 and 2008. 
• EU itself has enlarged, from 15 Member States in 2003 to 28 in 2014, with a 
corresponding increase in the EU population.  
• New medical data related to health complications from tattoo/PMU application and 
laser removal are available. 
• New information is available on ink ingredients. 
In addition, new aspects, such as analytical methods, statistics, market surveillance 
activities, experience with the CoE ResAPs, risk perception and communication and data 
gaps, needed to be taken into consideration to provide a comprehensive overview of the 
situation. 
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In order to explore the necessity of an EU harmonised approach on tattoos/PMU 
products, DG SANCO set up in June 2014 the Consumer Safety Network Subgroup on 
Tattoos and Permanent Make-up (CSN-STPM) which gathered representatives from 
EU/EFTA national authorities, and other stakeholders, such as the Council of Europe and 
associations of tattooists, ink manufacturers, consumers, dermatologists, etc. 
At the end of September 2014, DG SANCO tasked DG JRC with a new project on 
"Tattoos - Permanent Make-up" aimed to provide regulators with the scientific and 
technical basis needed for deciding whether EU measures are needed to ensure 
tattoo/PMU inks' safety and protect consumers1. 
The present report endeavours to take account of this new state of play, with a focus on 
quantifying the extent of the phenomenon: number and characteristics of nowadays 
tattoo/PMU recipients and removal candidates, incidence of adverse health effects, etc. 
The scope of this work includes the following topics and activities: 
• description of the present regulatory framework in European countries and 
beyond; 
• latest statistics on tattoo prevalence, both for applications and removals, 
influence of age and gender, size, localisation, market; 
• list the chemicals present in inks (ingredients and impurities), as well as the 
analytical methods to detect those mentioned in the CoE Resolutions; 
• to assess the RAPEX (Rapid alert system for non-food dangerous products) 
notifications and market surveillance carried out by EU Competent Authorities; 
• to analyse the experience gained from implementing the CoE Resolutions; 
• to investigate medical complications from tattoos (including henna-based 
temporary tattoos), and from their removal by laser devices; 
• to evaluate the public risk perception and how the risk is communicated by 
authorities; 
• to identify remaining data gaps, and need for further research. 
  
                                           
1 Administrative Arrangement 33617 "Tattoos - Permanent Make-up", signed by DG JRC, Unit I.1 Chemical 
Assessment and Testing, and DG SANCO, Unit B.3 Product and Service Safety, as from 1st January 2015 DG 
Justice and Consumers (JUST), Unit E.3 Product and Service Safety. 
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2. Methodology 
2.1. Work Programme 
The objectives of this 18-month project are to determine the size of the tattoo and PMU 
applications phenomenon; to understand what the current problems are and their 
dimension; and how they can be addressed to improve the safety of tattoo/PMU inks and 
practices.  
This project was divided into 4 work packages (Table 2.1): 
1. preparatory work [1]; 
2. state of play [2]; 
3. assessment and update of the CoE ResAP(2008)1 [3]; 
4. conclusions (final report). 
 
Table 2.1: Work plan and expected outputs of the Tattoo/PMU Project. 
 
 
2.2. Sources of information 
The information contained in this report was gathered as detailed below: 
• international webinar on tattoos on 24th April 2014; 
• CSN-STPM meetings; 
• replies to questionnaires prepared by DG JRC; 
• national legislative and guidelines texts; 
• harmonised analytical methods;  
• articles and books published in the literature;  
• national studies and surveys; 
• web search; 
• RAPEX notifications; 
• Presentations held at the meetings of the CSN-STPM. 
Work Package Objectives Topics Deliverables
Regulatory framework 1) CSN-STPM meeting11 Nov 2014
Analytical testing methods 2) WP 1 report
Current trends in tattoo practices
Prevalence
Data on inks market and 
composition 4) WP 2 report
Post marketing surveillance
Adverse health effects 5) CSN-STPM meeting
Lists of hazardous chemicals 9 Nov 2015
Impurities limits 6) WP 3 report
Risk perception and communication
Data gaps and research needs
7) CSN Plenary meeting with CSN-STPM
18 Mar 2016
8) Final report
3) CSN-STPM meeting
20 Apr 2015
WP3
Assessing & 
updating CoE 
ResAP (2008)1
WP4 Conclusions
Identifying the elements to be 
addressed by any EU action on the 
safety of tattoos and PMU.
WP1 Preparatory work
WP2 State of play
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2.2.1. International webinar 
Representatives from the European Commission, the Organisation for Economic Co-
operation and Development (OECD), Member States (Austria, Belgium, Denmark, 
Estonia, Finland, France, Germany, Hungary, Italy, Lithuania, Malta, The Netherlands), 
EFTA country (Norway) and other jurisdictions (Australia, Canada, Peru and the United 
States of America) took part in the webinar and exchanged information on safety issues 
related to tattoos. 
 
2.2.2. CSN-STPM meetings 
The CSN-STPM was set up in 2014 by DG SANCO. It was taken over by DG JRC in 
autumn 2014 when DG SANCO commissioned DG JRC to undertake this 18 month-
project. 
The members of the CSN-STPM included both experts from Competent Authorities and 
stakeholders, such as representatives from tattooists, ink manufacturers, dermatologists 
and consumers associations and the Council of Europe. Table 2.2 reports the list of 
participants in the CSN -STPM meetings. As much as 17 countries were represented by a 
total of 35 experts, plus 13 stakeholders. The meetings were held on: 
o 23th June 2014 
o 11th November 2014 
o 20th April 2015 
o 9th November 2015 
o 18th March 2016 
These meetings served to share the knowledge, discuss the data collected and propose 
recommendations. The minutes of those held in November 2014 and in April and 
November 2015 are collected in three JRC reports, respectively [1-3]. 
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Table 2.2: Participants in CSN - STPM meetings. 
 
 
2.2.3. Questionnaires 
Among the other sources of information, a number of questionnaires were prepared, 
distributed and analysed to extract data on the topics examined in this project.  
The questionnaires were designed according to the topic requirements and also tailor-
made according to the recipients. While the Member States were the principal audience, 
other input was sought according to the following mailing list distribution (Table 2.3): 
• CSN members - 28 EU MS and 4 EFTA countries (Iceland, Lichtenstein, Norway 
and Switzerland); 
Country Affiliation National Expert
Austria Austrian Agency for Health and Food Safety (AGES) ÖZELT Gregor
Federal ministry of labour, social affairs and consumer protection MEWED Disa
Belgium AZ Sint-Jan, Brugge - Ostende AV De CUYPER Christa
Czech Republic The ministry of health KAPOUN Miroslav
BJERREGAARD LERCHE Dorte
DUDECK Camilla 
PALUDAN Elisabeth
RASMUSSEN KOEFOED Julie
France Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) VERDIER Cécile
Ministère des Affaires Sociales, de la Santé et des Droits des Femmes MOKNI Walid
Bundesinstitut für Risikobewertung (BfR) BLUME Annegret
Federal Ministry of Food and Agriculture (BMEL) MEISNER Anke
CSENGODY Krisztina
JALTAI Judit
AGNELLO Manuela
FONTANA Marco
ALIMONTI Alessandro
BOCCA Beatrice
RENZONI Alberto
Luxemburg ILNAS - Surveillance du Marché DA SILVA AREDE Luis
HARTOG Peter
VAN GERWEN M.
National Institute for Public Health and the Environment (RIVM) JANSSEN Paul
De VRIES-HLAVACOVA Mariana
NIJBOER Lucas
Norway Norwegian Food Safety Authority  (Mattilsynet) STAVENES ANDERSEN Ingrid
Slovakia Public Health Authority of the Slovak Republic (UVZSR) KISACOVA Janka
Slovenia National laboratory of health- environment and food (NLZOH) HRŽENJAK Vesna
Spain Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) VIDAL ARESES Maria
CRONA Magnus
NOHRSTEDT Lena
Swedish Chemicals Agency SIMONSSON Elin
Switzerland Kantonales Laboratorium Basel-Stadt HOHL Christopher
LGC LTD AXFORD Ian
Royal Borough of Greenwich PINCHEN Robert
Affiliation Stakeholders
GIUSEPPIN Eliseo
ZOPPETTI Marco
European Society of Tattoo and Pigment Research (ESTP) SERUP Jorgen
FIALA Franz
VUERICH Michela
BAHRKE Susanne
SARACEVIC Amela
DIRKS Michael
WERNER Alexander
Sveriges Registrerade Tatuerare (SRT) BERGSTROM Jens
KEMNER Sina
MICHEL Ralf
University of Regensburg BAUMLER Wolfgang
Tattoo Ink Manufacturers in Europe (TIME)
Germany
H-A-N-Haus der Angewandten Naturwissenschaften-Gesellschaft mbH
Associazione tatuatori.it
National Institute of Chemical Safety (OKBI)Hungary
Consumer Council at the Austrian Standards Institute (ANEC)
Council of Europe (CoE)
Danish Environmental Protection Agency (EPA)
Ministry of Health Welfare and Sport (VWS)
Italy
Agenzia Regionale per la Protezione Ambientale Piemonte (ARPA)
Istituto Superiore di Sanità (ISS)
Denmark
Netherlands Food and Consumer Product Safety Authority (NVWA)
Medical Products Agency (MPA)
United Kingdom
Netherlands
Sweden
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• CSN- STPM members; 
• other jurisdictions via the Organisation for Economic Co-operation and 
Development (OECD) secretariat; 
• tattooists' and PMU professionals' associations; 
• ink manufacturers/distributors/private labels; 
• dermatologist associations. 
 
Table 2.3: Questionnaires' mailing list. 
 
 
A more detailed description of the content of the questionnaires put forward is available 
in the Table 2.4: 
1. regulatory framework (for Competent Authorities); 
2. analytical methods (for Competent Authorities and stakeholders); 
3. statistics (different questionnaires tailored for national authorities, for tattooist 
associations and for ink manufacturers); 
4. ink ingredients (different questionnaires tailored for national authorities, for 
tattooist associations and for ink manufacturers); 
5. health effects (for dermatologists); 
6. health effects, CoE ResAP(2008)1, risk communication and data gaps 
identification (for Competent Authorities). 
 
 
CSN members:
• 28 EU MS
• 4 EFTA countries
(by DG JUST)
CSN-STPM 
members 
(by DG JRC) 
Other non EU/EFTA 
countries
(by the OECD 
Secretariat)
Others
(by DG JRC)
1 Regulatory framework X X
2 Analytical methods X X
X X X
23 
tattooists' and PMU professionals' associations 
38 
ink manufacturers/distributors/private labels.
X X X
23 
tattooists' and PMU professionals' associations 
38 
ink manufacturers/distributors/private labels.
31
dermatologist associations
(inviting them to share it with their members)
X
(inviting them to distribute 
it to dermatologist 
associations, who had to 
further circulate it among 
their members)
6
Health effects
CoE Res
Risk communication 
and perception
Data gaps
X X
5 Health effects
Questionnaires
3 Statistics
4 Ink ingredients 
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Table 2.4: Questionnaires' content. 
 
 
A total of 144 replies to questionnaires were received and analysed. The results are 
shown in Table 2.5 involving between 14 (the health effects questionnaire) - 28 (the 
regulatory framework questionnaire) country responses per questionnaire. Only 7 
responses were received from manufacturers based in Germany and Italy (Table 2.6) 
and 10 from tattooist and PMU professional associations representing 7 countries (Table 
2.7).  
1 Regulatory framework
2 Analytical methods
Analysis of substances listed in the CoE ResAP(2008)1
in tattoo/PMU products:
a) international (ISO and EN) standard methods
b) national standard methods
c) in-house validated methods                                                           
d) methods described in the literature
a) primary aromatic amines (PAA)
b) colorants
c) elements
d) polycyclic aromatic hydrocarbons 
(PAHs)
4 Ink ingredients 
List of the ink composition: 
a) Identified ingredients listed to complete
b) Open answer part to add
5 Health effects
6
Health effects
CoE Res
Data gaps
Complications following a tattoo/PMU application or removal:
a) skin and systemic symptoms and their frequency and severity
b) proportion of people with previous skin diseases, including allergy
c) allergic skin reactions 
d) other inflammatory reactions
e) cutaneous/regional/systemic infections
f) tumours
g) correlations between health complications and certain tattoo characteristics/parameters (number of 
tattoos/patient, tattoo sizes, gender/age, colours, localisation)
a) Health effects: 
frequency of different health issues amongst people having undertaken tattoos/PMU applications or 
removals and factors correlated to higher frequency of medical complications
b) Experience gained with the CoE ResAP(2008)1: 
in terms of chemical, labelling, hygiene/sterility and other requirements
c) Risk communication and perception: 
information campaigns, information on risk perceived by the general public, signature of a prior informed 
consent
d) Data gaps identification: 
research or technical development to improve the safety of tattoo/PMU inks and practices
Title Questions
a) Structured as the requirements of the CoE ResAP(2008)1
b) Chemical, hygienic, labelling, packaging and information requirements
c) Provisions on risk assessment, tattoo processes and studios
d) Details about national legislations, both in place or in draft
e) Guidelines applicable to tattooing practices and/or products
3 Statistics
EU/EFTA countries:
a) % of tattooed/PMU population
b) number of tattoos per person
c) % of regrets or removals/year
d) number registered/non-registered studios/artists
e) national tattooist/PMU associations, ink manufacturers/importers
f) origin of inks imported, volume of sales and purchases
g) main problems and comments
Tattooist and PMU professional associations :
a) number of members
b) number of registered/non-registered tattoo/PMU studios/artists
c) suppliers of inks and yearly volume of purchased inks
d) existence of composition label on used products and type of container
e) suppliers of equipment and needles
f) main problems and comments
Ink manufacturers/distributors/private labels:
a) origin of ingredients and raw materials
b) purity certificate for raw materials
c) volumes of tattoo/PMU ink produced per year
d) composition and other information on label and type of container
e) average sale price/ml of ink
f) Good Manufacturing Practices (GMP)
g) main problems and comments
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Table 2.5: Questionnaires' responses. 
 
 
 
1 2 5 6
 
Count
 ries
Regulatory 
framework
Analytical 
methods
Health 
effects
Health effects
CoE ResAP
Risk 
perception/ 
communication    
Data gaps
AT X X X
BE X X 4 X
BG X X X X
CH X X X 1 X
CY X X
CZ X X X
DE X X 2 4 X 2 4 5 X
DK X X X 1 X 1 5 X
EE X
EL X
ES X X 1 X X
FI X X 1 X
FR X X X X X
HR X
HU X
IE X   
IS X
IT X X X 3 3 X 2 3 X
LI X X X
LT
LU X X X
LV X
MT X
NL X X X X 3 X
NO X X 1 X 1
PL X X
PT X
RO X X X
SE X X X 1 X 1 1 X
SI X X X X X
SK X X X X
UK X X
 Total 28
countries
10
countries
24
coun
tries
10
associ
ations
7*
manufa
cturers
13 
count
ries
6
associ
ations
7*
manufa
cturers
19
dermato
logists
14
countries
CA X X
MX X
NZ X
US X X
 Total
*
 In Europe
 Outside Europe
4 countries 2 countries
ink manufacturers/distributors/private labels
Resp 
onses
Questionnaires
3 4
Statistics Ink ingredients 
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Table 2.6: List of ink manufacturers respondents. 
 
 
Table 2.7: List of tattooist and/or PMU professional associations respondents. 
  
 
The response rate was very low in the case of the health effects questionnaires. 
Although 31 dermatologist associations in a representative sample of European countries 
were reached, only 19 dermatologists responded of which 15 reported less than 15 and 4 
up to 150 patients/year showing tattoo complications. In addition, only 5 national 
authorities completed the questionnaire in the part related to health effects. By 
consequence, the chapter regarding adverse health effects is based on the literature 
review. 
 
2.2.4. National legislative and guidelines texts 
The regulatory review, updated until November 2014, was based on the analysis of 93 
documents, including legislation in place and in draft, as well as guidelines. The list of 
the documents taken into consideration and a description of the main points addressed 
in each document is available in the JRC report on Wok Package 1 [1]. 
 
2.2.5. Harmonised analytical methods 
The information regarding available analytical methods for the determination of 
hazardous substances in tattoo/PMU products and other matrices was collected through 
questionnaires, web search of standard methods in the ISO (International Organization 
for Standardization) and CEN (European Committee for Standardization) catalogues and 
analysis of Standard Operating Procedures (SOPs), as well as literature review. 
 
 
 
Country Company
IT ABC INK 
IT Biotek srl
IT Clinita
DE DC-TP Europe GmbH
DE H-A-N Haus der Angewandten Naturwissenschaften-Gesellschaft GmbH
DE MT DERM GmbH
DE WEFA colors Jo Weinbach
Country Tattooist and/or PMU professional associations Acronym
CH Verband Schweizerischer Berufstätowierer VST
DE Bundesverband Tattoo BVT
DE United European Tattoo Artists UETA
DK Dansk Tatovør Laug DTL
ES Spanish National Union of Professional Tattooists UNTAP
IT Associazionetatuatori.it ART
IT Confederazione Nazionale Artigianato CNA
IT Associazione Tatuaggio Estetico Correttivo ATEC
NO Norwegian Tattoo Union NTU
SE Sveriges Registrerade Tatuerare SRT
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2.2.6. Literature 
Literature searches were carried out in PubMed and Scifinder data bases. The health 
effects chapter benefited from a review performed according to the guidelines named 
Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) [9]. 
Exclusion/inclusion criteria were applied to select the relevant articles (Figure 2.1): 
• years included 2004-2015; 
• key words present in abstract and title; 
• removal of duplicates, patents, some languages, documents classified as 
historical, dissertation, biography, commentary and conference; 
• priority given to 1) reviews, recent books and national reports; 2) clinical trials 
and 3) other papers; 
• filtering for relevance to tattoos or PMU. 
 
 
Figure 2.1: PRISMA flowchart on tattoo health effects. 
 
The full list of references used for the elaboration of the reports in this project can be 
found in the reference chapter.  
 
2.2.7. National studies and surveys 
The complete list of national studies reviewed to elaborate this report is available in 
Table 2.8 where 7 countries have undertaken studies on tattoos and PMUs. 
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Table 2.8: List of national studies/reports/surveys considered in this report. 
 
[10-38] 
Country Year  Institution Title
2015
8893 Produits de tatouage et de maquillage permanent et semi-
permanent - avis intermédiaire visant à limiter les complications 
et à accroître la sécurité des produits et techniques de tatouage 
et de maquillage permanent et semi-permanent en attendant 
une liste positive de produits pour ceux-ci
2011 8631 Semi-permanent makeup and tattoo
CH 2014 Gesundheitsdepartement des Kantons Basel-Stadt/Kantonales Laboratorium
Tinten für Tattoos und Permanent Make-Up/Pigmente, 
Konservierungsstoffe, Aromatische Amine, Polyaromatische 
Kohlenwasserstoffe und Nitrosamine
2012 Bundesinstitut für Risikobewertung (BfR) Requirements for tattoo inks
2013 Berichte zur Lebensmittelsicherheit – Monitoring  2013
2007 Berichte zur Lebensmittelsicherheit
2014 Recommendation from the Danish Environmental Protection Agency on the safety of Tattoo Ink
2012 Chemical Substances in Tattoo Ink: Survey of chemical 
substances in consumer products
2012 Risk Assessment of Hazardous Substances in Tattoo Inks based on the project "Chemical Substances in Tattoo Inks"
2011 Table of banned tattoo colours
2002 Investigation of pigments in tattoo colours
2015 Polycyclische aromatische koolwaterstoffen (PAK’s) in tatoeagekleurstoffen
2014 Resultaten onderzoek van kleurstoffen voor tatoeages en permanente make-up in de periode 2008 – 2013
2008 Nalevingsmonitor tatoeage en permanente make-up kleurstoffen (overzicht 2004 – 2007)
2015  Medical Products Agency (MPA) Control of tattoo inks for tattoo and permanent makeup
2012 Analysis of tattoo inks
2010 Hazardous substances in tattoo inks
2010  Analysis of tattoo inks
UK 2013 Public Health England Literature review on the epidemiology of tattooing and its 
complications
2011 Market survey of tattoo dyes: heavy metal testing
2011 Market survey of tattoo dyes: microbial testing
NZ 2013 Ministry of Health Survey of selected samples of tattoo inks for the presence of heavy metals
2012 Tattoo-associated nontuberculous mycobacterial skin infections-
-multiple states, 2011-2012
2006 Methicillin-resistant Staphylococcus aureus skin infections 
among tattoo recipients
2010 A portrait of generation next: confident. Connected. Open to 
change
2007  How Young People View Their Lives, Futures and Politics – A portait of "Generation Next"
2014 Los Angeles is America's "Most Inked Market"
2013 A867 – Tattoos, October 2013
2012 One in Five U.S. Adults Now Has a Tattoo
2008 Three in ten americans with a tattoo say having one makes them feel sexier
2003  A Third of Americans With Tattoos Say They Make Them Feel More Sexy, October 8
US
Pew Research Center
Health Canada
DE
Conseil Superieur de la Santé (CSS)
Danish Ministry of the Environment 
Environmental Protection Agency                 
(DK EPA)
Nederlandse Voedsel en waren autoriteit 
(NVWA)
Swedish Chemical Agency (KEMI)
Harris Poll Global Omnibus
BE
DK
NL
SE
CA
Bundesamt für Verbraucherschutz und 
Lebensmittelsicherheit (BVL)
Centers for Disease Control and 
Prevention (CDC)
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2.2.8. Web search 
To complete the findings, a web-based research was carried out on: 
• legislative framework in some countries; 
• analytical methods available at International Organization for Standardization 
(ISO) and Comité Européen de Normalisation (European Committee for 
Standardization – CEN) level; 
• tattoo/PMU market situation in terms of brands, suppliers and products sold 
online; 
• market share; 
• manufacturers/importers/suppliers/distributors; 
• inks ingredients. 
 
2.2.9. RAPEX notifications 
Since 2001, the Rapid Alert System for non-food dangerous products (RAPEX) shares 
information among 31 European countries and the European Commission regarding 
products presenting a serious health risk to consumers and measures taken. RAPEX 
notifications are published every week. The RAPEX database2 was searched in the years 
2005-2015 (until week 15) and data retrieved as described in Table 2.9.  
 
Table 2.9: RAPEX data base search and data. 
 
 
RAPEX notifications related to tattoo and PMU inks were identified and the risks linked to 
chemical and microbiological content evaluated.  
 
2.2.10. Presentations held at the meetings of the CSN-STPM 
Data presented in the meetings of the CSN-STPM held in Ispra were also taken into 
consideration, when adequate to complete the data.  
                                           
2 http://ec.europa.eu/consumers/safety/rapex/alerts/main/index.cfm?event=main.search 
Key word Tattoo
Years 2005-2015
Chemical
Microbiological
Product 
category Chemical products
Results 126 entries
Production country
Chemicals and the microbiological agents involved
Geographical production area
Brand name and type of product 
Year and week of the notification
Legal basis according to which the product was 
considered to pose an identified risk
Action taken by national authorities or 'voluntarily' by 
producers and distributors.
Risk types
Data
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3. Council of Europe Resolutions 
The Council of Europe3 is an international organisation which comprises 47 European 
countries, among which the 28 members of the European Union. It was set up to 
promote democracy and protect human rights and the rule of law in Europe. Its activities 
were then expanded to include among others also the health protection of consumers 
and the integration of people with disabilities into the community. In the CoE, the 
European Directorate for the Quality of Medicines and Health Care (EDQM) has been 
established to contribute to the basic human right of access to good quality medicines 
and healthcare and to promote and protect human and animal health. 
 
3.1. CoE ResAP(2003)2 
In 2003 the CoE published a ResAP on tattoos and permanent make-up [7] whose 
purpose was to contribute to the harmonisation of legislation in the public health field 
and to the preservation of consumer health through the insurance of tattoo and PMU 
products' safety. It took into account: 
1) the increasing popularity of tattoos and PMU; 
2) their possible resulting health risks (due to microbiological contamination, 
presence of hazardous chemicals in inks or weak hygiene habits); 
3) the importance of risk assessment for decision-making; 
4) the lack of national legislation in most member countries and of EC regulation; 
5) the advantage of regulation harmonisation at European level. 
This resolution makes recommendations to CoE member state governments to include its 
principles in their legislations on tattoos and permanent make-up. The overarching 
principle is that tattoo and PMU products should not endanger the health and or safety of 
persons or the environment. Therefore, a risk evaluation should be performed and 
products should comply with the following chemical, labelling, packaging, hygienic and 
information provisions. 
 
Risk evaluation 
The manufacturers or importers/distributors have to perform a risk evaluation based on 
recent toxicological data, and sent out this evaluation in a dossier available to the 
Competent Authorities before putting the product on the market. 
 
Chemical requirements 
The ResAp recommends that certain chemicals should not be present (or released, in the 
case of aromatic amines) in tattoo and PMU inks. The following negative lists are 
mentioned in the CoE ResAP(2003)2: 
1. Table 1 includes 26 aromatic amines, classified as carcinogenic substances with 
only two exceptions; 
2. Table 2 contains a non-exhaustive list of 35 pigments with carcinogenic, 
mutagenic, reprotoxic or sensitising properties; 
3. all ingredients listed in Annex II of the Cosmetics Directive 76/768/EEC (now 
substituted by EC Regulation 1223/2009, the Cosmetics Regulation) [39]; 
                                           
3 http://www.coe.int/aboutCoe 
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4. all colorant specified in Annex IV, with restrictions in columns 2 to 4 of Directive 
76/768/EEC (now substituted by EC Regulation 1223/2009, Annex IV, column g) 
[39]; 
5. carcinogenic, mutagenic and reprotoxic (CMR) substances of categories 1, 2 or 3 
that are classified under Directive 67/548/EEC (now substituted by EC Regulation 
1272/2008 on Classification, Labelling and Packaging (CLP), Table 3.1 in part 3 of 
Annex VI, categories 1A, 1B and 2) [40]. 
In addition, preservatives should not be present in tattoo/PMU inks. 
In the future, the CoE aims to establish positive lists of substances. 
 
Labelling requirements 
Tattoo and PMU products' packaging should contain the following information: 
• name and address of the manufacturer or the person responsible for placing the 
product on the market; 
• minimum date of durability; 
• conditions of use and warnings; 
• batch n° used by the manufacturer for batch identification; 
• list of ingredients according to their International Union of Pure and Applied 
Chemistry (IUPAC) name , CAS number (Chemical Abstract Service of the 
American Chemical Society) or Colour Index (CI) number; 
• guarantee of sterility of the contents. 
 
Hygienic and packaging requirements 
Tattoo and PMU products must be supplied in a container that maintains the sterility of 
the product until application. The packaging size should be supplied for single use on an 
individual consumer. 
Tattoo and PMU application and activities, including sterilisation and disinfection of the 
instruments, must be carried out by the tattooist in conformity with the hygiene 
regulations laid down by national public health services. 
 
Information requirements 
The public should be informed about the risks of tattooing by all appropriate means, 
such as mass information campaigns or via the Internet. Complete, reliable and 
comprehensible information to the consumer is mandatory for tattooists about the risks 
entailed by those practices, including the potential occurrence of sensitisation. 
 
3.2. CoE ResAP(2008)1 
On 20 February 2008, the CoE adopted a revised ResAP(2008)1 superseding the 
previous Resolution from 2003. The main differences are listed hereunder and 
summarised in Table 3.1. 
• Table 1 of CoE ResAP(2008)1 contains 27 aromatic amines, (compared to 26 in 
the previous version), paraphenylenediamine was added. These aromatic amines 
should not be present or released in concentrations that are technically avoidable 
according to Good Manufacturing Practices (GMP); their presence or release 
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should be determined by using appropriate test methods which should be 
harmonised across the member states. 
• Two analytical methods which could serve as models for harmonising test 
methods for the analysis of aromatic amines were added. 
• A new table was added listing the maximum concentrations of impurities. 
• Tattoo and PMU inks should also comply with the minimum requirements for 
further organic impurities for colorants used in foodstuffs and cosmetic products 
as set out in Directive 95/45/EEC [41]. 
• Preservatives can be used only after a safety assessment and in the lowest 
effective concentration to avoid the product contamination after opening and by 
no means to compensate for poor microbiologic quality during the manufacturing 
process or for questionable hygiene conditions while performing the tattoo/PMU 
application. 
• Single use packaging is preferred. In case of multi-use containers, their design 
should ensure that the contents will not be contaminated during the period of 
use. 
• Tattooists should duly inform the customer about care following the application of 
a tattoo, reversibility and removal of tattoos, and the advice of consulting a 
physician in case of medical complications. 
• The Competent Authorities should evaluate the specific safety data of ink 
ingredients (e.g physico-chemical properties and toxicological data), starting with 
colorants, in order to exclude the use of harmful substances by progressively 
establishing a positive list of safe substances in tattoos and PMU. 
 
Table 3.1: Main differences between CoE Resolutions (2003)2 and (2008)1. 
 
[Directive 95/45/EEC] [41] 
CoE ResAP(2003)2 CoE ResAP(2008)1
1) Risk evaluation Safety assessment
Done by 
manufacturers or 
importers/distributors
Manufacturers: Provide composition of products 
and toxicology of substances (using existing 
guidelines if any)
Authorities: Take steps to replace negative lists 
with positive lists of safe substances
Paraphenylenediamine added to Table 1
Concentrations should be lower than those 
technically avoidable and should be determined 
by test methods to be harmonised
Maximum allowed concentrations of metal and 
polycyclic aromatic hydrocarbon (PAH) 
impurities (Table 3)
Minimum requirements of organic colorant 
impurities for colorants used in foodstuffs and 
cosmetic products [Directive 95/45/EEC]
Only to ensure preservation after opening, not as 
purity correction nor inadequate hygiene
Only after safety assessment and in the lowest 
effective concentration
3) Hygienic and 
packaging 
requirements
Container size Single use 
recommended
If multi-use containers, designed to avoid 
contamination during use
4) Public information Risks risks including potential sensitisation
Added:
aftercare
removals
physician consultation if medical complications
2) Chemical 
requirements
Aromatic amines 
negative list
26 aromatic amines 
in Table 1
Purity criteria
none
Preservatives should not be used
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4. Legislative framework in the EU/EFTA countries and 
other jurisdictions  
The regulatory review of different EU (and beyond) national legislation and guidelines on 
tattoo/PMU prepared by DG JRC in 2003 [6] needed an update due to changes in the 
legislative framework of some countries, following the adoption of the two CoE 
Resolutions, and to the enlargement of the European Union (since 2004 13 new MS 
joined). Taking stock of these new developments, DG JRC collected in 2014 data on the 
regulatory framework of each EU and EFTA (Iceland, Liechtenstein, Norway and 
Switzerland) countries4, plus other jurisdictions. The findings, as of November 2014, are 
presented hereunder. More details are available in the JRC report on Work Package 1 
[1]. 
 
4.1. EU/EFTA countries 
The situation varies widely across Europe, as many countries have endorsed and, except 
in 3 MS, also enforced national legislation on tattoo/PMU products in line with the 
recommendations of the CoE ResAPs of 2003 and 2008, while some others do implement 
the chemicals legislation (CLP and REACH) [40, 42] and the general safety requirements 
of the GPSD [5] without referring specifically to tattoo/PMU products. 
According to the degree of development of ad hoc policy on tattoo/PMU products and 
practices, the various countries can be divided in four different groups (See Figure 4.1): 
1. Belgium, France, Germany, Norway and The Netherlands adopted 
regulatory provisions in line with CoE ResAP(2003)2, while Slovenia, Spain, 
Sweden and Switzerland (plus Liechtenstein, which follows the Swiss 
legislation) enforced the CoE ResAP(2008)1 recommendations. (see Table 4.1 of 
this document). 
2. Austria, Denmark and Latvia have notified national legislation based on the 
CoE ResAP(2008)1, but they have been kept on hold so far.5  
3. Czech Republic, Finland, Italy, Malta, Romania and Slovakia have taken 
health and safety measures regulating tattooing activities, including hygiene 
requirements of tattoo parlours. In addition, in the context of RAPEX notifications 
Italian and Slovakian health authorities carry out market surveillance activities on 
tattoo/PMU inks referring to the CoE ResAP(2008)1 lists of hazardous chemicals 
[43, 44]. 
4. Bulgaria, Croatia, Cyprus, Estonia, Greece, Ireland, Luxembourg, Poland 
and Portugal have not yet put in place any specific tattoo/PMU regulatory 
framework, though they are supposed to implement, as all other MS, general 
safety provisions regarding consumer products (GPSD), and follow up the 
chemicals legislation (REACH and CLP). 
The main elements of the regulatory framework existing in the various countries that 
have embodied the ResAP's recommendations can be summarised as follows.  
 
 
                                           
4 Hungary, Iceland, Lithuania and the United Kingdom did not reply to the enquiry. 
5 Denmark and Austria in 2013, and Latvia in 2014 have notified draft national legislation on tattooing products 
and services. The proposed drafts are currently put on hold by the European Commission as they are in conflict 
with REACH provisions. 
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Figure 4.1: Legislative framework on tattoo/PMU products in the EU/EFTA countries. 
 
4.1.1. Chemical requirements  
There are currently no EU harmonised legal requirements for chemicals in tattoo/PMU 
inks. A number of chemicals present in inks, either as ingredients or as impurities, are 
however banned in consumer products that get into direct contact with the skin under 
different legislative frameworks, like in cosmetics (Cosmetic Product Regulation) or in 
textiles (e.g. REACH restriction for aromatic amines). 
Table 4.1 reports an overview of the chemical recommendations mentioned in the CoE 
ResAPs (in columns) with the indication if they are included into the legislations in place 
in Belgium, France, Germany, Liechtenstein, Norway, Slovenia, Spain, Sweden, 
Switzerland and The Netherlands. Even though these legal acts are all based on the 
ResAPs from 2003 or 2008, differences are present among them either due to 
dissimilarities in the ResAPs or to deviations from them. 
For instance, even if the French and German national legislations are based on CoE 
ResAP(2003)2, the negative list for PAAs mentioned inhere includes also p-
phenylenediamine which is mentioned in the CoE ResAP (2008)1. Moreover, although the 
CoE ResAP(2003)2 does not allow the use of preservatives, the French and German 
legislations do not give any specific indication about this issue, while the Norwegian one 
includes a positive list with restrictions. 
Another example is the Swiss legislation that foresees a limit of 30 mg/kg for the total 
content of forbidden PAA in tattoo/PMU products, even if the CoE ResAP (2008)1 does 
not indicate specific thresholds for this class of compounds. 
Remarkably, the national legislations in place forbid all substances classified as CMR in 
categories 1A, 1B and 2 under the CLP Regulation (the only exception is Germany), as 
well as those listed in Annex II and Annex IV (with restrictions in column g) of the 
Cosmetics Regulation in tattoo/PMU products. Actually, the German act bans the 
substances classified as CMR before 2010 as they are included in Annex II of the 
Cosmetics Regulation. 
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It has to be noted that France and Switzerland have some additional requirements. The 
French regulation also forbids: 1) sensitising substances category 1 as defined in EC 
Regulation 1272/2008 [40]; 2) sensitising substances in hair dyes identified by opinions 
of the Scientific Committee on Consumer Safety (SCCS) and 3) CMRs and sensitising 
substances as specified in the Commission decision 2002/371/CE [45] establishing the 
ecological criteria for the award of the EU Ecolabel for textile products (now substituted 
by the Commission decision 2014/350/EU [46]). The Swiss law additionally bans 
fragrances and flavouring agents in tattoo/PMU inks. 
 
Table 4.1: Chemical requirements in the national legislations in place. 
 
*e.g. max concentrations and labelling 
** e.g. only after risk assessment and in the lowest effective concentration 
 
4.1.2. Packaging requirements  
Along the lines of the CoE Resolutions, Belgium, France, Liechtenstein, Norway, 
Slovenia, Spain, Sweden, Switzerland, The Netherlands, together with Italy, Malta and 
Romania, impose appropriate packaging ensuring sterility of tattoo inks before use. 
Single use containers are encouraged by authorities, who made it already mandatory in 
Malta and Spain, but not favoured by tattooists associations, who argue that such 
packaging make inks getting dry. They rather support multiple use containers provided 
that other sterility measures are taken, e.g., sterile water for diluting inks instead of tap 
water, plus low sensitisation preservatives. 
 
4.1.3. Labelling requirements  
Almost all current legislative frameworks for tattoo and PMU inks contain labelling 
requirements, in conformity with the CoE ResAP(2008)1. Besides, the period after 
opening (PAO), where inks are still safe, is indicated in Germany, Spain, Sweden and 
Norway. The latter applies similar standards as for cosmetic products. 
 
 
 
Country
National 
legislation 
based on 
the CoE 
ResAP
Negative list 
for PAAs
Negative list for 
colorants Impurity limits Preservatives
Negative list 
for 
substances 
EC Reg 
1223/2009 
Annex II
Negative list 
for colorants 
EC Reg 
1223/2009 
Annex IV 
(column g)
Negative list 
for CMRs         
EC Reg 
1272/2008 
Table 3.1
Dir 
95/45/E
EC
BE (2003)2 26 35 no banned yes yes yes yes
DE (2003)2
27 (26 + 
paraphenylene
diamine)
36 (35+ solvent 
yellow 14) no
no special 
provisions yes yes
no, however 
Annex II of EC 
Reg 1223/2009 
contains the 
substances 
classified as 
CMRs before 
2010
no
FR (2003)2 27 (26 + paraphenylene 35 no
no special 
provisions yes yes
yes, plus 
sensitisers cat. 1 no
NL (2003)2 22 36 no banned yes yes yes
NO (2003)2 26 35 no
positive list 
with several 
restrictions*
yes yes yes
CH, LI (2008)1
27 (CH - with 
specific limit for 
the sum, 30 
mg/kg)
35
yes (except for 
nickel and 
antimony)
positive list of 
26 allowed for 
prolonged 
contact with the 
skin (leave-on 
cosmetics)
yes, referring 
to the 
corresponding 
national 
legislation
yes, referring 
to the 
corresponding 
national 
legislation
yes, referring to 
the 
corresponding 
national 
legislation
no
ES, SE, SI (2008)1 27 35 yes (15 impurities)
tolerated under 
certain 
conditions**
yes yes yes yes (SE)
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4.1.4. Hygienic requirements  
Most of national laws/guidelines contain general provisions regulating cleaning of tattoo 
premises, sterility of tools (such as single use of needles) and hygiene of staff (e.g. skin 
disinfection). 
 
4.1.5. Requirements for risk assessment  
In some countries (such as Czech Republic, France, Norway, Slovenia or Spain) the 
manufacturer/importer has to submit to the Competent Authorities a safety assessment 
dossier of the tattoo/PMU product before placing it on the market, while in some other 
Member States the safety assessment file needs to be handed to Competent Authorities 
only if required. This dossier contains inks' composition, physical-chemical and 
toxicological properties, health risk assessment, data on microbiological status, together 
with details on manufacturing conditions and quality check. However, France and Norway 
forbid any animal testing for tattoo toxicological and risk assessment purposes. The 
tattooists operating in Romania and Spain, have to carry out an allergy test for the dye 
to be used prior to the tattoo application.  
In Sweden, data on potential adverse health effects of tattoo inks, including the 
preservatives contained in it, must be sent to the Medical Products Agency and to the 
Swedish Poisons Information Centre.  
The Spanish Competent Authority6 is the only one in the EU that established a positive 
list of tattoo and PMU inks allowed for use on the Spanish market.  
 
4.1.6. Information requirements  
Tattoo operators in France, Liechtenstein, Malta, Norway, Slovenia, Sweden, Switzerland 
and The Netherlands have to provide tattoo receivers before handling them, with 
complete, often written information, focusing on the potential risks of such application, 
on the aftercare treatment, on tattoo removal and emphasizing the necessity to consult 
a doctor should health complications arise. Many countries, like France, Italy, Norway, 
Switzerland or The Netherlands, impose a written consent from the customer, or from 
his legal guardian. 
Norway and The Netherlands, for instance, have put in place public information 
campaigns targeting tattoo customers about the possible health risks of tattooing/PMU 
procedures. Besides, the website http://www.veiligtatoeerenenpiercen.nl/ lists all Dutch 
licensed parlours and indicates client's age limits, providing also data on risks of tattoos, 
aftercare instructions, etc. See more details in Chapter 11 (risk perception and 
communication). 
 
4.1.7. Adverse health reactions notifications  
In France the national vigilance system put in place allows the public to retrieve 
information on health risks related to tattoo inks. The Italian market monitoring 
Authority ensures tattoo inks comply with the CoE ResAP(2008)1 and other 
hygienic/sanitary guidelines, initiating otherwise a market withdrawal procedure under 
the RAPEX system. In Sweden the producer or importer reports to a national register, 
while in Germany market surveillance authorities and the Poison Centres are at regional 
level. A reporting system of adverse health effects from tattoo inks exists also in e.g. 
Austria, France, Norway, Romania, and The Netherlands. The Dutch monitoring system 
(CESES, Consumer Exposure Skin Effects and Surveillance) registers all complications 
                                           
6 (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) 
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including allergic reactions caused by cosmetics. Instead of cross references to other 
legislation Norway proposed market surveillance Authorities should use "supporting lists" 
for the identification of banned substances. 
 
4.1.8. Requirements for processes and tattooists  
In Belgium, Czech Republic, Italy, Liechtenstein, Malta, Romania, Slovenia, Slovakia, 
Switzerland and The Netherlands, a license is compulsory for opening a tattoo studio and 
carrying out tattoo-related activities, delivered sometimes upon due medical examination 
(Czech Republic) or vaccination against Hepatitis B (Malta and Switzerland). Luxembourg 
requires a diploma of hairdresser, beautician or manicurist in order to open such a 
parlour.  
In Belgium, Czech Republic, France, Italy, Liechtenstein, Romania and Sweden, legal 
provisions specify which training courses tattooists must follow, e.g. on hygiene and 
health topics. Draft legislation in Austria, Denmark and Latvia also regulates access to 
the profession and ad hoc training for tattooists. 
Tattooing is forbidden to minors without a parental approval, i.e. under 18-s, in Belgium, 
Denmark, Malta, Romania and Spain. However, the customer's minimum age limits can 
sometimes be as low as 15 years in Slovenia, or 16 years in The Netherlands (down to 
12 years with parents' authorisation). Italy regulates such matters at regional level. 
Furthermore, according to the Danish Tattoo law some body parts, such as head, neck 
and hands may not be tattooed. 
The Netherlands and Romania consider tattoo removal as a medical act; hence it may 
only be carried out by qualified medical staff within hospital premises. 
 
4.2. Other jurisdictions  
The information has been collected by searching published regulations and guidelines in 
the internet and through an international webinar, which took place in April 2014. 
New Zealand is the only country outside Europe to expressively recommend tattoo/PMU 
guidelines based on the CoE ResAP(2008)1. Under the remit of the Environmental 
Protection Agency (NZ-EPA), a Tattoo and Permanent Make-up Substances Group 
Standard has been established to discuss the potential health risks provoked by the 
chemicals contained in those products. In line with the aforementioned Resolution, the 
NZ Authorities have established a list of 27 aromatic amines and 35 colorants that 
should not be present in tattoo inks, with the same limits for 15 impurities. 
In Australia, the public health department of each jurisdiction (e.g. New South Wales, 
Queensland, Tasmania, etc.) regulates its own Body Art practices and standards, leading 
to a wide variety of procedures. 
The Food and Drug Administration (FDA) of the United States of America has not yet 
developed legal scheme covering tattoo inks and parlours at federal level, though 
specific requirements do exist at state level, leading to a wide variety across the US. 
During the abovementioned webinar, the United States expressed their interest in 
envisaging further regulatory measures ensuring an improved safety of tattoo inks. 
Canada has no specific legislation on tattooing at central level. However, every 
provincial authority (such as in British Columbia, Ontario, Québec, etc.) edicts health 
guidance governing Personal services establishments (PSEs), and ensures their 
enforcement. 
In Japan, highly industrial chemicals entering in the composition of consumer products 
undergo strict marketing and use restrictions. However, to our knowledge, tattoo inks 
are not regulated as such, and tattoo studios are not covered by a specific legislative 
scheme. 
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To summarise, regulatory control of tattoo/PMU products and practices largely vary 
across the abovementioned developed countries (Australia, Canada, Japan, New Zealand 
and United States of America), but also inside each national jurisdiction. 
 
The different rules and guidelines mainly lay down requirements for tattoo processes and 
hygiene standards, and less on chemical ingredients contained in tattoo and PMU inks.  
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5. Statistical data related to tattoo and PMU practices  
In the 1950s and 1960s in the USA and in Europe, tattooing was a practice generally not 
well accepted by the middle classes and associated with certain groups of people, such 
as sailors, the military, criminals and prostitutes [47]. According to many experts, tattoo 
prevalence has increased over the years together with their acceptance by the society. 
Nowadays, tattoos are considered an artistic expression, referred to as body art, and 
getting tattoos has become more and more a fashion trend, in particular in the young 
generations. Popularity of tattooing has increased its visibility more recently, most likely 
through television and social media [47-49]. 
This chapter attempts to provide certain quantification to this evolution, despite all 
difficulties such as the fact that there is no official registration system whatsoever in the 
EU. It also provides information related to the tattoo market, in terms of studios, artists, 
associations, manufacturers, brand names, etc. As mentioned in chapter 2, data 
originates from replies to questionnaires, peer-reviewed literature, national reports and 
web searches. More details are available in the JRC report on Work Package 2 [2]. 
 
5.1. Prevalence 
5.1.1. General population  
Fig. 5.1 reports the available data on the tattoo prevalence in the general population in 
countries within and outside Europe. 13 Member States, plus Canada, New Zealand and 
the United States provided information through questionnaires. The uncertainties are 
unknown and, in many cases, also the sources. In the literature, data from Germany, 
Denmark, France, Sweden, United Kingdom, Australia and the United States were found 
[10, 13, 17, 34-38, 47, 48, 50-58]. They were generally in agreement with what 
reported in the questionnaires.  
Based on the figures from 14 MS (questionnaires: AT, BG, CY, DE, DK, FI, FR, HU, IT, 
LU, NL, PL and SE; literature: UK) weighed by the population of each of them, it can be 
estimated that: 
• 12%, of the whole European population has one tattoo or more 
This corresponds to more than 44 million tattooed people in the 14 considered countries 
and to more than 60 million people in the EU-28.7 
Fig. 6.2 shows the prevalence data used for the estimation. The darker the violet colour, 
the higher the prevalence is. Member States for which no information was available are 
represented in dark grey and countries not belonging to the European Union are in light 
grey. The picture also shows the estimated number of tattooed people expressed in 
millions. National tattoo prevalence in Europe ranged between 7 and 19%, with the 
exception of Luxembourg (60%), Hungary (50%) and Cyprus (30%). These three high 
values do not significantly impact the estimate that would be decreased to 11.8% in case 
the Luxembourgian and Cypriot data would not be taken into account and to 10.7% if 
the Hungarian one would be taken out from the calculation. 
The current estimate of 12% for the EU tattoo prevalence rates higher than the 5-10% 
reported for tattoos and piercing in a previous 2003 JRC report [6] and seems to indicate 
an increase over time. This can be supported particularly considering that: 1) only one 
decade have passed; 2) the prevalence in the general population is slowly influenced by 
changes in the prevalence of specific age groups (e.g. young people); 3) the estimate 
                                           
7 For the purpose of estimating the tattoo prevalence in Europe, the tattoo prevalence in each considered 
country has been multiplied by the number of people living there (including everyone, e.g. children), thus 
obtaining the number of tattooed people in that country. The total number of tattooed people in the 14 
countries considered was then used to calculate the tattoo prevalence in the EU-28. This might have led to a 
slight overestimation of this parameter. 
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done in 2003 overestimated the tattoo prevalence as it included also people who had 
just piercing. If in the following years tattoos will continue to be "trendy", the impacts 
will accumulate and the general prevalence will continue to increase.  
 
 
Figure 5.1: Tattoo prevalence in the general population in the world. 
 
 
Figure 5.2: Tattoo prevalence in the general population in Europe. 
 
The tattoo prevalence in the general population in Canada, New Zealand and the United 
States is higher than in Europe while in Australia is quite similar to Europe, as shown in 
Fig. 5.1 and Table 5.1.  
Permanent make-up was seldom reported and data vary considerably in Europe (Table 
5.2). No data were available for countries outside Europe. 
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Table 5.1 Tattoo prevalence in the general population in the world. 
 
 
Table 5.2: PMU prevalence in the general population in Europe. 
 
 
5.1.2. Influence of age 
Data on tattoo prevalence in various age ranges are available for some European 
countries (Austria, Denmark, Finland, France, Germany, Iceland, Italy, Norway and The 
Netherlands), plus Canada and the United States (questionnaires and [12, 34, 35, 38, 
51, 52, 55-57, 59-69]). As example, Figure 5.3 reports the situation in France. The 
horizontal red line represents the tattoo prevalence in the general population in this 
country. 
 
 
Figure 5.3: Tattoo prevalence in the various age ranges in France. 
 
The influence of age on the tattoo prevalence is remarkable. As shown in Figure 5.4, 
teenagers between 12-19 years old, whether from Europe or North America, have 
tattoos with prevalence in the range 2-9%. 
 
Countries Prevalence (%)
Europe 12
Australia 10-14.5
New Zealand 20
United States 21-24
Canada 24
Countries Prevalence (%)
Italy 3
Bulgaria 8
Cyprus 20
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Figure 5.4: Tattoo prevalence in teenagers in and outside Europe. 
 
Table 5.3 shows the prevalence of tattoos in the general population of some European 
and North America countries, as well as the ratio between the prevalence in certain age 
groups and the one in the general population of the considered country. Despite the 
difficulties of comparing data provided in different age ranges for various countries, 
common trends may be identified. 
1) More in the young 
The tattoo prevalence in the young generations is around 20-30% in Europe and up to 
almost 40% in the US (Figure 5.5). It is higher than in the general population in each 
country and can reach almost the double (Finland, France and Italy) and in some cases 
even more (Germany and The Netherlands). If this trend continues, the prevalence in 
the general population will increase in the next decades. 
2) Less in the older 
The tattoo prevalence significantly decreases for people over fifty and it is usually lower 
than 10%, with just few exceptions. 
The information taken into consideration come from the questionnaires, as well as from 
the literature [12, 34, 35, 38, 51, 52, 55-57, 59-69]. 
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Figure 5.5: Tattoo prevalence in the young generations in and outside Europe. 
 
Table 5.3: Influence of age on the tattoo prevalence in different age groups in and outside Europe. 
 
 
The first tattoo is very often got when people are young (less than 30 years old) or even 
adolescent. In Denmark 37% of the tattooed people got their first tattoo when they were 
less than 20 years old, this percentage becomes 44% and 18% (for teenagers less than 
18 years old) in France and Germany, respectively. Table 5.4 reports the percentage of 
people who received their tattoo(s) before the age indicated in the first column. The 
information was retrieved from the questionnaires, as well as in the following 
publications [56, 68, 70, 71]. 
Only little information was collected with regards to the age of getting the first PMU; 
however, the trend seems to be that, in general, this age is higher than the one for the 
first tattoo. 
 
 
 
 
Country
general tattoo 
prevalence          
(%)
Age 
range 
(years)
tattoo 
prevalence 
ratio
Age 
range 
(years)
tattoo 
prevalence 
ratio
Age 
range 
(years)
tattoo 
prevalence 
ratio
Age 
range 
(years)
tattoo 
prevalence 
ratio
Age 
range 
(years)
tattoo 
prevalence 
ratio
Age 
range 
(years)
tattoo 
prevalence 
ratio
AT 19 16 - 29 1.5 30 - 49 1.4 50+ 0.4
DE 9 16 - 29 2.6 30 - 44 1.1 45 - 59 0.7 59+ 0.2
DK 15 15 - 34 1.3 35 - 49 1.3 50 - 64 0.6 65 - 74 0.2
FI 10 15 - 19 0.9 20 - 24 1.2 25 - 29 1.9
FR 10 18 - 24 0.8 25 - 34 2.0 35 - 49 1.2 50 - 64 0.5 64+ 0.1
IT 12.8 12 - 17 0.6 18 - 24 1.7 25 - 34 1.8 35 - 44 1.9 45 - 54 1.2 54+ 0.2
NL 10 12 - 19 0.2 20 - 29 2.5 30 - 49 2.7 50 - 59 1.2 59+ 1
CA 24 12 - 18 0.3
US 21 16 - 24 1.0 25 - 29 1.4 30 - 39 1.8 40 - 49 1.3 50 - 64 0.5
23 16 - 29 1.6 30 - 45 1.4 46 - 64 0.6 64+ 0.3
14 18 - 24 0.6 25 - 29 2.3 30 - 39 1.8 40 - 49 0.9 50 - 64+ 0.6
24 18 - 25 1.5 26 - 40 1.7 41 - 64 0.4
24 18 - 29 1.5 30 - 40 1.0 41 - 50 0.6
16 18 - 24 0.8 25 - 29 2.2 30 - 39 1.7 40 - 49 0.9 50 - 64 0.6
21 14 - 16 0.1 17 - 21 0.4
In Europe
Outside Europe
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Table 5.4: Age of first tattoo. 
 
 
5.1.3. Influence of gender  
While in the past women represented a minority of the tattooed population, nowadays 
this is not always the case. According to recent studies, women represent the majority of 
the tattooed population in Denmark, Italy and the United States. This new tendency 
seems to be more pronounced in adolescents and young generations in Europe, Australia 
and North America (questionnaires and [38, 50, 52-57, 63-69, 72-76]). 
 
5.2. Exposure  
The level of exposure to chemicals due to the presence of tattoos depends on several 
factors, among which the quantity of inks injected in the derma and the number and size 
of the tattoo(s). 
The quantity of pigment used for performing a tattoo has been experimentally evaluated 
and described in the literature [77]. Just after the application, on average around 2.53 
mg of pigment were present in 1 cm² of skin. This would mean that for a tattoo of about 
400 cm², the skin contains a total amount of 1 g of pigment. 
The size of a tattoo can greatly vary and in the literature different classifications exist 
and various units are used (Table 5.5) [10, 13, 16, 17, 56, 70, 71, 77-79]. The Belgian 
"Conseil Supérieur de la Santé" (CSS) reported that a tattoo covering one arm, the back 
or the entire body is about 800, 4500 and 16400 cm2, respectively. Tattoos can broadly 
be divided into small, medium and large according to their area. 
 
Table 5.5: Size of tattoo. 
 
 
An internet survey with 3411 participants [70] showed that most tattooed German 
people (61%) have tattoos bigger than 300 cm² (16% even larger than 900 cm2), while 
in Denmark and the United States tattoos are smaller than 182 cm² in about 70% of 
cases according to studies with less than 350 participants [56, 80]. Regarding the 
difference between genders, tattoos in women tend to be smaller than in men, usually 
smaller than 182 cm², both in Europe and in the US.  
In the general tattooed population more than 50% usually have their tattoos placed on 
the extremities, followed by the trunk and by the head/neck, which generally represent 
less than 5%. Localisation seems to depend on gender and women more often tattoo 
Country Age (Years)
Frequency 
(%)
In Europe
Denmark <35 86
France <30 84,8
Germany <36 94,6
Outside Europe
Canada <43 60
United States <24 65
Ranges Surface (cm²) Localisation Surface (cm²) Units
Small ≤ 30 Arm 800 % of body skin
Medium 30 – 300 Back 4500 Hand palm
Large ≥ 300 Entire body 16400 cm²
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their trunk compared to men who rather do it on their extremities (arms and legs) [56, 
67, 70, 71, 74, 78] 
Apart from few exceptions, both data from the questionnaires and from the literature 
showed that at least half of the tattooed people have more than one tattoo. No clear 
trend related to gender can be derived from the data available. However, according to 
the biggest study [70] the majority of women and men have 2-3, or 4 and more tattoos 
respectively. 
Most tattoos are single coloured and black (50-60%). Other popular colours in 
descending order are red, blue, green, yellow and white [70, 80]. 
 
5.3. Regrets and removals  
Together with the increase of the number of tattooed people also the number of regrets, 
sometimes associated to a request for removal, has increased during the last years. 
Reasons behind the decision to undergo a removal procedure include aesthetic reason, 
medical problems or simply whish not to have it anymore [81]. 
Early removal procedures, no longer in use, consisted of mechanical destructive methods 
(often resulted in permanent scars, important residual tattoo and infections), such as 
dermabrasion or salabrasion. The use of trichloroacetic acid and of the so called glycolic 
acid mixture (lactic, tartaric, malic and glycolic acid) also became of routinely use and it 
is still used nowadays as cheap alternative to the modern laser technique. It is worth 
mentioning the surgical excision of tattoos that is still considered in emergency cases 
(strong allergic reaction to the tattoo to be treated immediately). Finally, thermal 
procedures such as electrocautery, infrared coagulation, argon lasers, and CO2 lasers 
have also been exploited with mediocre results. 
Nowadays, the most widespread technique to achieve a safe, selective and efficient 
tattoo removal is represented by Quality-switched lasers which represent, since early 
90s, the gold standard for tattoo removal [82, 83]. Although Q-switched lasers have 
made tremendous steps in advancing safety and selectivity of removal, both temporary 
and permanent side effects might still occur and are discussed in Chapter 9 of this 
document. QS Lasers produce short pulses of intense light that cross the skin to 
fragment the pigment into small particles [13]. 
Although data are scarce, questionnaires and publications did provide some figures that 
can be summarised as follows (Figure 5.6): regrets in Europe range from 5-20%, while 
in the United States values are more consistent and spread around 14-17% and in 
Canada are estimated at 17% [2, 10, 37, 38, 55-57, 67, 70, 78]. The number of 
removals is generally smaller than the number of regrets. 
However, in a recent review, Laux reported that up to 50% of the tattooed individuals 
regret their tattoos [84]. 
According to a German study, 33% of the individuals who did the removal process were 
not satisfied with the results, while 38% reported a complete removal of pigment [85]. 
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Figure 5.6: Prevalence of regrets and removals in and outside Europe. 
 
5.4. Market  
5.4.1. Studios and artists  
As expected, the bigger the country, the more tattooist studios, whether professional or 
non-professional, were reported in the questionnaires and/or in the literature: 50-8000 
registered studios and 100-5000 non-registered studios per European country. At the 
same time, 8-10000 and 16-30000 registered and non-registered artists were estimated, 
respectively. 
When comparing the ratio of number of professional tattooists to the number of 
inhabitants, the north of Europe takes the lead with up to 9.4 tattooist/30000 
inhabitants in Sweden, lowering down to around 1.4 in France or Italy for example. The 
data also show that tattooist usually work alone in their studio. In view of the 
widespread number of studios, the legislation application and overseeing can thus prove 
to be challenging. 
The detailed data set is available in the previous JRC report (JRC, Annexes III and VI) 
and in the literature [20, 27, 37, 47]. 
 
5.4.2. Tattooist associations  
Tattooist associations note that the distinction between professional and non-
professional studios/artists is a challenge as an official registration system is not in place 
(Sweden) and the estimation of so-called 'home scratchers' is difficult (Italy, Sweden, 
Spain). These associations are an attempt to 'monitor' somehow the profession. 
Although Sweden, Norway and Denmark have the most tattooists/inhabitant, two more 
southern countries (Italy, Germany) and the United Kingdom account for half of the 
identified European tattooist associations (Figure 5.7). According to the membership in 
these associations, a minority of tattooists are affiliated. 
Several tattooist associations were reported also for Canada and the United States, 10 
and 13 respectively. 
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Figure 5.7: Tattooist and/or PMU professional associations per European country. 
 
5.4.3. Ink origin and manufacture  
According to both questionnaires and literature [86], the majority (70-80%) of the tattoo 
inks available on the European market are manufactured outside Europe, mainly in the 
United States. According to Michel's presentation and paper, it seems that professional 
tattoo artists would preferably use the US inks, while the non-professionals favour the 
Chinese products [86, 87].  
On the contrary, 70-80% of the PMU inks on the EU market are made in Europe. 
Germany, Italy, Spain and the United Kingdom are the main EU manufacturers of 
tattoo/PMU inks.  
While the above market trends for identifying the major producing countries are clear, 
when searching deeper for more market details, the situation becomes more confused. 
This study identified a non-exhaustive list of ink manufacturers/distributors/private 
labels based on the member states responses to the questionnaires and an internet 
search with 92 and 35 companies producing and/or distributing tattoo and PMU inks, 
respectively. The situation is complex and it was not possible to differentiate between 
manufacturers and distributors. An additional difficulty is represented by the fact that 
the same manufacturer may produce more than one brand of products and that in the 
market there are the so called "private labels", meaning that some manufacturers 
produce for other companies that put their brand name on the final products. 
 
5.4.4. Brands and labelling  
Internet data also enabled to prepare a non-exhaustive list of 72 and 22 tattoo and PMU 
ink brands, some of which can be purchased online on many different web sites. This 
study identified as many as 39 tattoo ink web suppliers. The most popular brands were 
selected on the base of the number of web sites selling those (Tables 5.6 and 5.7). 
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Table 5.6: Top tattoo ink brands sold on-line (ordered by presence in web-sites). 
 
 
Table 5.7: Top PMU ink brands sold on-line (ordered by presence in web-sites). 
 
 
The responses of the manufacturers to the questionnaires were very low probably due to 
confidentiality and competition issues. Although the mailing list counted 38 recipients, 
only 7 answered and from 2 countries, Germany and Italy.  
The few data received regarding volume, price and container type are summarised in 
Table 5.8. 
 
Table 5.8: Tattoo and PMU inks in figures. 
 
 
The list of items on the label of ink containers is similar for all respondents even if some 
do add additional items in certain cases: 
• List of ingredients (using INCI, International Nomenclature of Cosmetic 
Ingredients, CI, Colour Index, or IUPAC, International Union of Pure and Applied 
Chemistry, numbers in decreasing order of concentration); 
• Manufacturer name and address; 
• Date of minimum durability; 
• Conditions of use and warnings; 
• Batch number; 
• Guarantee of sterility of the contents. 
Suppliers Price Capacity
Nr €/ml ml
Eternal Inks 28 0.35 30, 60, 120
Intenze Tattoo Inks 22 0.35 30, 60, 90
Panthera Tattoo Inks 19 0.20 150
Kuro Sumi Tattoo Inks 16 0.15 180
Starbrite Colors Inks 14 0.35 15, 30, 60, 90
Silverback Inks 13 0.30 120
Cheyenne Inks 12 0.35 50
Dynamic Tattoo Inks 12 0.15 240
Fusion Inks 10 0.35 60
Mom’s Inks 10 0.15 15, 30
Alla Prima Inks 8 0.35 30
Sacred Color Tattoo Inks 7 0.60 15, 30
Bloodline & Skin Candy Tattoo Inks 7 0.35 30, 60
Atomic Inks 6 0.65 30
Talens Inks 6 0.10 490
Makkuro Sumi Inks 5 0.15 120, 360
Fusion Inks 4 0.70 15, 30
Electric Inks 3 0.30 30, 60
Polynesian Inks 3 0.10 200
Brand name
Brand name Suppliers Price Capacity
Nr €/ml ml
Cosmetic Partner 2 3.8 15
Pure Colours 2 3.2 15
Bella Pigment 1 2.5 15
Glam Colours 1 4.3 2, 15
Maube 1 2.6 15
Production volume 
(m3/year)
Price 
(Euro/ml) Type of container
Tattoo 2-10 0.1-0.5 Single/Multiple use
PMU 0.05-1.15 0.45-5.9 Single/Multiple use
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6. Ingredients of tattoo and PMU inks  
Tattooing consists in the injection of inks in the derma stratum of the skin. Therefore, 
tattoos and PMUs are aimed to be permanent, causing a life-long exposure to chemicals 
which entails possible adverse health effect that may be linked to their toxicity. For such 
reason, the knowledge of ink ingredients and their fate in the body, including under light 
irradiation, is extremely important. 
This chapter aims to give an overview of the ingredients currently used in tattoo and 
PMU ink formulations and to present what is known about colorants' fate. For more 
detailed information, please refer to the JRC report on Work Package 2 [2]. 
As mentioned in chapter 2, the information was collected through questionnaires, as well 
as web and literature searches. 
Tattoo and PMU inks are complex formulations containing several ingredients, both 
inorganic and organic, plus by-products and impurities. Nowadays, they are generally 
ready-to-use-products that consist in mixtures of insoluble pigments (responsible for the 
colour) in a liquid made of binder(s) and solvent(s). The suspension is stabilised by 
additives, which among other actions help slowing down the sedimentation of pigments 
and re-dispersing them quickly under slight manual shaking. In order to avoid 
microbiological contamination, favoured by the usual high content of water and organic 
substances, preservatives are often added to the mixture [88]. Besides intentional 
ingredients (colorants and additives), other substances might be present as impurities 
for example originating from their synthetic processes. The main impurities found in 
tattoo and PMU inks are primary aromatic amines (PAA), from azo-colorants, polycyclic 
aromatic hydrocarbons (PAH), mainly from black inks, and metals, from inorganic and 
organometallic pigments. 
 
6.1. Colorants  
Colorants are by far the major ingredients of tattoo and PMU inks, being present in a 
concentration that can reach almost 60% by weight. They are responsible for the ink 
colour and can be classified into two main groups, namely pigments and dyes. While 
dyes are soluble in the vehicle in which they are incorporated and fast biodegradable, 
pigments are insoluble, photo-stable and chemical resistant thus making them the 
preferred choice for tattoo and PMU applications. Dyes are scarcely used and, when this 
is the case more often in PMU than in tattoo inks, they are made insoluble by 
precipitating them onto an insoluble inorganic compound, like barium sulphate and 
aluminium hydroxide, to form a lake, more stable to both light and other chemicals.  
From the chemical point of view, pigments can be classified as organic or inorganic 
substances. Inorganic pigments show dull and not-brilliant shadows of colour and for 
these properties they are more frequently used in PMU than in tattoo inks. They are 
oxides of several elements, in particular iron, titanium and chromium.  
In comparison, organic pigments, besides being more brilliant, show higher colour 
strength when mixed with barium sulphate and titanium oxide, cover a much wider 
range of colours and are mainly used in tattoo inks. Nevertheless, organic pigments 
show the drawback of having poorer dispersibility properties which are pivotal to obtain 
a good dispersion of the pigment (insoluble) into the vehicle.  
According to the Colour Index classification made by chemical structures, the organic 
colorants identified as currently in use in tattoo and PMU products belong to the 
following classes: monoazo, diazo, xanthene, natural dyes, indigoid, anthraquinone, 
aminoketone, heterocycle, quinoline, triarylmethane, phthalocyanine, pyrrole ketone and 
oxazine.  
The survey allowed identifying (Table 6.1) 113 colorants, currently used as ingredients in 
tattoo inks, and 100 in PMU inks (in total 126 different structures). 
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Table 6.1: Overview of colorants used in tattoo and PMU inks by colour. 
 
 
 
Figure 6.1: Classification of colorants. Organic/inorganic distribution and organic chemical classes. 
colorants organic 
colorants
azo 
colorants
inorganic 
colorants colorants
organic 
colorants
azo 
colorants
inorganic 
colorants
Colour number % % % number % % %
Red 44 93 68 5 42 95 64 5
Yellow 27 93 78 7 25 96 80 4
Orange 10 100 70 0 8 100 75 0
Blue 7 71 13 29 5 60 0 40
Green 4 75 0 25 5 60 0 40
Violet 9 78 0 22 6 83 0 17
Brown 3 33 33 33 2 50 50 50
Black 6 0 0 83 4 0 0 100
White 3 0 0 100 3 0 0 100
113 100
Tattoo PMU
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Figure 6.2: Number of organic/inorganic colorants used in tattoo and PMU inks by hue. 
 
The survey pointed out that organic colorants nowadays represent the large majority of 
the pigments in use. The situation about 20-30 years ago was the opposite. It also 
highlights the fact that inorganic pigments linked to negative health effects, such as 
cadmium or mercury sulphide, are no more employed. They have been mainly 
substituted by synthetic colorants. Our results are in line with what reported by Bäumler 
et al. in 2003 [89]. 
In details, Table 6.1 summarises the percentages of organic, azo and inorganic 
colorants, divided by colours, used in tattoo and PMU products, respectively. As shown 
also in Figure 6.1, the large majority consists of organic colorants (92 and 84 
corresponding to 81% and 84% for tattoo and PMU respectively). Among the organic 
colorants, the chemical class of azo pigments is the most represented (60 and 54, 
corresponding to 65% and 64% of the organic class and 53% and 54% of all colorants). 
It is worth noticing that for three colorants used in tattoo inks (pigment red 340, 
pigment brown 175 and pigment black 2) it was not possible to gather information on 
the chemical structure, therefore they were classified neither as inorganic nor as organic. 
Figure 6.1 provides also information about the frequency of organic classes. Organic 
pigments are dominated by azo colorants, followed by anthraquinone, phthalocyanine, 
indigoid, xanthene and aminoketone classes. 
Figure 6.2 shows the prevalence of identified organic/inorganic colorants (expressed as 
number of colorants) for each hue of tattoo and PMU inks. The pigments used for black 
and white hues are all inorganic, whereas the orange ones are all organic. 
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Although none of the colorants in use is classified as carcinogenic, mutagenic or 
reprotoxic (CMR) substance under the EC Regulation 1272/2008 on Classification, 
Labelling and Packaging (CLP), 18% and 21% of the colorants used respectively in tattoo 
and PMU inks are actually included in some negative lists mentioned in the CoE 
ResAP(2008)1. An overview of the aforementioned colorants, with the reference to the 
list where they are included, is given in Table 6.2. 
The following pigments are only listed in Annex II of the cosmetic regulation for their use 
in hair colorants (HC): solvent red 1, pigments red 4, 5, 48:1 and 63:1, pigment yellow 
12 and pigment blue 15. However, it is important to note that according to industry 
there is no better alternative to pigment blue 15. 
 
Table 6.2: List of colorants in use included in some negative lists mentioned in the CoE ResAP(2008)1. 
 
 
In addition, it is worth mentioning that only just above 30% of the colorants used in 
tattoo and PMU inks are authorised in cosmetic products without any restriction. 
An important problem highlighted by several authors [90-93] and stakeholders is that 
the pigments used in the formulation of tattoo and PMU inks are not produced for such 
purpose and do not undergo any risk assessment that takes into account their injection 
into the human body for long term permanence. They are usually produced by the 
Colour Index 
Generic Name Chemical class Tattoo(T)/PMU(P) Negative lists
BR 1 xanthene T/P CoEResAP(2008)1 Table 2
SR 1 monoazo P Cosmetics, Annex II  in HC
PR 3 monoazo T/P Cosmetics, column g Annex IV (only rinse-off)
PR 4 monoazo T/P Cosmetics, Annex II  in HC; permitted in Annex IV
PR 5 monoazo T/P Cosmetics, Annex II  in HC; permitted in Annex IV
PR 7 monoazo P Cosmetics, column g Annex IV (only for rinse-off)
PR 48:1 monoazo T Cosmetics, Annex II  in HC
PR 53:1 monoazo T/P CoEResAP(2008)1 Table 2 & Cosmetics, Annex II
PR 63:1 monoazo T/P Cosmetics, Annex II  in HC; permitted in Annex IV
PR 112 monoazo T/P Cosmetics, Annex II  in HC & column g Annex IV (only 
rinse-off)
PR 122 indigoid T/P Cosmetics, column g Annex IV (only rinse-off)
PY 1 monoazo T/P Cosmetics, column g Annex IV (no on mucous 
membranes)
PY 3 monoazo T/P  Cosmetics, column g Annex IV (no on mucous 
membranes)
PY 12 diazo T/P Cosmetics, Annex II  in HC
PY 83 diazo T/P Cosmetics, column g Annex IV (only rinse-off)
PB 15 phthalocyanine T/P Cosmetics, Annex II  in HC; permitted in Annex IV
DB 86 phthalocyanine T Annex II  in HC &  Annex IV (only rinse-off)
BV 10 xanthene T/P CoEResAP(2008)1 Table 2 & Cosmetics, Annex II
PV 19 indigoid T/P Cosmetics, Annex II  in HC &  column g Annex IV (only 
rinse-off)
PV 23 oxazine T/P Cosmetics, Annex II  in HC &  column g Annex IV (only 
rinse-off)
PO 5 monoazo T/P CoEResAP(2008)1 Table 2 & Cosmetics, Annex II
PO 43 anthraquinone T/P Cosmetics, column g  Annex IV (no on mucous 
membranes)
PG 7 phthalocyanine T/P Cosmetics, Annex II  in HC &  column g Annex IV (no in 
eye prods)
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chemical industry for outdoor applications in products like textiles, cars and plastics, 
because they show good light fastness properties. Pigment producers do not state that 
their colorants can be used in tattoo and PMU products, even if this happen, and they 
are reluctant to take responsibility. In certain cases they refuse to sell their products to 
ink manufacturers when they know they are going to be used for manufacturing tattoo 
inks.  
The fact that pigments are produced as technical products for different purposes poses 
the problem of their purity which has been reported to range between 70 and maximum 
90% (depending on the source). They may contain harmful impurities and by-products 
such as: chromium VI in chromium oxides; nickel, chromium, copper and cobalt in iron 
oxides; aromatic amines in azo-colorants; and polycyclic aromatic hydrocarbons in 
carbon black. 
Concerning the size of pigment particles, nanoparticles (NPs) can indeed be utilised to 
manufacture modern tattoo inks of high-quality and desired behaviour (e.g., 
brilliantness, fluorescence, persistence, photo stability) [94]. In a 2000 study on 41 
tattoo inks, 16 different synthetic colorants were determined and TiO2 was found as 
lightener, both in anatase and rutile form; the crystal size varied in the range 20 - 900 
nanometres [95]. In 2011, NPs were actually found in tattoo inks, with black pigments 
containing the smallest particles (< 100 nm), white pigments having the largest particles 
and coloured pigments (green, blue, red and yellow) in between [96]. In 2015, NPs of 
tattoo inks were observed in human skin tissue, as well as on dermal fibroblasts in vitro, 
and analysed by atomic force microscopy [97, 98]. Recently, some authors have 
reported that tattoo inks contained metal-based NPs [99, 100]. Black colours contained 
the smallest particles (< 100 nm), mainly constituted of carbon black. Coloured tattoo 
inks (violet, blue and green) contained aluminium (Al) and titanium (Ti) in the form of 
TiO2 as micron and submicron sized particles and aggregates. On the contrary, copper 
(Cu) was almost exclusively found (ca. 90%) in the form of NPs (< 100 nm) in blue, 
green and black pigments. 
The presence of NPs in tattoo inks requires an accurate assessment of their interaction 
with the human skin, as well as an investigation to understand if they can penetrate the 
derma reaching the bloodstream. 
 
6.2. Ingredients other than colorants  
Additives such as surfactants, thickening agents and preservatives are used in tattoo 
inks and PMUs, in concentrations generally lower than 5% by weight, to modify certain 
characteristics, stabilise the dispersion and avoid the growth of microorganisms in the 
product after opening.  
Auxiliaries include a variety of compounds, among which:  
• surfactants, employed to adjust surface tension, helping better dispersion and 
stabilisation of pigments; 
• thixotropic agents (e.g. silica), which inhibit the sedimentation of pigment 
dispersions during long storage time; 
• binding agents (e.g. polyethers, polyvinylpyrrolidone, block copolymer and 
Shellac) which are non-volatile high molecular mass compounds, whose function 
is to bind pigment particles both to each other and to the tattooing needle with 
the aim to make easier the injection of tattoo and PMU ink in the skin; 
• fillers, usually inorganic substances (e.g. silica and barium sulphate), which 
influence dispersibility properties helping better re-dispersion of pigments after 
long storage. Barium sulphate is used in the flocculation of organic pigments to 
optimise their dispersibility [94]. 
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Preservatives ensure the preservation of the product after opening and were found in 
concentration up to 1.5% by weight. 
Alcohols, for instance ethanol and isopropyl alcohol, can be used to modify the drying 
properties, viscosity and dispersibility of inks. Glycerine can be added as ingredients as it 
acts as humectant and helps increasing viscosity, while propylene glycol can be used as 
humectant and to increase dispersibility. Their concentration can reach up to 30% by 
weight. 
Finally, water is the main solvent in use, able to solubilise and solvate binder(s).  
The information collected allowed identifying a list of 100 auxiliaries and 48 
preservatives. 99 and 70 auxiliaries and 47 and 30 preservatives were reported to be 
used in tattoo and PMU inks, respectively.  
 
6.3. Fate of colorants  
As already mentioned, the large majority of the organic colorants used in tattoo and PMU 
formulations belong to the chemical class of azo pigments. The fate of these compounds 
is discussed hereafter. 
It is know from the literature that free azo dyes may undergo metabolic reductive 
cleavage into aromatic amines upon oral intake either in lumen of the gastric tract or in 
the liver after uptake from the intestine. According to Platzek T. et al. [101], such 
cleavage may occur even on the skin due to influence of the skin bacteria. 
Cui Y. et al. [102] showed that pigments could be metabolised in vitro by expressing 
cytochromes together with rat and human microsomal proteins. In addition, both in-vivo 
and in-vitro studies proved that the reductive cleavage of azo pigments into aromatic 
amines can also be triggered by solar, UV or laser irradiation, the latter being the 
preferred technique for tattoo removal [12, 26, 91, 103-108]. 
In total 31 out of the 67 azo colorants in use in tattoo and PMU products, corresponding 
to 46%, contain and might release, by simple reductive cleavage of the azo bond, one of 
the amines included in the negative lists cited in the CoE ResAP(2008)1, including Annex 
II of the cosmetic regulation and Table 3.1 of the CLP regulation. Figure 6.3 reports the 
example of solvent red 1. 
 
Figure 6.3: Possible decomposition pathway of Solvent Red 1. 
 
The scenario is further complicated by the fact that some of them may form aromatic 
amines included in the negative lists cited in the CoE ResAP(2008)1 also by cleavage of a 
different type of bond (e.g amide bond) [12, 26, 91, 103-108]. Therefore, it would be 
extremely important to take the full decomposition pathway, also under irradiation, in 
consideration when carrying out the risk assessment of a colorant for tattoo and PMU 
applications. One example of secondary reaction that leads to the formation aromatic 
amine classified as CMR is reported in Figure 6.4. 
o-Anisidine
Carc 1B
Muta 2
Solvent Red 1
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Figure 6.4: Possible decomposition pathway of Pigment Red 112. 
 
When amide hydrolysis and simple reductive cleavage are taken into account all 
together, the number of azo-colorants that could potentially lead to the formation of one 
of the amines included in the negative lists cited in the CoE ResAP (2008)1 rises up to 
44, corresponding to 66% of the 67 azo colorants in use (including tattoo and PMU). 
Table 6.3 contains the list of azo pigments in use that, theoretically, might release 
unsafe amines through one of the reaction mentioned above. 
 
Table 6.3: List of azo-colorants in use that might potentially lead to unsafe amines by decomposition. 
 
PIGMENT RED 112
o-Toluidine (95-53-4)
Carc 1B
Table 1
Annex II
Cleavage of azo bond Amide hydrolysis
PR 2 halogenated derivative of aniline (Annex II, 
ref 22)
62-53-3, aniline (Annex II ref 22, 
Table 3.1)
PR 7 95-69-2, 4-Cl-o-toluidine (Table 1, Annex II 
ref 32, Table 3.1)
95-69-2, 4-Cl-o-toluidine (Table 1, 
Annex II ref 32, Table 3.1)
PR 9 halogenated derivative of aniline (Annex II, 
ref 22)
90-04-0, o-anisidine (Table 1, 
Annex II ref 708, Table 3.1)
PR 12 95-53-4, o-toluidine (Table 1, Annex II ref 32, Table 3.1) 
PR 14 95-53-4, o-toluidine (Table 1, Annex II ref 32, Table 3.1) 
PR 15 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PR 17 99-55-8, 5-nitro-o-toluidine (Table 1, Annex II ref 1195, Table 3.1)
95-53-4, o-toluidine (Table 1, 
Annex II ref 32, Table 3.1) 
PR 22 99-55-8, 5-nitro-o-toluidine (Table 1, Annex II ref 1195, Table 3.1)
62-53-3, aniline (Annex II ref 22, 
Table 3.1)
PR 48:1 sulphonated and halogenated derivative of toluidine (Annex II, ref 32)
PR 51 sulphonated derivative of toluidine (Annex II, ref 32)
PR 53:1 sulphonated and halogenated derivative of toluidine (Annex II, ref 32)
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Cleavage of azo bond Amide hydrolysis
PR 57:1 sulphonated derivative of toluidine (Annex II, ref 32)
PR 57:2 sulphonated derivative of toluidine (Annex II, ref 32)
DR 53 92-87-5, benzidine (Table 1, Annex II ref 26, Table 3.1) 
PR 112 halogenated derivative of aniline (Annex II, 
ref 22)
95-53-4, o-toluidine (Table 1, 
Annex II ref 32, Table 3.1) 
PR 146 62-53-3, aniline (Annex II ref 22, table 3.1)
PR 210 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PR 222 106-50-3, p-phenilendiamine (Table 1, Table 3.1)
PR 269 62-53-3, aniline (Annex II ref 22, table 3.1)
SR 1 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PO 13 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
PO 16 119-90-4, 3,3'-dimethossibenzidine (Table 1, Annex II ref 709, Table 3.1) 
62-53-3, aniline (Annex II ref 22, 
table 3.1)
PO 22 halogenated derivative of aniline (Annex II, 
ref 22)
PO 34 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
PO 74 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
AY 9 sulphonated derivative of aniline (Annex II, 
ref 22)
AY 23 sulphonated derivative of aniline (Annex II, 
ref 22)
AY 104 sulphonated derivative of aniline (Annex II, 
ref 22)
Diarylide     
Y
91-94-1, 3,3'-dichlorobenzidine (Table 1, 
Annex II ref 712, Table 3.1) 
FY 3 sulphonated derivative of aniline (Annex II, 
ref 22)
PY 1 62-53-3, aniline (Annex II ref 22, table 3.1)
PY 12 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
62-53-3, aniline (Annex II ref 22, 
table 3.1)
PY 14 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
95-53-4, o-toluidine (Table 1, 
Annex II ref 32, Table 3.1) 
PY 55 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
95-53-4, p-toluidine (Annex II ref 
32, Table 3.1) 
PY 65 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PY 74 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PY 83 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
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It has been proved that the initial quantity of pigment injected in human skin during 
tattooing processes decreases over time [106, 109]. Several mechanisms, such as 
bleeding, dispersion in the skin, phagocytosis, metabolism, transportation through the 
lymphatic or blood vessel systems and photodecomposition, have been suggested to 
explain these findings [102, 110]. So far, pigment particles have been found in 
macrophages, in the cytoplasm of cells in secondary lysosomes and in lymph nodes 
[111-120]. Moreover, it has to be considered that, once the degradation occurs, the 
increased solubility of the aromatic amines thus formed makes the transportation into 
the body fluids more likely.  
Finally, it should not be neglected that not only colorants but also impurities, by-
products and additives could be transported away from the skin. In this view, the fate of 
toxic substances, such as polycyclic aromatic hydrocarbons, primary aromatic amines 
and heavy metals is a concern. Lehner [115] reports that PAHs (originally present in 
black inks) remain partially in skin or can be found in the regional lymph nodes. 
A further point to consider is the probable production of reactive oxygen species (ROS) 
from inks components and impurities in the presence of (sun) light. In particular if 
tattooed skin is exposed to UV radiation, some PAHs might generate singlet oxygen 
[121]. 
Høgsberg [122] proved that, in the absence of light, aggregation of tattoo pigment 
particles correlates with ROS production, independently of chemical composition 
including PAHs.  
Cellular lipids and proteins could be oxidised by ROS and thus their functions might be 
compromised up to the point of causing in tattooed parts of the body adverse effects like 
sensation of pain, itching and discomfort [121-123]. 
Notwithstanding the formation of ROS can be diminished by the use of physical barriers 
to light, by sunscreen application on tattoos and by the intake of antioxidants [123]. 
  
Cleavage of azo bond Amide hydrolysis
PY 87 91-94-1, 3,3'-dichlorobenzidine (Table 1, Annex II ref 712, Table 3.1) 
PY 93 halogenated derivative of toluidine (Annex II, ref 32)
PY 97
62-53-3, aniline (Annex II ref 22, 
table 3.1)-from sulphonamide 
hydrolysis
PY 100 sulphonated derivative of aniline (Annex II, 
ref 22)
PY 194 90-04-0, o-anisidine (Table 1, Annex II ref 708, Table 3.1)
PB 25 119-90-4, 3,3'-dimethossibenzidine (Table 1, Annex II ref 709, Table 3.1) 
62-53-3, aniline (Annex II ref 22, 
table 3.1)
PBr 25 halogenated derivative of aniline (Annex II, 
ref 22)
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7. Analytical methods  
The CoE ResAP(2008)1 includes some negative lists of dangerous chemicals that should 
not be present or should not exceed a certain recommended concentration in tattoo and 
PMU inks: 
• Table 1 (27 aromatic amines); 
• Table 2 (35 colorants); 
• Table 3 (suggested maximum concentration for 15 impurities). 
The resolution also recommends adopting additional negative lists available in various EU 
legislations: 
• Annexes II and IV (only colorants with restrictions in column g) of the Cosmetics 
Regulation [39]; 
• substances classified as carcinogenic, mutagenic and reprotoxic (CMR) categories 
1A, 1B and 2, in Annex VI, Table 3.1 of the CLP Regulation [40]. 
In addition, the minimum requirements for further organic impurities for colorants used 
in foodstuffs, as specified by the Directive 95/45/EEC [41], should be respected. 
The purpose of this chapter is to present the available analytical methods that can be 
used, as such or after modifications, for detecting the presence of these hazardous 
chemicals in tattoo/PMU products. 
Particular attention was devoted to the test methods to determine aromatic amines, 
colorants, elements and polycyclic aromatic hydrocarbons (PAHs). Some of those 
substances are in Tables 1-3 of the CoE ResAP(2008)1, as well as in the other negative 
lists mentioned in the ResAP. More details about test methods and the complete 
inventory of the substances belonging to the before mentioned classes, which should not 
be present in tattoo/PMU inks, can be found in the JRC report on Work Package 1 [1]. It 
has to be noted, however, that the document does not have any legal value. 
Phthalates and nitrosamines were also considered to some extent, as they were found in 
tattoo and PMU products and some of them are CMRs and are listed in Annex II of the 
cosmetic regulation [12, 122, 124]. 
Data on available methods were collected through a questionnaire that was specifically 
aimed to gather information on the following issues and via a web search of standard 
methods in the ISO (International Organization for Standardization) and CEN (European 
Committee for Standardization) catalogues: 
1. international standard methods (harmonised at ISO and/or CEN level); 
2. national standard methods (harmonised at national level, e.g. in Germany by 
DIN); 
3. in-house validated methods (developed and validated in Member States' 
laboratories, not harmonised neither at national nor at international level); 
4. analytical methods described in the literature.  
As no standard test methods are available for the analysis of tattoo and PMU inks, 
analytical methods applicable to similar matrices, for instance cosmetics, food, textiles, 
toys and environment, were taken into consideration. With an adaptation of the sample 
preparation procedure these methods could be applied to tattoo and PMU products. 
To complete the investigation, some analytical methods described in the literature were 
also collected. 
A short description of all the identified test methods, including information about scope 
and field of application, principle, description of test method, type of instrumental 
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analysis, repeatability (r) and reproducibility (R), limit of detection (LOD) and limit of 
quantification (LOQ) was reported in the JRC report on Work Package 1 [1].  
For each chemical class taken into consideration, Table 7.1 reports the current 
availability of analytical methods. 
 
Table 7.1. Availability of analytical methods for the chemical classes of concern. 
 
 
Primary Aromatic Amines (PAA): The presence of PAA in tattoo/PMU inks is linked to 
the use of azo pigments. PAA represent either impurities of these colorants ("free 
aromatic amines") or degradation products of them (in this case they are released 
through a mechanism called "reductive cleavage"). According to Table 1 of the CoE 
ResAP(2008)1, 27 aromatic amines should neither be present nor released from azo 
colorants in tattoo and PMU products; 25 of them are classified as CMR in categories 1A, 
1B or 2 and 19 are listed in Annex II of the cosmetic Regulation. 
No specific limit value is established for their content; nevertheless the resolution states 
that they should not exceed the concentration defined as "technically avoidable" when 
operating according to Good Manufacturing Practices. The same resolution states that 
"these aromatic amines should be determined by using appropriate test methods which 
should be harmonised across the Member States in order to ensure comparable health 
protection of the consumers and to avoid divergent enforcement, drawing on existing 
methods which can serve as models". Two analytical methods, which can serve as 
models for harmonising test methods, are proposed and summarised in the document. 
They are the adjustment of two existing international standard methods (EN 71-7:2002 
and EN 14362-1) for the determination of aromatic amines in toys and textiles. Both of 
them entail the chromatographic (either GC-MS or LC-MS) analysis of the primary 
aromatic amines after a reductive approach that allows quantifying the sum of free and 
releasable aromatic amines. It is worth mentioning that EN 71-7:2002 reports also the 
conditions to be applied for the determination of just the free aromatic amines 
(impurities). 
Colorants: Among the 35 colorants in the negative list (Table 2) of the CoE 
ResAP(2008)1, 7 are CMRs in categories 1A, 1B or 2, 13 are listed in Annex II of the 
cosmetic regulation and none of them is allowed to be used in cosmetics as they are not 
listed in Annex IV to the same regulation. The pigments in Table 2 belong to the 
following chemical classes of colorants: azo (16), triarylmethane (11), antraquinone (4), 
xanthene (3) and nitro (1). 
In the resolution, no limit values are set and no analytical methods are proposed for the 
determination of their content. 
Impurities: The impurities reported in Table 3 of the CoE ResAP(2008)1 include 13 
elements (As, Ba, Cd, Co, Cr, Cu, Hg, Ni, Pb, Se, Sb, Sn, and Zn), mainly originating 
from inorganic pigments, the chemical class of polycyclic aromatic hydrocarbons (PAHs) 
and benzo[a]pyrene (one of the most toxic PAH), which can be found in tattoo inks 
based on carbon black. 
Concerning elements, cadmium, mercury and nickel are of particular concern as they are 
classified CMRs in categories 1A, 1B or 2. Moreover, arsenic, cadmium, chromium, 
Chemical 
class
International 
standard methods 
on different 
matrices
International 
standard methods 
adapted for 
tattoo/PMU matrix
National standard 
methods on 
different matrices
National standard 
methods adapted for 
tattoo/PMU matrix
In-house 
validated 
methods
Methods 
described in 
literature
PAAs x x x x x
Colorants x x x
PAHs x x x x
Heavy metals x x x x x
Phthalates x x
Nitrosamines x x x
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mercury, nickel, lead and selenium are also in the negative list of the cosmetic 
regulation (Annex II). The Resolution states that the presence of chromium (VI) and 
nickel should be clearly indicated on the package together with a warning, as they can 
cause allergic reactions.  
Analogously, benzo[a]pyrene and the PAHs mentioned in parenthesis 
(dibenzo[a,h]anthracene, benzo[a]anthracene, benzo[e]pyrene, benzo[j]fluoranthene, 
benzo(e)acephenanthrylene, benzo(k)fluoranthene and chrysene) are CMRs and are 
listed in Annex II of the cosmetic regulation too. 
Contrary to aromatic amines and colorants, maximum recommended concentration 
values are indicated for the content of impurities. However, no methods are proposed in 
the resolution for their identification and quantification in tattoo and PMU inks.  
Nickel is often found when inorganic pigments based on iron oxides are used as 
pigments. Its concentration shall be as low as technically achievable. This requirement 
may originate problems when implemented, as the test results obtained by the analysis 
of products cannot be compared to a numerical value to decide if the products are or not 
compliant. As a consequence, various actors could interpret differently the same 
analytical results. For such reason, it would be recommendable to establish a limit value 
for nickel. 
Chromium (VI) impurities may be found in inorganic pigments based on chromium 
oxides. The recommended limit of 0.2 ppm (parts per million, mg/kg) applies to 
chromium (VI) and not to its total content. This means that the analytical methods shall 
allow the speciation of chromium and the separation of chromium (VI) and (III).  
25 ppm is the limit recommended for soluble copper. The Resolution prescribes that 
soluble copper should be determined after extraction to an aqueous solution with pH 5.5. 
Various phthalocyanines (organic pigments of green or blue colour) contain copper in 
their structure, however this copper is linked and not soluble under the experimental 
conditions just mentioned for the extraction of soluble copper. 
For the other elements the limits apply to their total content and are: 50 ppm for 
barium, tin and zinc; 25 ppm for cobalt; 2 ppm for arsenic, lead, selenium and 
antimony; 0.2 ppm for mercury and cadmium. 
PAHs can be found as impurities in black tattoo and PMU inks, in particular carbon black, 
depending on the production processes. The limit of 0.5 ppm applies to the sum of the 
PAHs found in tattoo and PMU products; only benzo[a]pyrene has an individual limit 
equal to 5 ppb (parts per billion, µg/kg). 
 
7.1. International standard methods  
As anticipated, neither ISO nor EN standard methods are available specifically for the 
analysis of aromatic amines, colorants, elements, polycyclic aromatic hydrocarbons, 
phthalates and nitrosamines in tattoo and PMU inks. However, some international 
standard methods for aromatic amines and elements, developed for other matrices, have 
been adapted by some Member States. Table 7.2 shows the complete list of available 
international standard methods with the indication of those adapted to the analysis of 
tattoo and PMU products. 
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Table 7.2: List of available international standard methods by chemical classes. 
 
Field of 
application Analytical technique(s)
Adapted to the 
analysis of tattoo inks
EN 71-11:2005 Toys GC-MS
EN ISO 17234-1:2010 Leather GC-MS Italy
EN ISO 17234-2:2011 Leather HPLC-DAD; HPLC/DAD/MS; CE/DAD; TLC;  HPTLC Italy
EN 14362-1:2012 
(corresponding to ISO 
24362-1:2014)
Textiles HPTLC; HPLC-DAD or HPLC-MS; GC-FID or GC-MS; CE-DAD Slovenia and Sweden
EN 14362-3:2012 
(corresponding to ISO 
24362-3:2014)
Textiles GC-MS; HPLC-DAD Slovenia and Sweden
EN 71-7:2014 Toys GC-MS; HPLC-DAD
EN 71-7:2014 Toys GC-MS
CEN/TS 16621:2014 Food  HPLC-FD
EN 71-11:2005 Toys HPLC-DAD; HPLC-MS
EN ISO 16373-2:2014 Textiles HPLC-DAD; HPLC-MS
EN ISO 16373-3:2014 Textiles HPLC-DAD; HPLC-MS
EN 16521:2014 Cosmetics  GC/MS
EN ISO 14389:2014 Textiles GC/MS
ISO 8124-6:2014 Toys
ISO 10130:2009 Cosmetics  HPLC
EN 71-12:2013 Toys  HPLC-MS/MS
ISO 15819:2014 Cosmetics  HPLC-MS-MS
EN 13806:2002 Food CVAAS (Hg) Germany
EN 14082:2003 Food AAS
EN 14083:2003 Food GFAAS (Pb, Cd, Cr, Mo) Germany
EN 14084:2003 Food AAS
EN ISO 17294-2:2003 Water ICP-MS Austria and Sweden
EN 14332:2004 Food GFAAS
EN 14546:2005 Food HGAAS
EN 14627:2005 Food HGAAS
EN 15111:2007 Food ICP-MS
EN ISO 5398-1:2007 Leather Titration
EN ISO 5398-3:2007 Leather AAS
EN ISO 5398-4:2007 Leather ICP-OES
EN ISO 11885:2007 Water ICP-OES (Total metal content) Sweden
EN ISO 17075:2007 Leather
EN 15517:2008 Food HGAAS
EN 15505:2008 Food AAS
EN ISO 5398-2:2009 Leather Colorimetry
EN 15763:2009 Food ICP-MS (As, Cd, Hg, Pb) Austria
EN 15764:2009 Food FAAS; GFAAS
EN 15765:2009 Food ICP-MS
EN ISO 17072-1:2011 Leather
ICP; AAS; SFA (All metals 
extractable in an acidic perspiration 
solution)
Italy
EN ISO 17072-2:2011 Leather ICP; AAS; SFA (Total metal content) Italy
EN ISO 12846:2012 Water AAS (Hg)
ISO/TR 17276:2014 Cosmetics
EN 71-
3:2013+A1:2014 (see 
also ISO 8124-3:2010)
Toys  ICP-MS; ICP-OES; CVAAS; GC-MS (General elements, Cr (III and VI), Sn)
EN 13805:2014 Food
EPA 3051A (and EPA 
3051) Environment
FLAAS, GFAA, ICP-AES, ICP-MS 
(Total metal content) Italy
EPA 3052 Environment FLAA, CVAA, GFAA, ICP-AES, ICP-MS (Total metal content) Italy
EPA 3060A Environment
Ion Chromatography with ICP-MS 
detection; HPLC-ICP-MS; CE-ICP-
MS (Cr(VI))
Italy
EPA 218.7 Environment Ion chromatography (Cr(VI)) Italy
AROMATIC AMINES
PAH
COLORANTS
PHTALATES
NITROSAMINES
INORGANIC IMPURITIES
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Aromatic amines 
Test methods for aromatic amines can quantify the sum of free and releasable aromatic 
amines. These two types of aromatic amines show different hazard scenarios: the 
aromatic amines released from azo-colorants, assuming only a partial conversion, could 
produce a potential low level of chronic contamination; whereas the free aromatic 
amines are immediately available and could potentially cause high single dose exposure. 
Furthermore, there is strong evidence of photo degradation of pigments into aromatic 
amines under solar, UV and laser exposure. Therefore, it would be important to have a 
method able to discriminate between the two types of aromatic amines. However, a 
single analysis cannot provide information on the different scenarios and in order to 
evaluate the concentration of free aromatic amines a second analysis with a different 
test method, without the reductive cleavage, is needed. 
The standard methods available show poor reproducibility and may provide both false 
negative and positive results. In fact, they were developed to quantify aromatic amines 
released from soluble azo-dyes and, when they are applied to insoluble pigments, only a 
small fraction of them, very much dependent on the experimental conditions of the test 
methods, are transformed into the original reagents (aromatic amines). Hauri (P2015) 
proved that only about 4% of the initial amount of pigment yellow 14 and orange 13 is 
transformed into aromatic amines using EN ISO 14362-1 and EN ISO 17234-1 modified, 
e.g. by adding dimethylformamide, to increase the solubility of pigments. The same 
author proved that pigments considered compliant when analysed with EN ISO 14362-1, 
actually resulted non-compliant when analysed with three different improved protocols of 
this test method. 
The listed standard methods could also provide false positives. In fact, as reported by 
Hauri H. [91], when pigments like pigments yellow 65 and 74 are analysed using EN ISO 
14362-1 and EN ISO 17234-1, results show the presence of o-anisidine deriving from 
the cleavage of the amide and not the azo bond. These test methods may also produce 
the reduction of nitro groups to amino groups. 
Elements 
The majority of the listed methods are useful to determine the total content of elements. 
Italy exploits a modified version of EN ISO 17072-1 to determine the soluble part of 
copper and EN ISO 17072-2, EPA 3051A and EPA 3052, which are based on microwave 
digestion of samples, for the determination of the total content of elements. EPA 3060A 
and EPA 218.7 are used for the determination of chromium VI. In Germany, modified 
versions of the standard methods EN 13806 and EN 14083 developed for foodstuffs, to 
analyse mercury and other elements, respectively, are used for tattoo and PMU inks. A 
German official method for cosmetic products (§ 64 LFGB K 84.00-29) is applied for the 
extraction and microwave digestion of tattoo or PMU samples. Austrian experts make use 
of EN 15763, Austrians and Slovenians use EN ISO 17294-2 and Swedish apply EN ISO 
11885. 
 
7.2. National standard methods 
There are very few national standard methods for the analysis of aromatic amines, 
elements and polycyclic aromatic hydrocarbons (see Table 7.3). None of them was 
validated for tattoo and PMU products. They are applicable to textiles, water and 
polymer samples. In principle, they could serve as a model to develop specific methods 
for tattoo and PMU products.  
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Table 7.3: List of available national standard methods by chemical classes. 
 
 
7.3. In-house validated methods 
Table 7.4 lists all the available in-house test methods, validated either for the analysis of 
tattoo and PMU inks or for other matrices. 
 
Table 7.4: List of available in-house validated methods by chemical classes. 
 
Country Field of application Analytical technique(s)
Sweden                          
(64§ LFGB 82-02-2 ) Textiles
HPTLC; HPLC/DAD or HPLC/MS; 
GC/FID or GC/MS; CE/DAD
Sweden                       
(ZEK 01.2-08 then ZEK 
01.4-08)
Consumer products GC/MS
Austria K 84.00-29 (nach 
§ 64 LFGB) Cosmetics Pb, Cd, Hg
Germany                       
(DIN EN ISO 11885) Water ICP/OES (Total metal content)
Germany (DIN EN 1483 
superseded by DIN EN 
ISO 12846:2012)
Water AAS (Hg)
Germany  (K 84.00-29 
nach § 64 LFGB) Cosmetics
AROMATIC AMINES
PAH
INORGANIC IMPURITIES
Country Field of application Analytical technique(s)
United Kingdom Environment  HPLC
Austria Food  HPLC/MS/MS
France Dyes, cosmetics, finger paints and inks for pens and tattoos  HPLC/MS
Switzerland Tattoo inks HPLC/MS/MS 
Switzerland Tattoo inks HPLC/MS/MS
Slovenia Tattoo inks HPLC
The Netherlands Tattoo/PMU ink, and textile GC/MS 
Denmark Tattoo inks GC/MS 
Denmark Tattoo inks GC/MS 
Switzerland Tattoo inks HPLC/UV/FLD
The Netherlands Tattoo inks GC/MS 
Italy Tattoo inks  GC/MS
Switzerland Tattoo inks  MALDI/TOF  
Switzerland Tattoo inks Colorimetry
Sweden Cosmetics  HPLC/MS
Slovakia
Austria Cosmetics  GC/MS 
Slovakia Cosmetics HPLC/DAD 
Switzerland Cosmetics, finger paints and tattoo inks HPLC/MS/MS 
France ICP/MS
Slovenia Tattoo inks ICP/MS (Total metal content)
The Netherlands Tattoo inks ICP/MS 
Denmark Tattoo inks ICP/MS  
Slovakia Cosmetics and food GFAAS (Cd, Pb, Ni)
Slovakia Cosmetics and food AAS/AMA (Hg)
Slovakia Cosmetics and food Hg, Zn, Cu, Cr (VI), Co, Sb
Italy Cosmetics ICP/MS (Cd, Co, Cr, Ni, Pb)
NITROSAMINES
INORGANIC IMPURITIES
AROMATIC AMINES
PAH
COLORANTS
PHTALATES
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Aromatic amines 
Among all the available in-house validated test methods, two of them (France and 
Denmark) are suitable for the quantification of the free aromatic amines present as 
impurities. All the other methods are based on the reductive cleavage of the azo bond of 
colorants and can therefore quantify the sum of the free and releasable aromatic amines.  
It is worth noticing that the British and Austrian methods were in-house validated in air 
and food. 
Colorants 
Switzerland reported two in-house validated analytical methods for the analysis of 
colorants in tattoo and PMU inks. One using an expensive and not widely available high 
resolution mass spectrometer, the Matrix-Assisted Laser Desorption/Ionization Time Of 
Flight (MALDI/TOF) and a second method, based on simple colorimetric detection, which 
can identify, when used as main ingredients, several hazardous colorants, such as 
pigments violet 19 and 23, pigment red 122, pigment blue 15 and pigment green 7, and 
some possible replacements, like pigment red 202 and pigment green 36. 
Methods were developed by Sweden and Slovakia for the identification of colorants in 
matrices other than tattoo and PMU inks. 
Elements 
Out of 8 analytical methods, 3 were specifically validated for tattoo and PMU products. 
Namely they are Slovenian, Danish and Dutch methods. They require the sample 
digestion in microwave oven in the presence of strong acids or acids and hydrogen 
peroxide mixtures and allow the determination of the total content of elements. They all 
use Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the instrumental 
analysis. 
Other methods have been in-house validated in other countries on matrices other than 
tattoo and PMU inks (mainly food contact materials and cosmetics). 
Polycyclic aromatic hydrocarbons 
Three in-house validated methods are available for the analysis of PAH in tattoo and PMU 
products.  
PAHs are extracted from the tattoo inks either with benzene/acetone mixture in 
ultrasonic bath, or with toluene in pressurised microwave oven or with toluene/acetone 
mixture. The quantification is carried out either with gas chromatography coupled with 
Mass Spectrometer detector or with high performance liquid chromatography coupled 
with UV or fluorescence detector (FLD). 
Nitrosamines 
One in-house validated method, proposed by Switzerland, is available for the 
determination of N-nitrosamines by Liquid Chromatography with tandem Mass 
Spectrometry (LC/MS/MS). 
Phthalates 
No analytical methods were in-house validated for tattoo and PMU products. They are 
applicable to cosmetics and could be, in principle, adapted to tattoo and PMU inks. 
 
7.4. Methods described in the literature 
A non-exhaustive list of test methods published in the literature and used for the 
analysis of aromatic amines, colorants, elements and PAHs in tattoo and PMU inks and 
other products is presented hereafter (Table 7.5).  
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Table 7.5: List of analytical methods available in the literature by chemical classes. 
 
Author Title Applied to tattoo/ PMU inks
AROMATIC AMINES
2012, Margraf Determination and Quantification of Primary Aromatic Amine in Printer Inks 
2012, The Danish 
EPA
Chemical Substances in Tattoo Ink Survey of chemical 
substances in consumer products X
2005, Mortensen
Specific determination of 20 primary aromatic amines (PAA) in 
aqueous food simulants by liquid chromatography-electrospray 
ionization-tandem mass spectrometry
PAH
2012, The Danish 
EPA
Chemical Substances in Tattoo Ink Survey of chemical 
substances in consumer products X
2010, Regensburger Tattoo inks contain polycyclic aromatic hydrocarbons that 
additionally generate deleterious singlet oxygen X
COLORANTS
2013, Djelal 
The use of HPTLC and Direct Analysis in Real Time-Of-Flight 
Mass Spectrometry (DART-TOF-MS) for rapid analysis of 
degradation by oxidation and sonication of an azo dye 
2012, The Danish 
EPA
Chemical Substances in Tattoo Ink Survey of chemical 
substances in consumer products X
2012, Vila Analysis of the chemical composition of red pigments and inks for the characterization and differentiation of contemporary prints X
2011, Hauri 
Inks for tattoos and PMU (permanent make-up)/organic pigments, 
preservatives and impurities such as primary aromatic amines 
and nitrosamines 
X
2009, Schäning Pigment classification of synthetic organic pigments by 
multivariate data analysis of FTIR spectra 
2008, Poon In situ chemical analysis of modern organic tattooing inks and pigments by micro-Raman spectroscopy X
2006, Engel
Establishment of an extraction method for the recovery of tattoo 
pigments from human skin using HPLC diode array detector 
technology
2006, FBI 
Laboratory 
Chemistry Unit
FTIR Analysis of Paints, Tapes, and Polymers 
2006, Instrument 
data sheet
Analysis of organic pigments using a direct exposure probe on 
JMS-T100GC ‘AccuTOF GC’ X
2005, Fang Determination of EU-Banned Disperse Dyes by LC/MSD TOF 
2004, Cui Photodecomposition of Pigment Yellow 74, a pigment used in tattoo inks X
2004, Vasold Tattoo pigments are cleaved by laser light- the chemical analysis in vitro provide evidence for hazardous compounds X
2001, Timko In vitro quantitative chemical analysis of tattoo pigments X
2001, 
Vandenabeele
Non-destructive analysis of paintings using Fourier transform 
Raman spectroscopy with fibre optics
2000, Bäumler Q-Switch laser and tattoo pigments: first results of the chemical 
and photophysical analysis of 41 compounds X
Learner The use of a diamond cell for the FTIR characterization of paints 
and varnishes available to twentieth century artists 
INORGANIC IMPURITIES
2014, Eghbali Determination of heavy metals in tattoo inks X
2013, Wellington 
Ministry of Health 
Survey of Selected Samples of Tattoo Inks for the Presence of 
Heavy Metals X
2012, The Danish 
EPA
Chemical Substances in Tattoo Ink Survey of chemical 
substances in consumer products X
2009, Forte Market survey on toxic metals contained in tattoo inks X
2006, Kang Quantification of para-phenylenediamine and heavy metals in henna dye X
2006, Kang Determination of hexavalent chromium in cosmetic products by ion chromatography and post-column derivatisation 
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[12, 17, 31, 58, 95, 103, 104, 121, 122, 124-141] 
 
 
Author Title Applied to tattoo/ PMU inks
2013, Høgsberg
Black tattoo inks induce reactive oxygen species production 
correlating with aggregation of pigment nanoparticles and product 
brand but not with the polycyclic aromatic hydrocarbon content
X
2011, Lehner Black tattoo inks are a source of problematic substances such as dibutyl phthalate X
2014, Hauri 
Tinten für Tattoos und Permanent Make-Up / Pigmente, 
Konservierungsstoffe, Aromatische Amine, Polyaromatische 
Kohlenwasserstoffe und Nitrosamine
X
NITROSAMINES
PHTALATES
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8. RAPEX notifications and market surveillance 
This chapter aims to give an overview of the alerts notified through RAPEX (Rapid Alert 
System for non-food dangerous products) in the last decade and of the results of market 
surveillance activities carried out in the European countries. 
For more detailed information, please refer to the JRC report on Work Package 2 [2]. 
 
8.1. RAPEX notifications  
As foreseen by the General Product Safety Directive 2001/95/EC (GPSD), since 2004 a 
rapid alert system for non-food dangerous products, called RAPEX, has been set up. This 
tool facilitates communication among 31 countries (28 EU MS, plus Norway, Iceland and 
Liechtenstein) and the Commission on products posing serious risks to consumers' health 
and safety and on the emergency measures taken by national authorities or 
manufacturers. 
Reports on current RAPEX alerts are published weekly. During the last decade (2005-
2015, week 15), 126 alerts related to tattoo and PMU inks have been reported, as shown 
in Figure 8.1. 
 
 
Figure 8.1: Notifications by year. 
 
Out of the 126 notifications, 120 (109 referring to tattoo and 11 to PMU inks) were 
related to chemical risks, while the remaining 6 implicated microbiological risks of tattoo 
inks. Many of the notifications referred to inks containing two or more hazardous 
substances. Figure 8.2 gives the proportions among the type of risks and the category of 
products.  
 
 
Figure 8.2: Notifications by category of products and type of risks. 
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As shown in Figure 8.3, two thirds of the notified inks were produced in the United 
States, 25% came from China, Japan and some European countries, whereas the 
provenience of 9% of products was unknown. Consistently, the majority (64%) of 
products not in line with CoE ResAP(2008)1 recommendations or with national 
legislations belonged to three American brands, Intenze (35%), Eternal ink (21%) and 
Starbrite 2 (8%). 
 
 
Figure 8.3: Notifications by country of origin of the products. 
 
Most notifications were related to the presence of impurities, mainly primary aromatic 
amines (40%) followed by polycyclic aromatic hydrocarbons (30%, including 10% 
benzo[a]pyrene) and heavy metals (28%), see Figure 8.4.  
 
 
Figure 8.4: Chemical notifications by chemical class.  
 
Amounts of primary aromatic amines in the range 3.4 – 5521 mg/kg were detected. The 
levels of total content of PAHs and of benzo[a]pyrene ranged between 0.5 - 96.5 mg/kg 
and 0.02 - 0.6 mg/kg, the suggested threshold values of the Resolution being 0.5 and 
0.005 mg/kg, respectively.  
Among all notifications, 28% showed heavy metals' contents above the threshold values 
in the CoE ResAP(2008)1. Alerts were related in particular to As, Ba, Cd, Cr(VI), Cu 
(soluble), Pb, Ni and Zn. High concentrations especially of Ba and Cu (soluble) were 
reached (7800 and 4310 mg/kg, respectively). Despite the content of nickel should be 
'as low as technically achievable', the levels reported in RAPEX notifications ranged from 
12 to 9690 mg/kg. 
Notifications linked to microbiological risks are mostly related to the presence of aerobic 
mesophilic bacteria (up to 106 cfu/ml) that compromises the sterility of ink packages 
before their opening. Recognised pathogenic species, such as Staphylococcus and 
Pseudomonas, were identified in some samples. 
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Different actions were taken after the identification of the risky products notified in the 
alerts, ranging from the voluntary recall from the market by the importer to the 
destruction of the products ordered by the authorities. As shown in figure 8.5, withdraw 
from the market was the measure taken in one third of the cases, followed by the ban 
on the marketing of the product.  
 
 
Figure 8.5: Notifications by measure/action taken. 
 
8.2. Market surveillance in European countries 
Data presented in this section was collected from market surveillance surveys carried out 
in some countries, national studies, peer reviewed articles, books and presentations 
given during the meetings of the CSN-STPM.  
The highest number of analyses related to tattoo and PMU products were carried out in 
The Netherlands, Germany, Switzerland and Italy, see Table 8.1, [12, 14, 15, 21-23, 
100, 142-144] and the most studied classes of impurities were PAHs, PAAs and heavy 
metals. Preservatives were also monitored in some campaigns. Additional market 
surveillance activities were performed in Slovenia [145], Sweden [24, 25, 27], Denmark 
[17, 146] and Belgium [10]. 
 
Table 8.1: Major market surveillance campaigns conducted in the last decade. 
 
 
Figure 8.6 summarises the percentages of samples not respecting the chemical and 
microbiological requirements of the CoE ResAP(2008)1 and/or of national legislation in 
relation to the content of impurities, preservatives and microorganisms. The data do not 
refer to a single study or publication, but are derived from the analysis of several 
documents taken into account during this project.  
Considering all information sources, overall 43% of the 358 inks analysed for total PAHs 
content presented concentrations well above the threshold of 0.5 mg/kg suggested by 
the CoE ResAP(2008)1 (0.5 – 55000 mg/kg) [12, 115, 121, 122, 147, 148]. The fact 
that 57% of them were compliant proves that it is technically feasible to produce carbon 
black with low levels of PAHs and that these products are also present on the market. 
Among PAHs, the following substances are classified as CMR in the CLP regulation: 
benzo[a]pyrene, dibenz[a,h]anthracene, benzo[a]anthracene, benzo[e]pyrene 
benzo[j]fluorantene benzo[k]fluorantene, benz[e]acephenanthrylene and chrysene. 
Concerning benzo[a]pyrene, 24% of the 300 samples analysed contained this substance 
Country Year Samples analysed (approx. number)
Substances analysed                        
(chemical class)
CH 2009-2014 600 PAAs, PAHs, preservatives, 
nitrosamines, pigments
DE 2007-2014 1000 PAAs, PAHs, heavy metals, preservatives, nitrosamines
IT 2007-2014 300 PAAs, PAHs, heavy metals
NL 2004-2015 3000 PAAs, heavy metals, preservatives
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in levels higher than the maximum recommended quantity of 0.005 mg/kg (0.005 – 6.8 
mg/kg). 
 
 
Figure 8.6: Percentage of analysed samples not respecting the chemical requirements of the CoE 
ResAP(2008)1 or of national legislation by chemical class (The red bar refers to microbiological 
contaminations). 
 
Even if primary aromatic amines should not be present in tattoo/PMU inks, 14% out of 
the 3282 products analysed for the total content of PAAs contained these carcinogenic 
substances [12, 23, 142, 143, 148-150]. The PAAs that were mainly detected (o-
anisidine, 4-chloroaniline, 3,3'-dichlorobenzidine, 4-methyl-m-phenylendiamine, o-
toluidine and 5-nitro-o-toluidine) are reported in Figure 8.7, with the indication of the 
numbers of samples containing them against the numbers of the analysed ones. The 
measured concentrations ranged from 0.1 to 6900 mg/kg. 
 
 
Figure 8.7: Percentage of analysed samples containing some carcinogenic aromatic amines. 
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Regarding the presence of metals [29, 58, 151-153], overall among all tattoo and PMU 
products analysed 9% of samples exceeded the recommended maximum concentrations 
mentioned in the CoE ResAP(2008)1. The percentages ranged from 1.4% to 32%, 
depending on the metals, as shown in Figure 8.8. 
It was not possible to estimate the percentage of analysed samples containing Ni and Cr 
(VI). In the case of nickel because the CoE ResAP(2008)1 does not recommend a specific 
limit but suggests that the concentration should be as low as technically achievable. In 
the case of Cr(VI) because many studies reported only the total concentration of this 
element, even if the recommended limit applies to Cr(VI). 
 
 
Figure 8.8: Percentage of analysed samples containing metals. 
 
In 2007, 2008 and 2014 three studies from Germany, Switzerland and The Netherlands, 
which included nearly 2000 test results on preservatives, were published [12, 15, 23]. 
As shown in Figure 8.6, 6% of all considered products did not fulfil the recommendations 
or national requirements. In particular, Hauri [12] reported that benzoisothiazolinone, 
methylisothiazolinone and formaldehyde were found respectively in 24%, 8% and 7% 
out of the 229 inks analysed in his survey. 
Other impurities like nitrosamines [12] and phthalates [122, 124] were detected in some 
cases. Some of them are classified as carcinogenic or toxic for reproduction or are listed 
in Annex II of the cosmetic regulation thus the CoE ResAP(2008)1 recommends they 
should not be present in tattoo/PMU inks.  
Regarding microbiological contamination [15, 30, 78, 154-158], considering all the data 
collected in more than 3800 products, 11% of the ink bottles (sealed or in use) were not 
sterile (Figure 8.6). Pathogenic reported micro-organisms included Pseudomonas, 
Staphylococcus, Streptococcus and Enterococcus. The Netherlands was very active in 
this domain and conducted massive surveillance campaigns from 2004 to 2014 on more 
than 3000 samples [22, 23]. In particular, the presence of bacteria in 20% out of more 
than 800 analysed samples was revealed in the 2004 Dutch study. 
Summarising, results indicated that tattoo/PMU products containing dangerous 
substances or biologically contaminated are available on the EU market. The main risks 
identified, in descending order, are the presence of PAHs, PAAs, microorganisms, heavy 
metals and preservatives. Thus it is of primary importance to continue market 
surveillance activities in all European countries. 
It has to be noted that the total number of "non-complying" samples identified in market 
surveillance campaigns is by far higher than the total number of RAPEX notifications, 
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which concerns only those inks that are considered as causing serious risk to the health 
of consumers and fulfil the conditions to be notified through RAPEX. 
Furthermore, some national studies carried out in various European countries, such as 
Belgium [10, 11], Denmark [17], Germany [14], Slovenia [145], Sweden [24] 
Switzerland [12] and The Netherlands [22] highlighted incomplete or missing 
information on the labelling of tattoo and PMU products. The absence of life date after 
opening and the incomplete list of ingredients were mostly reported; often there was no 
indication of durability, manufacturer, batch number or indication of use. A further issue 
raised from different studies was the presence on the market of counterfeit inks with not 
only fake product and manufacturers' names, but also false batch numbers with a list of 
ingredients not corresponding to the actual composition of the product. 
A considerable market surveillance campaign has been conducted in the Netherlands 
from 2004 to 2014 [22], revealing that in 37% out of the 3000 samples analysed 
mandatory information were absent, thus non-complying with labelling requirements.  
Incorrect labelling concerning the chemical composition of inks was also spotted in 1/3 of 
the samples collected by the German regional authorities [142], and highlighted both by 
the Slovenian [145] and Swiss [12] Competent Authorities in their national reports. 
In Italy, campaigns carried out between 2009 and 2014 [150] showed that, even though 
nickel was present in nearly all samples, in no one this element was declared, as 
requested by the CoE ResAP(2008)1.  
All details about data collected and summarized in this Chapter are available in the 
Annexes V and VIII of the JRC report 'Safety of tattoos and permanent make-up. State 
of play and trends in tattoo practices', by Piccinini et al. [2]. 
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9. Adverse health effects linked to tattoo/PMU applications 
and removal 
With the recent increase of popularity of tattooing and permanent make-Up among the 
general population, and particularly in the young generation, medical complications from 
tattoo applications and removal are more and more frequently described by physicians 
and medical literature. However the perception from the medical viewpoint might be 
partial, as tattoo recipients experiencing an adverse event are probably reluctant to seek 
medical care, especially if symptoms are minor. In the Klügl study [70] (see below) 
performed in German-speaking countries, only 1% of the tattooed people who took part 
in the survey consulted a physician, even though respectively 67.5% and 6.6% of them 
experienced skin or systemic problems directly after tattooing, and 6% and 3% of them 
experienced persistent problems linked or not to the skin. In the US, the Brady study 
[159] (see below) shows a higher proportion, i.e. 29% of the tattooed people with some 
adverse reaction had obtained medical care (16% from a dermatologist). 
Serup [160] makes the distinction between (i) minor complaints of "discomfort and (ii) 
more serious "complications" requiring a medical advice and states that life-threatening 
incidents are extremely rare. Citing Kluger [161] "Dermatologists deal with two types of 
tattooed patients: most often those desiring tattoo removal and, more rarely, patients 
presenting with cutaneous reactions associated with tattoos". For PMU applications this 
aphorism is even more valid, as the most frequent complaint there relates to "patient's 
dissatisfaction resulting from misapplication of the pigment, pigment migration, and 
pigment fanning" [4]. Laux reported that up to 50% of the tattooed individuals regret 
their tattoos [84]. These psycho-social sequels are also to be considered after tattoo 
removals, which are in constant increase [162], due to regrets, aesthetic reason or 
medical complications of tattoos [85]. The post-removal side-effects presented in the 
following paragraphs focus only on the use of Q-switched lasers (QS), the gold standard 
for tattoo removal [82, 83], leaving voluntarily aside other sporadic and/or outdated 
removal techniques such as surgical, chemical and thermal procedures, or argon and 
CO2 lasers. Complete pigment removal is successful in only 38% of cases, according to a 
self-reported non-medical study [85]. 
Adverse tattoo reactions may start either early, right after the tattoo procedure, or occur 
later on, months and years afterwards. Acute aseptic inflammation takes place already 
while the tattoo is placed or removed, immediately followed by a wound healing process. 
Skin bacterial infection (for permanent tattoo application) may occur after some days, 
while for allergic reactions, it can be delayed to weeks, or even years and decades for 
chronic dermatosis and immune reactions. A 2015 study performed by Brady [159] on 
300 randomly selected tattooed people in Central Park (New York), reported 10.3% of 
adverse tattoo reactions. Out of these 31 individuals, 13 (4.3% of total participants) had 
mild acute effects (pain, itching, swelling) and 18 (6.0%) showed chronic reaction linked 
to a specific colour which lasted more than 4 months. However the author admits the 
limitations of such a survey approach, where self-reported reactions were not clinically 
ascertained, concluding that the overall extent and prevalence of post-tattoo adverse 
events is currently unknown because of scarce epidemiological data, and this is 
confirmed by other experts in this field, such as Kluger [161], or Desai [163]. 
Carrying out a web survey among tattoo recipients in 2010 [70] Klügl found that two 
thirds of the 3411 responders had acute dermal complaints, which were probably simple 
inconveniences, actually. This proportion is in the same range as the 76% of tattoo-
recipients complaining of bleeding, in the Carney study [164], but much bigger if 
compared with the rate of acute minor disturbances reported by most authors (see point 
9.1 below). After one month 9% of the German-speaking individuals declared to still 
present symptoms, be it local (for 6%) or general e.g. dizziness, headache, or nausea 
(for 3%) [70]. However the reliability of these responses to a questionnaire, without 
validation by a physician, is challenged by Wenzel et al, [165], and Klügl himself 
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recognises these figures might be inflated, as "people with health problems may be more 
willing to participate in such a survey".  
Speaking about adverse health effects linked to laser tattoo removal, a similar internet 
survey performed by Klein [85] on 157 patients having undergone a laser tattoo 
removal, revealed the following rates of systemic effects: 6% (headache), 4% 
(dizziness), 1% (fever, vomiting). In two thirds of the individuals these complaints 
persisted up to 5 weeks, in 7% of them it lasted 6–9 weeks, and beyond 10 weeks in 4% 
of participants to the survey. 
Apart the obvious dichotomy existing between infectious (only for permanent tattoo/PMU 
applications) and non-infectious diseases, a systematic categorisation of tattoo adverse 
events remains a challenging task, even under controlled clinical circumstances, 
according to Brady [159]. For the purpose of this report the adverse effects have been 
subdivided into the following categories: 
• acute aseptic inflammation; 
• infectious risks (bacterial and viral); 
• allergic/hypersensitivity and auto-immune type reactions: 
o allergic reactions; 
o underlying dermatosis reactivated by tattooing; 
o other secondary effects; 
• other secondary effects: 
o pigmentary disorders; 
o tumours; 
o medical diagnostic and treatment interference; 
o contraindication to tattoo procedure. 
Among the inflammatory non-infectious events, an unavoidable step is represented by 
the acute needle trauma or laser burn, and subsequent inflammation always 
accompanying the tattoo application or removal (see point 9.1). In contrast with these 
mild discomfort claims, the main serious complications of tattoo procedures consist of 
infectious, hypersensitivity reactions (so called "allergic phenomenon") and chronic 
inflammation with possible immunity component, where the tattoo may reactivate 
underlying dermatoses. Further complications, like pigmentation disorders, are 
specifically linked to the laser removal process, but chronic post-inflammatory 
discolouration changes may also occur. Tumours form a separate group, because of the 
uncertainty of their pathogenesis. In addition tattoos can hamper or delay medical 
diagnosis and treatment.  
Information reported in some key papers on adverse health effects are summarised in 
tables 9.1 (relationship between type of adverse effects and their prevalence) and 9.2 
(type of adverse effects and onset). 
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Table 9.1: Prevalence of various types of adverse health effects. 
 
[56, 70, 74, 80, 84, 85, 123, 159, 165-167] 
 
Number of persons 
surveyed
Number or % of persons with 
problems Adverse effects Type of study Location Reference
10%  (31/300) experienced adverse tattoo reaction
of which 29% (9/31) medical care for their syntoms
 of which 16% (5/31) care from dermatologists
6% (18/300) of which 44% (8/18) to 
red and 33% (6/18) to black ink 
23%  (4/18) to other colours
chronic reaction releated to specific colour (>4 
months)-itchy,scaly,raised,oedematous syntoms
4.3% (13/300) acute reactions (up to 4 months)-pain,itching,swelling,scabbing
Unknown 1-5% of tattooed people in general
bacterial infections after receiving a tattoo (from 
superficial skin infections to more severe systemic 
cases-pathogens bacteria, blood borne viruses 
hepatitis and HIV)
2016, Laux 
35000 patients treated 
in the hospital (the 
number of tattooed is 
unknown)
0.02% (7/35000 )
severe adverse reactions (inflammatory lichenoid 
reaction, itch, acute edema,sarcoidal reaction, 
dermal granulomatous reaction, erythema nodosum, 
nodules, ulceration)
survey in 
dermatologic 
department of 
Dresda hospital
Germany 2012, Wollina 
42% (60/144) complaints
of which 52% (31/60) 
sun induced reaction (red and black tattoos)-
swelling (18/31),itching/pain (16/31), redness (8/31), 
more than one problem (11/31)
of which 48% (29/60) reaction independent of sun-swelling (9/29), 
reaction to heat (12/29),allergic reaction (3/29)
of which 1% (2/60) asked medical assistance
97% (152/157) reactions (blistering, edema, crusting, erythema and pain)
69% (108/157) local effects within 5 weeks
24% (38/157) slightly visible scars
8% (12/157) important scars
6% (9/157) headache
5% (8/157) local effects persisted up to 30 weeks
5% (8/157) needed medicat treatment for side effects
4% (6/157) dizziness
2% (3/157) temporary disability
1% (2/157) vomiting
1% (2/157) fever
1% (2/157) more than 10 visits to their medical practitioner
151/280 (54%) of which 21/151 
(13.9%) black inks, 47/151(31.1%) 
coloured inks and 83/151 (55.0%) 
unknown colour 
infections
96/280 (34%) of which 12/96 
(12.5%) black inks, 80/96 (83.3%) 
coloured inks and 4/96 (4.2%) 
unknown colour 
granulomatous, lichenoid or hypersensitivity allergic 
reactions
33/280 (12%) of which 10/33 
(30.3%) black inks, 18/33(54.5%) 
coloured inks and 5/33 (15.2%) 
unknown colour 
tumors
2% (6/151) hepatitis C
27% (41/154) complains after 3 months (related to black  and red pigments)-skin elevation and itching
16% (24/154) complains related to sun exposure -skin elevation 
and itching  (19/24 related to black tattoos) 
15% (23/154) early complains (up to 3 months)-skin elevation, itching, ulceration, redness, fever, local infection
67% (2285/3411) immediate adverse tattoo reaction (bleeding, crusts, itching edema,pain, bacterial skin infections)
8% (273/3411) still have reactions after 4 weeks
7% (239/3411) systemic reactions directly after tattooing (dizziness, headache, nausea, fever)
6% (205/3411) persistent on going reaction (intermittent edemas, papules, itching,skin elevation)
3% (102/3411) psychic problems and light sensitivity of tattoos
0.6% (20/3411) positive to hepatitis test after tattooing
33% (1126/3411) no problems
234 tattooed 2.1% (5/234) tattoo complications-infectious,allergic and granuloma complications
study in 
dermatology 
clinic
Bulgaria 2007, Kazandjeva 
18% (15/120) medical problems during the first 2 weeks (disconfort, pain, tenderness, itching, bleeding, pus)
of which 20% (3/15) sun sensitivity within the first 2 weeks
454 (106 tattooed) 0 no reported medical complication from tattooing students survey US 2002, Mayers 
500 (120 tattooed)
280 (all tattooed 
patients reporting 
health effects)
internet survey
German 
speaking 
countries
Denmark
phone survey US 2006, Laumann 
2014, Hutton 
review 2013, Wenzel 
internet survey
German 
speaking 
countries
2014, Klein 
2015, Brady 300 tattooed
3411 tattooed
154 tattooed (342 
tattoos)
2010, Klügl 
2013, 
Høgsberg 
study in a clinic of 
sexual 
transmitted 
diseases
beach survey Denmark
street survey US, New York
157 (ex tattooed 
reporting side effects 
after tattoo removal)
467 (144 tattooed)
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Table 9.2: Onset of various types of adverse health effects. 
 
[168-171] 
 
 
 
Onset after tattooing Comments Reference
Spongiotic reaction red and black tattoos
Psoriasis form reaction 1 week-few months
Interface (lichenoid/vacuolar) reaction few weeks black tattoo
Nodular and diffuse (granulomatous) reaction Tuberculoid granuloma
Sarcoidal granuloma
Suppurative granuloma 1/3 weeks gray/black tattoos
Necrobiotic/Palisading granuloma 7 months- 1 year blue and black tattoos
Nodular and diffuse (pseudolymphomatous) reaction extremely variable red tattoos but also purple/blue-green/black
Vesiculobullous reaction
Vasculitis days- 1 month
Fibrosing reaction
Pseudoepitheliomatous reaction 1 week-few months
Acute Pyogenic infections within days to few weeks
Atypical Mycobacterial infections Non-tuberculous mycobacterial within one month
Mycobacterium infections Lupus vulgaris/leprosy years
Syphilis
Fungal infections
Leishmaniasis
Viral infections HCV/HIV
Herpex Simplex virus
Human Papilloma virus months to years
Molluscum contagiosum weeks to months
Granulomatous reactions Sarcoidosis from weeks to years 50 reported cases of interferon induced sarcoidosis
Pseudolymphoma months to years red tattoos
Lichenoid recent tattoos preponderant red tattoos but also other colors
Connective Tissue Disease
Reactivation/Exacerbation of underlying dermatoses Psoriasis
Atopic dermatitis
Pyoderma gangrenosum
Lichen sclerosus
Pseudoepitheliomatous hyperplasia
Squamous-cell carcinoma and keratoacanthoma Keratoacanthoma recent tattoos red tattoos
Melanocytic neoplasms and malignant melanoma
Sarcoidosis on tattoos (59 cases-mostly traditional tattoos) 6 weeks - 45 years red and black tattoos mostly involved
Sarcoidosis on PMU (8 cases) 2 years- 25 years red and brown PMU
Isolated uveitis (8 cases) 6 months- 12 years light blue tattoos
Squamous-cell carcinoma and keratoacanthoma (23 cases) days - 20 years red tattoos
Melanoma (16 cases) 3 months-40 years black and dark colored tattoos
Basal-cell carcinoma (11 cases) 1 year- 55 years black and dark colored tattoos
2012, Kluger
Adverse effects
2015, Thum
Skin cancer 
Inflammatory 
reactions in  
tattoos
Inflammatory 
reactions in  
tattoos
2013, Kluger
2014, Simunovic
Infectious 
complications of 
tattoos
Inflammatory 
reactions in  
tattoos
Neoplasms in  
tattoos
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9.1. Acute aseptic inflammation  
In this paragraph, reactions such pain, redness, blistering, swelling, itching, erythema, 
flush, mild bleeding during the healing process, are considered evidences of an on-going 
acute aseptic inflammation that could follow tattoo application and/or removal. 
Except for henna-based temporary body art decoration, which are applied on the skin in 
a non-invasive way, placing a tattoo implies to breach skin layers with a needle, hence 
to trigger an injury to the superficial vessels. Such inevitable bleeding usually disappears 
within few days without treatment. Other minor discomfort symptoms include redness, 
swelling, and lymphadenopathy. As long as the wound is not contaminated by 
microorganisms the inflammation process remains aseptic and phases out within one 
month, during which clients present an induration of the tattoo with superficial crusting. 
Possible complaints range from pain to itching and blistering. In rare cases this injection 
of foreign substances inside the skin may provoke a general flush. 
The acute thermal stress inflammation induced by laser removal on the epidermis may 
give rise to various transient effects, crusting and blistering being the most frequent, the 
latter especially with unexperienced laser operators applying inappropriate parameters 
such as too low light intensity or too long pulse duration. Dermal capillary damage 
caused by higher peaks of laser energy may result in transient erythema and pinpoint 
bleeding, usually self-resolving after few days by ice application [172, 173]. One case of 
persistent erythema has been reported when using a long pulsed device [174]. Textural 
changes heal usually within 1-2 months [172]. Additional acute effects may include 
fibrosis, scaling, and induration.  
As seen earlier, prevalence of such transient tattoo disturbances is difficult to measure 
because self-report questionnaires might be flawed by selection bias. In addition, 
tattooed individuals might confuse between true medical disorders and mild symptoms 
inherent to the wound healing process. The results reported in different surveys are thus 
extremely variable. While the Klügl on-line enquiry showed a complication rate of 67.5% 
in tattooed people, other authors give much lower figures based on much smaller 
samples. Kluger in a review [175], reports together with Klügl's results, two other 
studies where the prevalence of acute symptoms was estimated between 12.5% [56] to 
31% [176], with pruritus on top of the list (21.6%). Brady, [159], calculates 10.3% 
adverse events among 300 US tattooed individuals, with only 4.3% of total participants 
showing acute symptoms (pain, itching, swelling). Serup, [177] contends that one third 
of tattooed people experience swelling and itching, the latter being also the main 
complaints reported by 60 tattoo recipients out of 144 by Hutton Carlsen study [123], 
the majority (31/60) in relation with sun exposure, the others described as "acne-like 
changes" or secondary to "alcohol or tomatoes consumption 
This variability in prevalence is mirrored by the degree of symptom severity which can 
be evaluated very differently from one tattooed person to another. In the Klügl internet 
study, 11% of the subjects qualified their symptoms as "moderate”, and 1.8% as 
“intense” or “very intense”. In the abovementioned Klein internet study [85], almost half 
of the 157 patients having experienced a removal by laser therapy declared it was much 
more painful than tattooing itself, while a third of them said the level of pain of both 
processes was comparable. 
27% these acute symptoms may become chronic (beyond 3 months) as evidenced by 
Hogsberg's 2013 survey of 154 tattooed Danes [80]. 16% of the same sample reported 
lasting sun-induced swelling and itching. In his New York study, Brady counted 6% of 
chronic complaints (beyond 4 months) among his 300 tattooed patients.  
Other reported collateral effects include neurologic pain in upper limbs, papulo-nodular 
skin elevation from pigment overload, soft tissue lymph oedema, skin pigmentation 
around the tattooed area and in the regional lymph nodes [160, 177]. 
Apart from the adverse effects described on loco-regional level, also generalised contact 
dermatitis can be triggered by impurities present in tattoo inks, such as metals usually 
 64 
but not always at trace levels (almost all inks contain nickel), or preservatives (e.g. 
parabens, methylisothiazolinone). Such hypersensitivity reactions may be confused with 
microbial infections or injury repairing inflammation, especially if they don't diffuse 
beyond the tattooed area. 
Even if Klügl's survey showed more frequent skin reactions to coloured tattoos (83%) 
comparing to black tattoos (80%) calculated on the total of replies that could be 
multiple, Brady [159] notes the frequencies of reactions provoked by black tattoos are 
reported in the literature in an inconsistent way, emphasizing the need for larger studies 
in order to show the respective proportions of adverse effects for each tattoo colour.  
 
9.2. Infectious risks 
In the context of tattoo/PMU application pathogens may proliferate for various reasons, 
starting at the ink manufacturing step, or once the bottle has been opened and used 
without respecting the standard rules of asepsis. A common bad practice consists of 
diluting black ink with tap water in order to get different shades of grey. Other 
contamination sources include the tattooist poor hygiene, or the inappropriate use of 
tattoo equipment, such as using the same needle for successive clients without proper 
sterilisation. In registered parlours implementing standard hygiene guidelines, 
professional tattoo artists have succeeded in reducing the rate of contamination through 
pathogens, especially in the PMU sector. After the tattoo procedure, the wound may also 
be subject to infection, in particular if hygiene recommendations are not followed by the 
tattooed person. 
In developed countries most frequent infectious complications are caused by bacteria. 
Blood borne viral transmission may also be involved if minimal hygiene requirements are 
not met, such as in prisons or in non-professional parlours or during home-tattooing 
parties [178]. Mycotic or parasitic diseases have only been described in exotic or 
anecdotal cases. 
 
9.2.1. Bacterial infections  
Within a couple of days after the tattoo application pyogenic bacteria (e.g. streptococcus 
or staphylococcus aureus) may seldom give rise to superficial skin papulo-pustules, 
folliculitis, impetigo or ecthyma. Rare cases of deeper regional infections, such as 
furunculosis, erysipelas and cellulitis of the entire limb, have been described [161]. 
However, following proper hygiene protocols, systemic infection, with associated 
gangrene, osteomyelitis, epidural abscesses, septicaemia, toxic shock syndrome 
involving lethal prognostic is exceptional, provided that there is no underlying heart 
valvular diseases or other previous health conditions. Having large and multiple tattoos 
increases the risk of complications like bacterial endocarditis [179] and it is advised to 
patients with known story of cardiac valvular disease (1% of the general population, 
[180]) to avoid tattooing, or at least to perform it under strict antibiotic umbrella [181]. 
Kluger [175] contends the actual incidence rate of superficial skin infections is unknown 
since many tattooed persons are reluctant to seek medical advice for minor transient 
symptoms. Furthermore, medical statistics do not exist. However, some authors like 
Laux [84] and Klügl [70] have estimated it at respectively 1-5% and 0.5% of the 
tattoo-recipients. Kaatz [157] suggests that the risk of infection is increased when the 
patient suffers simultaneously of concomitant diseases such as sarcoidosis (see below), 
but this rate depends first and foremost on the hygienic settings of the studio and the 
tattooist's experience and the way he uses material and tools. Bacterial contamination is 
for instance uncommon in the case of PMU application, usually performed by licensed 
and trained aestheticians in well-established shops [182]. Another important factor is the 
tattoo inks' sterility. In the literature ink contamination figures of sealed tattoo/PMU ink 
bottles range from 10 to 50% according to various authors (see Table 9.3), pointing out 
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the urgent need to enforce regulatory measures ensuring inks sterility. The survival 
characteristics of vegetative bacteria and endospores, fungi, and bacteriophage (as virus 
surrogate) in tattooing solutions have been documented [183]. 
 
Table 9.3: Bacterial contamination rate of sealed tattoo/PMU inks. 
 
[30, 78, 156-158] 
 
It has to be pointed out that opportunistic germs, such as pseudomonas or Non 
Tuberculosis Mycobacteriae (NTM), have also emerged. This phenomenon may be linked 
to either the presence of these pathogenic bacteria in unopened tattoo ink bottles [32] 
or unsterile tap water used to dilute black inks in order to obtain different grey shades 
[184]. Atypical Mycobacteriae infections may appear on the grey lines of the tattoo from 
3 days up to 1 month after application, as unspecific red papules, pustules or lichenoid 
plaques accompanied by pruritus. Histologic examination shows suppurated or 
tuberculoid granulomatous patterns, which may be confused with pseudoepitheliomatous 
hyperplasia (PEH, see below). Mycobacterium abscessus, a species of rapidly growing 
mycobacteria, was also reported causing skin infections with erythematous papules 
[185]. 
Home tattooists operating under questionable hygiene conditions have also been 
associated with emerging "cluster outbreaks" of Community acquired-Methicillin-
resistant Staphylococcus aureus (CA-MRSA) infections, facilitated by the high percentage 
of asymptomatic carriers in some US Communities [33, 186]. Tap water used for ink 
diluting purposes has been incriminated as well in the proliferation of these germs [165]. 
Last but not least, as with any antibiotics use (here in the form of topical aftercare 
ointment) there is the theoretical risk of germs developing resistance against some 
antibiotics. 
 
9.2.2. Viral infections  
Tattooists operating in unsanitary facilities may also contaminate tattoo recipients with 
the human papilloma virus (HPV) or molluscum contagiosum (MCV) because of a poor 
hygiene causing so viral warts after 2 weeks to 10 years after tattoo application (Wenzel, 
2013, dermatology). Given such a long latency Kluger [161] has equated these viral 
reactions to a Köbner phenomenon (tattoo reactions on pre-existing skin lesions, see 
below section 9.3.2). Latent HPV can be also reactivated by UV exposure 2.5 years after 
tattooing took place [187]. So far only one case of a herpes rash within a tattoo has 
been reported by Kluger [175], but since it occurred 3 days after the application, Kaatz, 
[157] wonders whether the virus was directly inoculated during the tattoo procedure 
itself, or if the latter only reactivated a latent herpes infection. 
Hepatitis viruses (HBV or HCV) which are responsible for severe systemic diseases, such 
as hepatic failure, can be transmitted during tattoo application. Conflicting results are 
available in the literature regarding the risk of hepatitis among tattooed people. On this 
basis in 2012 and 2010, Jafari published two systematic literature reviews and meta-
analyses which aimed to determine whether tattooing can be considered a risk factor for 
the transmission of hepatitis C and B, respectively [188, 189]. The odds ratio (OR) was 
used to quantify how strongly hepatitis was associated with having tattoos in a given 
population. As reported in Figure 9.5, the calculated odds ratios are higher than one, 
Author Year Ink contamination 
rate (%)
Høgsberg et al. 2013 10 (6/58)
Health Canada 2011 20 (3/15)
Kaatz et al. 2008 37 (3/8)
Baümgartner et al. 2011 44 (17/39)
Charnock et al. 2004 50 (1/2)
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meaning that having tattoos (compared to not having them) raises the chances of 
getting hepatitis. Even considering the limitations of the studies and the fact that these 
findings do not establish a formal causality between the two events, the association 
between tattooing and the risk of transmitting hepatitis was present in all subgroups, 
strong in the case of hepatitis C with ORs values higher than 2. In addition, results 
suggested a stronger association between tattoos made in non-professional parlours and 
hepatitis C (pooled OR 2.80 based on 4 studies) compared to those made in professional 
studios (pooled OR 1.28 based on 4 studies). Jafari [189] reported that in countries with 
tattoo prevalence of 11-27% among inmates and 8% in the general population, 12-25% 
and 6% of hepatitis C in prison and in the community, respectively, are related to 
tattooing. Regarding hepatitis, in particular hepatitis C, similar conclusions were reported 
also by Aiyedun [28] that evidenced how needle stick injury and exposure prone 
procedures, including tattooing, are predisposing factors for the transmission of blood 
borne virus. 
 
Table 9.4: Tattooing as risk factor for the transmission of hepatitis. 
 
[188, 189] 
 
Recent unpublished data, reported in an epidemiological study realised by Italian 
Surveillance System (SEIEVA) in the period 2010-2014, showed strong association 
between placing a tattoo and acute B- or C-hepatitis without proving a formal causality 
between the two events: subjects who had placed a tattoo in the last 6 months had a 
significant and almost double risk of acute B- or C-hepatitis as compared to subjects 
without a tattoo (in the age group 15-54 year-old, adjusted OR=2.1 with confidence 
interval (CI) at 95% 1.4-3.1 for hepatitis B and OR=2.2 with CI at 95% 1.1-4.4, for 
hepatitis C were calculated). Klügl [70] calculated a post-tattoo hepato-seroconversion 
rate of 0.6% against the total number of tattooed people showing any kind of adverse 
reaction.  
In contrast to hepatitis virus, which can easily infect a person, direct transmission of the 
HIV virus needs a huge and prolonged body fluid contact, hence AIDS contamination 
through tattoo application remains theoretical, and has been indeed documented only 
once in the whole medical literature, in a possible case that concerned two inmates in 
1988 [175]. 
 
9.3. Allergic/hypersensitivity and auto-immune type reactions  
This group of inflammatory unpredictable responses includes both acute allergic and 
delayed hypersensitivity reactions, very close clinically and histologically to auto-immune 
skin pathologies reactivated up to years after by tattoo procedures. 
 
9.3.1. Allergic reactions  
Though hypersensitivity is cited in medical literature as the most common reaction to 
tattoos and PMU inks, in particular the classical lichenoid reaction to red pigments (in the 
past often related to the mercury contained in cinnabar), classifying a tattoo reaction 
specifically as an ‘allergy’ remains a challenge for Brady [159]. Some 
"granulomatous/lichenoid" response may be mixed up, both clinically and histologically, 
Hepatitis
Papers 
included in the 
meta-analysis
Total participants Type of study
Pooled odds ratio 
(confidence 
interval at 95%)
Highest odds ratio in subgroup 
analysis (confidence interval at 
95%)
45 cross-sectional
30 case-control
8 cohort
19 cross-sectional
9 case-control
3 cohort
132145                                          
(from 26 countries)
2.74 (2.38-3.15)              
based on all studies
5.74 (1.98-16.66)                                          
(non-injection drug users)                 
based on 6 studies
Jafari, 2010 C 83
1.64 (1.32-2.03)                                
(high risk behaviour group)                       
based on 5 studies
Jafari, 2012 B 31 665169                    (from 19 cuntries)
1.48 (1.30-1.68)        
based on all studies
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with and in some case be the first stage of underlying systemic disorders like 
sarcoidosis, lichen planus, or lupus erythematosus (see below point 9.3.2). 
In the past, pigments based on or containing mercury sulphide (cinnabar, once used in 
tattoo red inks), chromium (in green), cobalt (in blue), cadmium (in yellow) or 
manganese (in purple) have been traditionally linked to allergic phenomena, but these 
pigments have been mainly phased out in most modern inks, being present only as trace 
level [168], and yet allergy continues to be mostly associated with red tattoos, throwing 
suspicion to primary aromatic amines (PAA)-containing azodyes. Besides use of 
compounds and elements such as cadmium selenide, ferric hydrate, aluminium, carbon, 
barium, copper and strontium still remains frequent. Titanium oxides are used in white 
pigments but trigger no allergic response [190]. Light-blue and green pigments cause 
seldom allergic reactions, mostly in relation to elements and compounds such as 
chromium, aluminium or chloride cobalt [190]. Despite granulomatous allergies reported 
for magnesium, chromium, mercury, cobalt, Serup [177] sustains that chromate VI and 
nickel are apparently not a clinically important inducers of delayed allergy (sometimes 
after months or years), as nickel, even if present in all inks [191], is swiftly washed out 
of the tattooed skin. We already mentioned that predisposed patients may experience a 
few days after the tattoo/PMU placement a widespread rash due to impurities such as 
nickel. Preservatives like parabens can provoke similar systemic eczema, sometimes 2 
months later [192]. 
As far as black pigment is concerned, only a few allergic reactions have been so far 
described [168]. On the contrary, for temporary black henna body decorations, made of 
combination of red henna (little sensitising) plus PPD (p-phenylenediamine, a powerful 
antigen, used also in permanent black hair dye), and applied by street artisans to young 
people in fashionable venues (e.g. holiday resorts, festivals, attraction parks), the bulk 
of reported side-effects are of hypersensitivity type, i.e. local or widespread contact 
dermatitis, and hypertrophic or keloid scars [168, 193-195]. However, Calogiuri [196] 
stressed the possibility that metals (e.g. nickel, cobalt, mercury) and other ingredients 
such as thiurams and latex proteins might contaminate henna preparations, inducing 
hence as well contact dermatitis. 
Overall the mediator of such allergic responses is hard to determine because the 
composition of these low-purity industrial products remains generally undocumented. 
Furthermore, superficial skin patch tests are mostly of no help, in particular with the 
granulomatous and lichenoid types of allergy (see below). The patch test study on 90 
patients realised by Serup [191] suggests that chronic allergy is not induced by specific 
ink components as such, but by a slow intra-skin formation of pigment protein complex 
called "hapten" in the following months or years.  
Both onset and duration of the hypersensitivity reaction are unpredictable, as they can 
start right after the tattoo procedure, or decades after (up to 45 years!), and may last 
lifelong [197]. The clinical appearance is not specific (papules, oedema and induration), 
and can be limited to tenderness and itching of extremities (typical), or develop until a 
tumour-like wart. Especially red tattoos show ulceration, necrosis and hyperkeratosis. 
Plaque elevation is very frequent in red, appears sometimes also in blue/green tattoos. 
[160]. 
In the case of tattoo removal inks degradation products scattered by the laser beam may 
elicit an hypersensitivity local response [82, 84, 167, 198, 199], or widespread 
immediately to the whole organism through the lymphatic system, provoking an 
anaphylactic shock [82, 83, 167]. Such a risk is increased if allergy already occurred at 
tattoo placement stage. 
Histopathology classically distinguishes "lichenoid, granulomatous, or 
pseudolymphomatous" patterns, but such a classification does not correspond to a clear-
cut clinical diagnosis and is rather challenging, as different patterns may coexist in the 
same biopsy. The following disorders may thus not be used to define specific tattoo 
reactions [165]. 
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The development of allergy to latex proteins originating from the tattooist’s gloves 
and introduced into the skin via the needle has been reported [177]. Serious 
complication may arise, with a risk of life-threatening anaphylaxis upon further 
exposure to latex. Sensitised persons can immediately elicit anaphylactic shock 
when they get into contact with latex particles either by a new tattooing session or 
by another direct contact with latex containing articles. 
 
9.3.1.1. Eczematous dermatitis 
Acute or chronic eczema appears generally as a scaly and itchy papulovesicular rash 
after a tattoo application or removal, usually in individuals sensitized to medications such 
as topical disinfectants and antibiotics. This contact dermatitis is more frequent with red 
pigments, but may also involve black pigments or other dyes (green, blue, yellow). 
Originally limited to the tattooed area the erythema can then spread to the entire body, 
as reported by Caucanas [200] in the case of paraphenylenediamine contained in "black 
henna" temporary tattoos . For the latter, the incubation period may vary from 1 to 20 
days, and is shorter in case of previous sensitisation.  
 
9.3.1.2. Photosensitivity 
Light sensitivity may touch about 20% of tattooed individuals [201], mainly on sun-
exposed body parts, such as face and hands. Hogsberg's 2013 survey [80] reported that 
16 % of 154 tattooed Danes showed lasting sun-induced swelling and itching. Yellow 
cadmium-containing pigments after laser removal might also elicit local photo allergy 
[163]. 
Hutton Carlsen [123] performed a survey on sunbathers, 144 of which were tattooed. 
Among them, 21.5% experienced complaints linked to sun exposure. The major 
symptoms were swelling, itching/stinging/pain and redness, predominantly correlated to 
black and red tattoos, with blue following. The onset may vary from few second to the 
following day lasting from minutes up to several weeks. Results in terms of sun-induced 
complaints related to tattoo colour are reported in Table 9.5 (31 people expressed sun-
related complaints, however multiple replies were allowed). Black tattoos were 
responsible for the larger number of complaints, but in percentage red tattoos were 
predominant. 
 
Table 9.5: Sun-induced complaints related to tattoo colour (data from [123]). 
 
 
9.3.1.3. Lichenoid and granulomatous reactions 
Lichenoid (the most frequent type made of plaques and papules which can widespread 
to the whole body) and granulomatous (firm indurated nodules) patterns affect mostly 
the red portion of the tattooed area and provoke itching. Both lichenoid and 
granulomatous types can coexist in the same patient [202]. Mercuric sulphide (cinnabar) 
once used in red inks has been traditionally associated to the lichenoid type, but the 
recent shift towards organic pigments has not eliminated these kind of reactions, present 
Tattoo 
colour
N° of 
persons
N° of 
complaints
% of 
complaints
Black 133 20 15
Red 45 14 31
Pink 8 1 13
Orange 9 1 11
Purple 5 1 20
Blue 25 7 28
Green 31 2 6
White 10 1 10
Yellow 25 4 16
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also after temporary henna tattoos application [168]. Greens and blues containing 
copper phthalocyanine pigments induce fewer allergies than those elicited by cobalt or 
chromium pigments. The role of manganese in inducing granulomatous allergic reactions 
in purple tattoos has not been proved [190]. 
Most of granulomatous reactions are foreign body encapsulation forms, appearing like 
papulo-nodular skin deposits of black pigment. They are not considered as allergic 
reactions by Serup, who classifies them as inflammatory non-infectious [192]. An allergic 
form with eczema and inflammation, probably due to aluminium, present in almost all 
tattoo inks as additive or pigment, may sometimes mimic the granulomatous forms [18] 
The purely allergic characteristic of such aluminium-induced granulomatous responses 
has been challenged, since they might also appear as sarcoidal granuloma involving, in 
predisposed patients, immunotoxic factors responsible for systemic sarcoidosis [17]. 
Sweeney, [203], reports a case of uveitis (eye inflammation) concomitant with a tattoo 
reaction probably to cobalt-containing pigments, while Setlur, [204], described a fatal 
case of granulomatous reaction in a patient died from pneumonia upon foreign body type 
response to his tattoo. Post-tattoo ocular involvement has also been reported by 
Ostheimer [205] (bilateral uveitis in all 7 patients with elevated and indurated black 
tattoos on various locations, e.g. arms, chest and abdomen), and by Kaatz [157] 
(concomitant retinal vasculitis and cystoid macular oedema). 
Other types of granuloma are extremely rare, and in the case of tuberculoid 
granulomatous reactions to ferric oxide and chromium salts used in eyebrow PMU, they 
can have similarities with skin infections practically erased from developed countries, 
such as tuberculosis or leprosy. Cases of inoculation cutaneous tuberculosis and leprosy 
have been observed after tattoing in jail, in communities with high disease prevalence or 
in endemic regions [169]. 
 
9.3.1.4. Lymphomatoid reactions 
Called also pseudolymphomatous reactions, these erythematous indurated and 
sometimes itchy nodulo-papules and plaques mimic clinically and histologically skin 
lymphomas, but in 80-90% of cases fail to transform into malignant tumours [206]. Only 
one case of such evolution has been described so far in relation to tattoo reactions 
[169]. This delayed (from weeks to 42 years after the tattoo event) hypersensitivity 
infiltrates mostly start within the red parts of the tattoos (79% of the 19 cases studied 
by Marchesi [206]) but may also grow beyond the tattooed area, and involve other 
pigments: blue (cobalt), green (chromium) and black. Patch-tests to detect the culprit 
antigen are inconclusive. Pérez-Cotapos [207] sustains that months or years after 
tattooing people allergic to metal can display eczema, lichenoid reactions, or pseudo 
lymphoma. 
 
9.3.1.5. Pseudoepitheliomatous hyperplasia (PEH) 
Weeks or months after a tattoo application these infrequent wart-like nodules or plaques 
warrant a skin biopsy to differentiate them from tumours (see section 9.4.2.1). They 
might also be associated to cutaneous infectious [163]. 
 
9.3.1.6. Scleroderma and scars 
In the long run the inflammatory processes described above may end up to a fibrotic and 
indurated aspect including scarring and keloids, labelled as scleroderma or pruritic 
morphea-like pathology, very similar to isomorphic reactions (see next section) 
developed in patients suffering from underlying connective tissue disorders [169]. The 
etiopathogenesis mentions prior needle trauma (like in tattooing or vaccination), but 
Thum [168] found no correlation between these traumas and morphea/scleroderma 
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diagnosis, suggesting to be due to persistent inflammatory process elicited by ink 
ingredients. 
In the case of rare sequels to allergic reaction to black henna, hypertrophic or keloid 
scars have been reported [168, 193, 194].  
As far as tattoo removal is concerned, permanent hypertrophic scars may develop if the 
Q-switched laser therapy causes deep damage under misappropriate conditions, or is 
applied at high energies required by resistant multi-coloured tattoo's containing iron 
oxide or titanium dioxide [162, 207]. 
 
9.3.2. Underlying Dermatoses reactivated by tattooing  
9.3.2.1. Köbner phenomenon  
Köbner described in 1872 the "isomorphic" phenomenon: a psoriasis-like eruption 
emerging within the tattooed area of an already psoriatic patient. In addition to psoriasis 
similar flaring reaction may concern many more chronic dermatoses such as lichen 
planus/sclerosus, lupus erythematosus, atopic dermatitis, sarcoidosis, pyoderma 
gangrenosum, vitiligo, and skin vasculitis. Patients suffering from such underlying 
disorders, and also those presenting latent herpes infections, have the risk to see their 
disease being reactivated by the tattooing procedure. This "Köbner phenomenon" is 
clinically difficult to grasp, being more frequent in immunosuppressed patients. The 
incubation period of this flaring ranges from 1 week up to decades after the skin injury 
(usually within 10-20 days. Thum [168] observed a case of psoriatic arthritis within a 
week after skin lesions. An unambiguous link between tattooing and widespread flare-up 
remains to be proved, according to Kluger [161]. 
 
9.3.2.2. Sarcoidosis 
One of the main "dermatologic masqueraders", as defined by Selim [208] remains 
sarcoidosis, whose etiopathogenesis and diagnostic are mysterious [209], just as its 
controversial links with tattooing [157]. This systemic autoimmune pathology affects 
between 10 and 20 individuals on 100,000 in the general population [170]. Genetic 
predisposition is a requisite, but needs added environmental factors, like old skin injuries 
and scars, or embedded foreign bodies (e.g. in the opinion of some authors, tattoo inks) 
to trigger the disease, in particular with patients treated with interferon [169]. 
Granulomatous skin reaction, even of the non sarcoidal type, may reveal the systemic 
sarcoidosis in 25-30% of latent patients. This may happen from some weeks after the 
trauma, up to 45 years later, as mentioned by Kluger who considers that "The tattoo is 
most probably the target of sarcoidosis, rather that its cause" [170]. 
Clinically, the local symptoms are unspecific, ranging from no complaints to tender itchy 
papulo-nodules, plaques or infiltrations within the tattoo. Accompanying lesions may 
include scaling, ulcers or blisters. Reviewing 75 patients with sarcoidotic skin reaction to 
tattoos/PMU, Kluger [170] found that cases with lesions confined to the tattooed area 
were twice as numerous as those where the nodules were present outside the tattoo, on 
other scars, or elsewhere on the skin. Histopathologically difficult to differentiate from 
foreign-body granuloma, cutaneous sarcoidal manifestations restricted to one colour of 
the tattoo might represent hypersensitivity to the ink pigment (red and black being the 
most frequent), or the initial and often sole symptom of a general sarcoidosis (extra 
cutaneous involvement). The latter involves typically blue pigments, but green and 
brown may be encountered as well. Most of multi-coloured tattoos' patients react within 
a single colour of the tattooed area. However in 40% of cases, different colours were 
involved simultaneously. 70% of patients suffered from systemic sarcoidosis (no follow 
up for the remaining 30% which might potentially also develop symptoms in the long 
run), and from those 69% had their mediastinal lymph nodes infiltrated, and some had 
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their lungs affected. Lo Schiavo [210] reported that 74% of patients with skin 
sarcoidosis in a tattoo would be diagnosed later a systemic form.  
 
9.3.2.3. Vasculitis 
According to Thum, so far only 4 cases of post tattoo cutaneous vasculitis have been 
documented in the medical literature [168] with an incubation period comprised between 
10 days to 28 years after the tattooing. The responsibility of ink ingredients has not 
been substantiated [175]. 
 
9.3.2.4. Lupus erythematosus 
Thum Chee reported one case of cutaneous lupus erythematosus lesions developed in a 
black tattoo 3 weeks after its application, which later on spread beyond the tattooed 
area. Patients without signs of systemic lupus erythematosus may present “Skin lupus 
erythematosus–like tattoo reaction” to an old tattoo. Several cases of patients with 
known systemic lupus erythematosus developing, sometimes 15 years later, discoid 
lupus erythematosus–like reactions within tattoos, have been published in the medical 
literature [157, 161, 168, 211]. 
 
9.3.2.5. Lichen 
In post-tattoo lichenoid eruption, differential diagnosis between a true lichen planus and 
a generalized lichenoid tattoo reaction can be difficult. Some other anecdotal 
manifestations include lichen sclerosus and atrophicus, perforating collagenosis 
granuloma annulare (associated with red tattoos), erythema multiform and scleroderma-
like reaction restricted to the red parts of a tattoo, Darier’s disease (genetic Keratosis 
follicularis) [161, 169, 212]. 
 
9.3.2.5. Other chronic dermatoses 
Juhas [198] mentions an usual complication, morphea. Other rare manifestations such 
as Pyoderma Gangrenosum (PG), especially in the lower limbs, have been described in 
only two patients, one of them affected concomitantly by hematologic cancer [169].  
 
9.4. Other secondary effects  
Other types of tattoo collateral effects relate to pigmentary disorders, especially after 
laser removal, and to diseases such as cutaneous tumours, which may appear 
coincidentally within a tattooed area, but without any clear link to the tattoo procedure. 
However, even though tattoos might not elicit skin cancer, they can blur its surveillance, 
and interfere with the diagnostic and treatment of several other pathologies. Finally, a 
recap of main contra-indications to tattooing is presented in 9.4.4. 
 
9.4.1. Pigmentary disorders  
QS Laser removal is major responsible of pigmentary disruptions, grouped in 
hypopigmentation, hyperpigmentation, and paradoxical darkening. As part of the risk 
communication strategy, tattoo candidates should be warned that due to these collateral 
effects, the laser therapy, on top of being painful, might represent a lengthy and 
frustrating process, sometimes without achieving the same level of completeness as the 
patient expected. Table 9.6 lists the main Q-Switched lasers in use together with the 
indication of the wavelength at which they operate. 
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Table 9.6: Summary of Q-Switched lasers currently in use. 
 
 
9.4.1.1. Hypopigmentation 
At certain QS laser wavelengths (especially in the ultraviolet range) the epidermal 
melanocytes are destroyed preferentially, leading, from one up to several months after 
treatment, to unwanted hypopigmentation, especially present in patients with tanned or 
darker skin [83, 173]. Sun exposure should therefore be avoided before laser treatment, 
while proper 10-days aftercare (treated area to be kept elevated and cooled) reduces the 
formation of bulla in most cases. Operating with Nd:YAG laser at its longest wavelength 
(1064 nm) would minimise that risk [162]. However, in order to remove tattoos coloured 
in red, yellow and orange, its shorter wavelength (532 nm) is required, making 
hypopigmentation unavoidable. This melanin pigment deficit is usually transient, but 
might last for years and or even life long, in particular in case of multiple laser sessions 
[82, 163, 172, 173]. Such permanent hypopigmentation could affect up to 10% of the 
individuals having removed their tattoos with laser [82, 162, 163]. 
 
9.4.1.2. Hyperpigmentation  
Especially with darker-skin individuals and people having been treated before with gold 
salts for diseases such as rheumatoid arthritis, laser irradiation increases dermal UV 
sensitivity, leading to transient hyperpigmentation in 5-10% of cases, the incidence 
climbing with repeated laser treatment [82, 162, 172, 173, 213]. 
The use of gold salts and exposure to UV light sources is known to induce chrysiasis 
(permanent alteration of skin pigmentation due to deposition of gold and triggered by UV 
radiation). For this reason, people treated with such salts or affected by chrysiasis 
should be advised to carefully consider the possibility to undergo QS laser tattoo removal 
in order to avoid worsening hyperpigmentation disorders. 
 
9.4.1.3. Paradoxical darkening  
Occurring frequently after QS laser therapy, and in particular removal of multicolour 
tattoos, paradoxical darkening is probably induced by metals oxides contained in tattoo 
pigments. Therefore, it is often observed while treating white inks based on titanium 
oxide and flesh-toned colours for PMU containing iron oxides. This modification is 
commonly temporary, but can sometimes become permanent [82, 83, 168, 207, 213]. 
In a study of 184 patients [213] having removed their non-black tattoo with QS laser, 33 
suffered colour shifts from white, flesh-coloured, red, brown, yellow and crimson areas 
of their tattoos to mild grey or black. 
 
9.4.2. Tumours  
It is unclear whether tattoo inks may induce tumours, be it local or general. On the one 
hand, many substances contained in tattoo inks (such as PAHs in black pigments or 
PAAs) and their (photo) degradation products, sometimes with increased solubility 
properties, are classified as mutagenic, genotoxic and carcinogenic. On the other hand, 
cancer is considered a multifactorial disease, which may take decades to express. Thus a 
direct correlation between tattoo and tumour is challenging to establish and a 
straightforward causality between tattooing and cancer formation is far from being 
Q-Switched Laser Wavelenght (nm) Tattoo Colours
532 Red; Orange
1064 Black; Blue
Ruby 694 Black; Blue; Green
Alexandrite 755 Black; Blue; Green
Nd:YAG
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demonstrated.. Hence most authors consider the growth of cutaneous tumours within 
tattooed areas as purely incidental [171, 203]. 
Considering that millions of people are tattooed, and compared to the 2-3 millions of 
skin cancers arising each year [177, 192], the 50 cases of skin tumours developed in 
tattoo areas reported during the last 40 years seem negligible and in the authors' 
opinion has to be considered thus far as coincidental [171]: 16 cases of melanoma, 11 
cases of basal cell carcinoma (BCC) [214], and 23 cases of squamous Cell Carcinoma, 
SCC (difficult to distinguish from keratoacanthoma, KA), with a latency ranging from 1 
month to 55 years after the tattoo. While melanoma and BCCs are more frequent within 
dark coloured tattoos, SCCs, KAs and pseudoepitheliomatous hyperplasia (PEH) appear 
mostly on red tattooed areas [171]. Further, old concerns about epidermal neoplasms 
following lumbar puncture through lower back tattoos have been discarded by Kluger 
[215], who stresses that "there has never been a case of malignant melanoma, basal-
cell carcinoma (BCC), or squamous-cell carcinoma (SCC) occurring on a single tattoo". 
 
9.4.2.1. Pseudoepitheliomatous Hyperplasia 
These benign nodules, warts, plaques or ulcerated lesions may develop from one week 
to a few months after tattooing, mainly within red coloured areas, in connection with 
infectious, inflammatory affections (see section 9.3.1.5). Kluger in his review reports 10 
cases in the last 40 years [171]. Clinically and histologically, the distinction with KA or 
verrucous tumours remains a challenge [169]. 
9.4.2.2. Keratoacanthoma and Squamous Cell Carcinoma 
Post tattoo appearance and evolution helps to distinguish between benign PEH, 
borderline KAs (develop from one week to a year after tattoo, only associated to red inks 
in 82% of cases, regress spontaneously within a few months), and malignant SCC, which 
may grow more than 20 years after tattoo, albeit without causative link with it (Kluger 
2012 Lancet onc) [167]. 
 
9.4.2.3. Basal cell carcinoma 
Rarely growing after a skin injury, this tumour may invade secondarily a tattoo from the 
adjacent non-tattooed skin. 
 
9.4.2.4. Melanoma  
Kaatz' risk analysis [157] could not show tattooing was a meaningful risk factor for the 
growth of malignant melanoma. However this neoplastic lesion should not be confused 
with benign nevi which can also arise within a tattooed area, rendering the differential 
diagnosis very arduous (see point 9.4.3 hereunder). 
 
9.4.2.5. Cutaneous lymphoma and other rare skin tumours  
The only documented case of pseudo lymphoma in tattooed area transforming after 
years into an invading skin lymphoma has been reported by Kluger [171], who also 
mentions other extremely rare malignancies appearing years after tattooing, yet without 
any causality with it, such as dermatofibrosarcoma protuberans, or leiomyosarcoma. 
Baker [216] reported one case of dermatofibrosarcoma protuberans (uncommon, locally 
aggressive cutaneous tumour of intermediate grade malignancy) arising in a tattoo. 
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9.4.3. Medical diagnostic and treatment interference  
Dark coloured pigments used in tattoos may deposit in both skin and regional lymph 
nodes, and mask the possible growth and malignant transformation of pre-existing nevi 
in the tattooed area (false negative), or mimic metastatic invasion of a lymph node by a 
melanoma (false positive). However using modern immunohistochemical techniques it is 
now possible to distinguish between the two types of pigmentation. 
Other false-positive results may occur in mammography when tattoo inks contain 
metals, and especially iron oxides able to blur diagnostic imaging such as MRI8 and PET9 
scan. In rare cases MRI exams may also lead to complaints of pruritus and burning in 
tattooed individuals [157, 207, 217]. Spinal anaesthesia in the lumbar region, frequently 
used in obstetrics, is more difficult to carry out if the skin area is tattooed, in particular 
with dark colours, but the potential risks of such a procedure are still under debate with 
different opinions expressed by various authors [215].  
 
9.4.4. Contra-indications to tattoo procedures  
Many physicians advice to avoid tattoo procedures in customers, both presenting specific 
clinical peculiarities and suffering of different disorders, at dermal or systemic level. 
 
9.4.4.1. Skin Disorders  
• Pre-existing moles or other pigmented dermal lesions in the tattooed area may 
display histological post-injury atypical changes, and complicate the surveillance 
of any potential malignant transformation years after the tattooing. Suspicious 
nevus or infectious reaction within the tattooed area warrants postponement of 
tattoo procedures until a reliable diagnosis is established and appropriate 
treatment carried out [82, 83, 162, 213, 218]. 
• Sun baths should be avoided in the period preceding laser removal to diminish 
the risk of skin blistering.  
• Prior sensitivity to latex, nickel or other chemicals used in tattoo inks can be 
reactivated by the tattoo procedure. Eczematous patients may encounter a more 
difficult aftercare wound healing process. People having experienced an allergic 
reaction at tattoo placement stage should be warned against the risk of 
anaphylactic shock during the laser removal stage, and thus could be treated 
preventively by corticosteroids and antihistamines [83, 167]. 
• Years after the tattoo procedure, chronic skin disorders, such as psoriasis or 
lichen, might reactivate and induce a rash within the tattoo (Köbner 
phenomenon) [161]. Tattooing on the edge of a vitiligo lesion may trigger its 
extension [219]. Prior latent cutaneous herpes might be reactivated by tattooing 
procedures. 
• Patients previously treated with gold salts and those suffering from chrysiasis 
(UV-induced skin hyperpigmentation due to deposition of gold) should be 
prevented from tattoo removal by QS laser to avoid aggravating the pigmentation 
disorder [82]. 
• Traumatic tattoos with embedded combustible material involve the risk of re-
ignition during the laser treatment stage, which can give rise to substantial 
scarring [83, 213]. 
                                           
8 Magnetic resonance imaging (MRI), or Nuclear magnetic resonance imaging (NMRI) 
9 Positron emission tomography (PET) 
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• Patients with known pre-existing Pyoderma Gangrenosum should be strongly 
advised against tattooing, particularly on the lower extremities [169]. 
 
9.4.4.2. Systemic Disorders  
• Haemophilic patients or those with coagulation disturbances may display 
extensive bleeding secondary to the needle injury, and need medical approval 
prior to proceed with tattooing [219]. 
• Patients with heart valvulopathy (1% of the general population) need antibiotic 
coverage before any tattoo procedure, or otherwise take the risk of infective 
endocarditis and fatal septicaemia [181].  
• Underlying autoimmune systemic diseases (sarcoidosis, lupus erythematous, etc.) 
or treatment with interferon, might trigger delayed flaring of the latent disease 
within the tattoo [169]. 
• Immunosuppressed and diabetic patients should be aware that their risk of 
getting a post-tattoo infection or undergo a delayed wound healing process 
(during application or removal) can be increased [82]. 
• As a general preventive measure, it is advisable not to perform any tattoo 
procedure in pregnant or breast feeding women, even though no specific risk 
could ever be shown ([198]). 
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10. Experience with the CoE ResAP(2008)1 
The first CoE ResAP was published in 2003 and it was substituted by an updated version 
in 2008. Since then various European countries have gained experience in the 
implementation of the recommendations of the resolutions, either because they have 
adopted national legislation largely based on them or because they perform market 
surveillance activities using the list of chemicals contained in the CoE ResAP(2008)1 as a 
reference for the RAPEX notifications on dangerous tattoo/PMU inks. 
This chapter aims to revise such experience on the basis of the replies gathered via a 
questionnaire and the discussions held during the meetings of the CSN-STPM with the 
intention to evaluate if new recommendations to improve the safety of tattoo/PMU inks 
would be needed and could be put forward. 
For more detailed information please refer to the JRC report on the Work Package 3 of 
the project [3]. 
 
10.1. Chemical requirements  
The CoE ResAP(2008)1 recommends not to use about two thousands substances in 
tattoo/PMU inks. Some of them are listed in its Table 1 (27 aromatic amines) and Table 
2 (35 colorants), but the large majority is enumerated in lists which are part of European 
legislations referred to in the resolution (cosmetics and CLP regulations, as well as 
Directive 95/45/EEC). In addition, Table 3 of the CoE ResAP(2008)1 suggests the 
maximum recommended concentrations for impurities. 
On the one hand, many repetitions exist in the chemical recommendations of the 
resolution and the same substance is often cited in more than one list. For instance, out 
of the 27 aromatic amines present in Table 1 of the resolution, 25 are also classified as 
CMR in the CLP regulation and 19 are mentioned in Annex II of the cosmetics one. A 
similar situation is observed for colorants. 
On the other hand, Table 1 and 2 do not list all the aromatic amines and colorants that 
the resolution advices not to be used in tattoo/PMU products; many additional ones are 
present in Annexes II and IV (with restrictions in column g) of the cosmetic regulation 
and in Annex VI (Table 3.1) of the CLP one, they were identified and listed in Annex I of 
the JRC report on Work Package 1 [1]. 
The presence of various negative lists in different documents complicates the 
implementation of the recommendation by stakeholders, such as enforcement 
laboratories and manufacturers. From this point of view, the preparation of 
comprehensive negative lists at least for the most important ingredients (colorants) and 
impurities/degradation products (aromatic amines) of inks was judged positively by a 
number of experts. In addition, several stakeholders indicated that the chemical 
requirements should be EU harmonised. 
The aromatic amines in Table 1 of the CoE ResAP(2008)1 should neither be present in 
tattoos and PMU products nor released from azo-colorants in concentrations that are 
technically avoidable according to Good Manufacturing Practices. The experts of the 
CSN-STPM agreed on the need to specify limits for these compounds, even though not 
on the value(s) to be adopted. 
Based on the discussions held during the CSN-STPM meetings and the replies to the 
questionnaires, the aromatic amines and colorants reported in Tables 10.1 and 10.2 
could/should be evaluated for addition to the negative lists of Table 1 or 2 of the CoE 
ResAP(2008)1, respectively. The last column of Table 10.2 presents possible degradation 
products classified as CMRs, which might be formed by reductive cleavage of an azo 
bond or by break of an amide link. In the same Table, the colorants listed with an 
asterisk do not belong to those reported as currently in use. 
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Table 10.1: Aromatic amines that could be evaluated for inclusion in Table 1 of CoE ResAP(2008)1. 
 
 
Table 10.2: Colorants that could be evaluated for inclusion in Table 2 of CoE ResAP(2008)1. 
 
EC Reg 1223/2009
Substances CAS 
number
Annex II                 
(ref. number)
Annex VI                    
Table 3.1                          
(index number)
Classification 
(CMR, 
Skin/Eye 
Irrir./Sens.)
aniline 62-53-3
X (22)                      
(its salts and its 
halogenated and 
sulphonated 
derivatives)
X (612-008-00-7)
Carc. 2, Muta. 
2, Eye Dam. 1, 
Skin Sens. 1
2-ethoxyaniline 94-70-2
N-isopropyl-N'-phenyl-1,4-
phenylenediamine 101-72-4 Skin Sens. 1
EC Reg 1272/2008
CI         
Generic 
Name
 CAS number 
Colorant 
class
Annex II                 
(reference n.)
Annex IV 
(column g) 
(reference n.)
Annex VI                    
Table 3.1                          
(index number)
Classification 
(CMR, 
Skin/Eye 
Irrir./Sens.)
Possible 
degradation 
products
P Blue 15 147-14-8 phthalocyanine 
X  (1367)           
(when used as a 
substance in hair 
dye products)
P Green 7 1328-53-6 phthalocyanine
X (1369)         
(when used as a 
substance in hair 
dye products)
X (107)                
(not to be used 
in eye 
products)
P Red 5 6410-41-9 
monoazo
X (1347)                 
(and its salts when 
used as a 
substance in hair 
dye products)
P Red 17 6655-84-1 
monoazo
5-nitro-o-toluidine 
(Table 1, Annex II, 
CMR)                            
o-toluidine (Table 1, 
Annex II, CMR)                           
P Red 181                                                          
VAT Red 1
2379-74-0 
indigoid
X (1365)          
(when used as a 
substance in hair 
dye products)
it may cause reactions 
in the skin
P Violet 1 1326-03-0 
xanthene
P Yellow 1 2512-29-0 
monoazo
X (4)                     
(not to be used 
in products 
applied on 
mucous 
membranes)
 aniline (Annex II, 
CMR)
P Yellow 2* 6486-26-6 
monoazo
p-chloroaniline (Table 
1, CMR)
P Yellow 3 6486-23-3 
monoazo
X (5)                     
(not to be used 
in products 
applied on 
mucous 
membranes)
P Yellow 5* 4106-67-6 
monoazo
aniline (Annex II, CMR)
P Yellow 74 6358-31-2 
monoazo
o-anisidine                        
(Table 1, CMR)
S Yellow 14* 842-07-9  
monoazo
X (1107) X (611-056-00-6) Carc. 2, Muta. 2, Skin Sens. 1 aniline (Annex II, CMR)
EC Reg 1223/2009 EC Reg 1272/2008
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Considering the scientific evidences of the possible degradation of azo pigments in the 
skin and under light irradiation, for aromatic amines a different approach could also be 
taken into consideration. In fact, all those azo pigments that by reductive cleavage or 
break of amide bond could give rise to aromatic amines classified as CMRs or mentioned 
in Annex II of the cosmetic regulation could be inserted in the negative list of colorants. 
Several national Competent Authorities and stakeholders would welcome an EU 
harmonised legislation on the chemicals present in the CoE ResAP(2008)1, as well as the 
establishment of a positive list of colorants allowed to be used in tattoo/PMU products 
and the harmonisation of analytical methods. 
There was also a consensus among experts that limits for impurities in Table 3 of the 
CoE ResAP(2008)1 need to be revised or established, for instance for nickel, or added 
(strontium); however further discussions and evidences would be necessary to agree on 
values. 
 
10.2. Labelling requirements  
A general consensus was gathered on the need to add the following labelling 
requirements: 
• period of maximum durability after opening (PAO); 
• storage conditions; 
• product type (ink for tattoo or PMU); 
• health warnings; 
• quantitative composition label. 
No agreement was reached on the benefit to include in the label the production date, the 
distributor's address and the indication of the sterilisation method used for the inks. 
 
10.3. Register of complaints/side effects and pre-marketing 
requirements 
The majority of respondents were in favour of the establishment of a compulsory register 
of complaints and side effects. 
On the contrary, opinions diverged on the proposal to set up a pre-marketing 
authorisation for tattoo/PMU inks.  
 
10.4. Hygiene/sterility requirements 
Some national Competent Authorities were in favour of making compulsory the 
specification of the ink and tool sterilisation methods (in the label), as well as the 
premise disinfection methods. 
 
10.5. Other proposals  
Among the additional proposals, the following were suggested by several Competent 
Authorities: 
• to establish Good Manufacturing Practices for tattoo/PMU inks; 
• to make safety assessment of inks compulsory; 
• to prepare guidelines for risk assessment of tattoo/PMU products; 
• to develop harmonised hygiene guidelines; 
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• to carry out market surveillance on products sold on the web; 
• to establish compulsory training for tattooists (in accordance with national 
legislations); 
• to enhance the collaboration among manufacturers and authorities; 
• to ban backyard tattooing and illegal sales of "start-kits". 
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11. Risk perception and communication 
Information about communication and perception of the risk associated to the 
permanent tattooing practice was collected through a questionnaire distributed to 
national authorities, as well as through a literature survey. The results are presented in 
the following sections. 
 
11.1. Answers to questionnaires  
Risk communication 
Nine national Competent Authorities provided data about the information campaigns that 
were conducted either at national or at local level in their countries. Their characteristics 
in terms of target audience and means used are summarised in Figure 11.1. 
Targets included possible customers, tattoo artists and studios, physicians and school 
teachers; while means comprised printed materials, media coverage and events. 
 
Figure 11.1: Characteristics of the information campaigns carried out by respondents. 
 
General public seemed to be the preferred recipient of information campaigns, having 
been indicated by four different Member States with media (newspapers, radio, TV and 
internet) as the preferred means distribution, mainly at national level. 
 
Figure 11.2: Need for additional information campaigns. 
 
In the opinion of the majority of respondents and of experts of the CSN-STPM, to provide 
information on the risks of tattooing is indispensable to improve the safety of tattoo/PMU 
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practices and campaigns should be intensified towards tattoo artists, potential clients 
(including students) and general public (Figure 11.2).  
If and when used, the prior informed consent document is a way to inform customers 
about the risks associated to the practice they are going through. One Member State, 
Italy, replied that a compulsory prior inform consent has to be signed by customers and 
seven that this is not mandatory, even if three of them recommend tattooists to use it. A 
recent survey performed by the Italian Institute of Health, in 2014-2015 on 7608 
persons aged 12-75+ years old, showed that 50.8% of tattooed people signed the 
informed consent, 22.3% did not remember and 26.8% did not sign. Figure 11.3 reports 
the replies of six national authorities regarding the information available or requested in 
the prior informed consent document. 
 
Figure 11.3: Content of the prior informed consent document. 
 
Risk perception 
Only three national Competent Authorities were able to provide indications about risk 
perception of risks among the general and/or tattooed population, while six reported that 
they had no information at all. In their opinion, risk perception is mainly based on: 
• awareness of prior aggravating medical conditions; 
• awareness of the risks, such as infections and disease transmission. 
Surprisingly, the choice of tattooists (professional or not), the safety of premises and 
tools in terms of sterility and hygiene, or the permanency and risks associated to 
removal options were not mentioned as reasons of concern for the general and/or 
tattooed population. 
 
11.2. Literature  
The perception of the risks linked to tattoo/PMU application and removal and their 
communication has been approached in many studies on adverse health effects, as a 
consequent issue [10, 70, 164, 188, 220, 221]. 
As for risk perception, these studies revealed that individuals desiring a tattoo are 
usually not aware of the ink ingredients, safety of tattoo inks and health risks connected 
to tattoo application/removal, including prior aggravating medical conditions. For 
instance, in an internet survey launched by Klügl and collaborators [70], emerged that 
41% of the sample (3411 tattooed individuals) were not interested in the chemicals 
injected in their skin and about 33% of participants considered safe the injection of 
tattoo colorants in the human body. 
Concerning risk communication, information campaigns and educational programs 
addressed to public, tattoo artists, ink and pigment manufacturers, and health care 
professionals and covering adverse health effects linked to both tattoo application and 
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removal are considered pivotal by many authors, e.g. to avoid the risk of bloodborne 
infections such as hepatitis [164, 188] and non-tuberculous mycobacterium skin 
infections [220]. Young people were identified as the most important target of 
information campaigns by the Belgian Superior Health Council [10]. 
Finally, all the aforementioned authors agree on the fact that tattoo artists should be 
obliged to keep records of their clients and to report any adverse effects related to 
tattoos to health authorities.  
In the literature eight studies focussed specifically on risk perception related to body art 
practices, including both tattoo/PMU practices and piercing. Six were conducted in Italy 
[63, 64, 222-225], one in Denmark [226] and one in Canada [75]. They were all based 
on anonymous questionnaires addressed to students (ranging from secondary school to 
university), except the Danish study that was targeted to a representative sample of 
Danish population. 6.3-31.7% of the participants taken into consideration had at least 
one tattoo. When reported, the mean age at first tattoo was below 18 years old. The 
prevalence of interviewed people interested in getting a tattoo was in the range 25-57%. 
Among the tattooed and/or pierced individuals, 27-90% referred to an authorised 
operator to get their body art practiced and 28-76% observed the use of 
sterile/disposable instruments. Table 11.1 summarises the main findings linked to risk 
perception and communication. 
Among the people aware of the possible risks associated to body art practices, those 
able to identify infections as a source of risks (36-90% of respondents) were by far more 
than the ones aware of non-infectious risks (26-65%). This knowledge seemed to be 
superficial as only 3.5-60% of respondents could correctly identify hepatitis B, C and HIV 
viruses among the transmittable agents and 2-5% were able to identify allergies, 
bleeding and cysts as non-infectious risks. These results support the opinion that 
information campaigns are needed. 
Tattoo artists and piercers were reported as being the main source of information on 
possible risks. The informed consent was signed by 7-31% of Italian respondents and 
was considered the source of information about possible risk by 19% of the 
undergraduate university student interviewed by Quaranta and collaborators [64]. 
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Table 11.1: Available literature data on risk perception/communication. 
 
[61, 63, 64, 68, 223-226] 
 
Sample Target Awareness of a 
"General Risk"
Information 
before 
undergoing the 
practice
Signed 
informed 
consent
From 
tattoois/piercer
From 
another 
person
From 
informed 
consent
General
Ability to 
identify HBV, 
HCV, HIV as 
infectious risks
Ability to 
identify tetanus 
as infectious 
risks
General
Ability to identify 
any of  non-
infectious risks
2013, DK YouGov Danish population
34% (HCV, 
HBV); 29% (HIV)
48% (allergies);              
37% (swelling);            
35% (inflammation);            
33% (photosens.);                  
19% (cancer);                       
15% (lump/node 
formation)
55%
11% (swelling); 
11% (allergies); 
6% (inflamm.); 
4% (lump/node 
formation);        
2% (cancer)
2013, Majori 2712 Italian Students 81.6% 50%
2012, Gallè 3132 Italian Students 84.4% 4.1% 59.2% 5.4% 57.9%
2011, Quaranta 1598 Italian Students 90% 34-60% 34% 65% 74% 31% 52% 29% 19%
3610
Italian 
Students 
(university)
57.1% 87% 15% 59% 3% 15.30% Main
9322
Italian 
Students 
(high 
school)
24.7% 79% 3.50% 46% 2% 6.90% Main
2010, Sidoti 1200
Italian 
Students 36.5% 26%
2010, Cegolon 4277
Italian 
Students 54.4%
2006, Deschesnes 2145
Canadian 
Students
2011, Gallè
Awareness of a non-
infectious risksAwareness of a infection risks
Risk perception Risk Communication
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12. Data gaps and research needs 
The data gaps and research needs described in this chapter were identified during the 
project through a questionnaire sent to national authorities (10 replied), data available 
in the literature and the discussions held during the meetings of the Consumer Safety 
Network Subgroup on Tattoos and Permanent Make-up. 
In order to improve the safety of tattoo/PMU inks and practices the following actions 
were considered essential: 
• to develop guidelines for the risk assessment of tattoo/PMU products; 
• to develop and harmonise analytical methods for ingredients and impurities 
(heavy metals, AAs and PAHs) in tattoo/PMU products; 
• to gather data on normal usage of inks, including on the amount applied when 
tattooing, and on exposure to tattoo inks (surface of application, body area, 
colour, population group); 
• to collect further data on inks' chemical composition, stability and shelf-life, as 
well as ingredients' purity and concentration; 
• to gather data needed to carry out the risk assessment of both inks' ingredients 
and inks, such as: 
o physical-chemical properties of ingredients, including their stability (to 
solar/UV and laser irradiation, enzymes, bacteria), cleavage products and 
impurities; 
o absorption level, distribution, metabolism and excretion (ADME) of 
ingredients, including their fate in the body in particular pigments migration 
and photo-degradation [10, 191]; 
o derivation of No Adverse Effect Level (NOAEL); 
o toxicological data on ingredients (also nanoparticles), such as corrosion, 
irritation (skin, mucous membranes), phototoxicity, immunotoxicity 
(sensitisation, photo-sensitisation, etc.), in vitro genotoxicity, including test 
of cleavage products and photo-genotoxicity; 
• although costly, to perform long term epidemiological and prospective cohort 
studies in order to investigate the correlation between tattoos and adverse health 
effects, in particular skin carcinogenesis [10, 171, 211]. 
As several adverse reactions linked to tattoo removal were registered in the last years, 
more studies on the techniques employed for tattoo removals are required. Interesting 
starting points could be the development of tattoo pigments easier to be removed if 
needed, the study on the wavelengths of absorption of colorants involved in the 
tattooing process and the development of more efficient lasers equipment for easier 
laser removals [82, 227].  
Finally, according to Kluger, the addition of tattoo data in national skin cancer registries 
would help define the true prevalence of malignancies in tattoos [171]. 
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13. Conclusions  
Legislative framework 
DG JRC made a regulatory review of legal schemes on tattoo/PMU in all EU/EFTA 
countries plus other jurisdictions, available as of November 2014. The outcome of that 
review underlines a complex and varied situation in the different European countries. 
EU/EFTA countries 
Across EU/EFTA countries, 10 of them (Belgium, France, Germany, Liechtenstein, 
Norway, Slovenia, Spain, Sweden, Switzerland and The Netherlands) have 
embedded in their national regulatory framework recommendations from the 2003/2008 
Council of Europe Resolutions on tattoo/PMU products and services. In addition Austria, 
Denmark and Latvia have notified draft national legislation in line with CoE 
ResAP(2008)1, which are on hold as were not in line with REACH provisions. Czech 
Republic, Finland, Italy, Malta, Romania and Slovakia have regulated several health 
and safety aspects of tattoo practice, in particular the hygiene standards of parlours. 
Moreover, two of them i.e. Italy and Slovakia, ensure tattoo inks do not contain the 
hazardous chemicals listed in ResAP(2008)1. Bulgaria, Croatia, Cyprus, Estonia, 
Greece, Ireland, Luxembourg, Poland and Portugal, while not having yet put in 
place any specific legislation on tattoo/PMU, implement the EU legislation on consumer 
products safety, cosmetics and chemicals. No information was available for Hungary, 
Iceland, Lithuania and the United Kingdom.  
Those EU/EFTA countries following the ResAP recommendations have embodied into 
domestic regulations and guidelines different types of requirements applying to tattoo 
products and services. Chemical requirements impose to ban some harmful chemicals 
contained in tattoo/PMU inks. Most countries have adopted provisions along the lines of 
CoE ResAP(2008)1 hygienic (tattoo premises, tools and staff) and labelling (inks) 
requirements. Ink packaging criteria, followed by the 10 abovementioned countries, plus 
Italy, Malta and Romania, ensure sterility of tattoo inks before use. The safety period 
after opening of the bottle is indicated in Germany, Norway Spain and Sweden. Several 
countries (e.g. Czech Republic, France, Norway, Slovenia or Spain) impose to the 
manufacturer/importer of the tattoo/PMU product the obligation to prepare a safety 
assessment dossier prior to put it on the market, and to submit this file to the 
Competent Authorities. Spain is the only MS to have established a positive list of inks 
allowed for tattoo/PMU purpose on the Spanish market. Various forms of 
reporting/registering or monitoring system for adverse health effects from tattoo inks 
exist in different countries such as Austria, France, Norway, Romania, Sweden and The 
Netherlands. Tattooists in France, Liechtenstein, Malta, Norway, Slovenia, Sweden, 
Switzerland and The Netherlands, must duly inform the clients about the potential health 
risks and medical complications entailed by the tattoo application, including aftercare 
instructions and removal possibilities. In some countries like Norway and The 
Netherlands, such information is conveyed by the authorities through public campaigns 
targeting potential customers. To open and run a tattoo parlour, a specific license or 
diploma is mandatory in Belgium, Czech Republic, Italy, Liechtenstein, Luxembourg, 
Malta, Romania, Slovenia, Slovakia, Switzerland and The Netherlands, while specific 
training is required in France. Access to the profession and ad hoc training is also 
contemplated in draft legislation of Austria, Denmark and Latvia. With some exceptions, 
tattooing is generally forbidden to minors without a parental approval. 
As far as tattoo removal is concerned, The Netherlands and Romania consider it as a 
medical act, to be performed only under medical supervision. 
Other jurisdictions 
Beyond Europe, other developed countries have tackled the tattoo issue. New Zealand 
has adopted tattoo/PMU guidelines inspired by the last Council of Europe Resolution, and 
therefore limits the same chemicals as those listed in ResAP(2008)1. In Australia, 
Canada and the USA, tattoo procedures are regulated at respectively government 
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entities, provinces and states level, generating hence a wide variety of guidelines and 
hygiene standards. To our knowledge, tattoo inks are not regulated as such, and tattoo 
studios are not covered by a specific legislative scheme in Japan. 
Analytical methods 
In order to implement the chemical recommendations of the CoE ResAP(2008)1 
analytical methods aimed to detect and quantify different hazardous chemicals should be 
available. Yet standard methods specifically developed for the analysis of tattoo and PMU 
inks are lacking, both at national and international level. However, a number of test 
methods applicable in other areas (e.g. cosmetics, food and textiles) do exist and in 
some cases were adapted for tattoo/PMU products. In–house validated methods have 
also been developed by Member States' laboratories expressly for the analysis of 
aromatic amines, colorants, elements, PAHs and nitrosamines in tattoo and PMU 
products, but not yet for phthalates. These methods could represent the starting point 
for inter-laboratory validation and harmonisation. In addition a number of test methods 
for the analysis of tattoo and PMU products have been described in the literature. 
Tattoo/PMU prevalence and market 
The tattoo phenomenon is no more linked as before to certain marginal. 12% of the 
European general population is now tattooed (21-24% in the USA). This trend is 
upwards from the previous surveys. In Europe, when breaking the data down according 
to age, 2-9% of teenagers placed a tattoo, and a peak of 20-30% is reached before 30 
years-old. A net decrease happens after 50 years-old. There is not a standard size for 
tattoos, but they can range from less than 30 cm² (small) to more than 300 cm² (large). 
More than half of the tattooed individuals have more than one tattoo. Gender differences 
tend to disappear regarding the prevalence between women and men, but do include a 
reduced size for women (<300 cm²), a preferred localisation (trunk for women and 
extremities for men) and a smaller number/person for women (2-3 compared to ≥4). Up 
to 50% of the tattooed people have regrets, but only a fraction of those do the 
removal.10 Amongst the latter, two thirds are satisfied with the results. 
Depending on the country size the surveys vary between 50-8000 registered studios and 
100-5000 for non-registered studios. Although tattooists associations exist in most 
countries, only a limited number of tattooists are affiliated. Most tattoo inks on the EU 
market are manufactured in the United States, while PMU inks are generally produced in 
Europe, in particular in Germany, Italy, Spain and the United Kingdom. Non-professional 
tattooists, outnumbering the official ones in many countries, might not follow 
appropriate hygienic procedures and use cheap inks available on internet.  
Inks Ingredients 
Colorants represent by far the major ingredient of tattoo inks (up to 60% by weight), 
followed by additives, usually in concentration lower than 5% by weight. Inks may also 
contain impurities. Currently, as the tattoo ink market represents only a marginal 
fraction of the global production of colorants, the pigments used in tattoo and PMU inks 
are not specifically produced for such purposes. This poses the problem of lacking high 
purity. Moreover, they do not undergo any risk assessment procedure that takes into 
account their intra-dermis injection and long term permanence in the human body. 
There are a number of chemicals present in inks, either as ingredients or as impurities, 
which are banned in consumer products that get into direct contact with the skin under 
different legislative frameworks, like in cosmetics (Cosmetic Product Regulation) or in 
                                           
10 This estimate is different from what was reported in a previous JRC report (2. Piccinini, P., et al., Safety of 
tattoos and permanent make-up. State of play and trends in tattoo practices., 2015: JRC Report, EUR 27528 
EN, 10.2788/924128. p. 1-193,  http://bookshop.europa.eu/en/safety-of-tattoos-and-permanent-make-up-
pbLBNA27528/.), as new data have been published in 2016 and taken into consideration (84. Laux, P., et 
al., A medical-toxicological view of tattooing. The Lancet, 2016. 387(10016): p. 395-402.). 
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textiles (e.g. REACH restriction for aromatic amines), but so far tattoo inks are not 
covered by these legislations. 
Many of the colorants in use are actually included in the negative lists mentioned in the 
CoE ResAp (2008)1 and the majority are not allowed as ingredients in cosmetic 
formulations. More than 80% of the pigments in use are organic, and the majority of 
them are azo pigments. These colorants have been proved to undergo degradation via 
cleavage of azo bonds in the skin (sometimes induced by light irradiation) with formation 
of primary aromatic amines that can be carcinogenic. Colorants and other impurities 
contained in pigments (e.g. PAH in carbon black) were found in lymph nodes and could 
be widespread via the lymphatic or blood systems to the whole organism. They might 
eventually cause systemic toxicity, but further studies are needed to support such 
hypothesis. Limited information is available concerning the quality of additives. 
RAPEX and market surveillance 
The main issues identified from the analysis of RAPEX notifications are in line with the 
results of market surveillance campaigns conducted in different countries and confirm 
that tattoo/PMU products containing hazardous chemicals, mainly produced in the United 
States, are on the European market. Polycyclic Aromatic Hydrocarbons (43%), Primary 
Aromatic Amines (14%), heavy metals (9%) and preservatives (6%), as well as 
microbiological contamination (11%) were detected in the indicated percentages of the 
analysed samples. On this basis, it is of paramount importance that the national 
authorities keep on monitoring the market situation through national surveillance 
campaigns. 
Adverse health effects linked to tattoo application and removal 
As result of the trending popularity of tattoo and PMU practices, especially among 
youngsters, the literature reports more and more complications prompted by tattoo 
application and subsequent laser removal. Unfortunately, they may not reflect the full 
picture, as tattoo recipients are usually keener, especially for minor complaints, to return 
to their tattooist rather than to seek medical advice. As a matter of fact, and because 
there are no systematic data gathering on this issue, the actual extent and prevalence of 
tattoo adverse events is currently unknown and mainly of dermatological nature. In non-
clinical studies based on self-reporting, precise incidence figures are variable and up to 
67%, according to the definition of "adverse reaction", which may include factual 
medical symptoms or mere disturbance claims (e.g. pain, itching, swelling and redness), 
which are inherent to the wound healing process and usually disappear swiftly without 
treatment. Severe complications are not common and fatal cases exceptional. 
Adverse effects can been subdivided into the following categories: acute aseptic 
inflammation, infectious risks (bacterial and viral), allergic/hypersensitivity and auto-
immune type reactions and other secondary effects. 
Acute local effects such as pain, swelling, redness, lymphadenopathy, bleeding and 
blistering are very common during and/or immediately after the tattoo procedure 
(placing or removal), in the form of an acute aseptic inflammation provoked by the 
needle trauma or laser burn (for the latter, especially if incorrect parameters are 
applied). They generally disappear after some days, unless the wound gets infected by 
microorganisms. Systemic symptoms (headache, dizziness, fever, vomiting) and chronic 
itching have also been described. 
Infectious diseases, mainly from bacterial inoculation, sometimes from viruses, may 
complicate a tattoo/PMU application if minimal hygiene conditions (tattoo premises, tools 
and inks) are not fully met. The true incidence of such cutaneous bacterial infections 
appearing within several days after the placing of the tattoo remains unknown, but some 
estimations point at a range between 1 and 5% of all tattoo-recipients. Very rarely 
infections can further widespread, leading to regional abscesses and necrosis. Infective 
endocarditis with fatal septicaemia is exceptional in the general population, but should 
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be prevented in patients with prior valve heart disease, by an antibiotic umbrella before 
any tattoo application. 
Blood borne viral transmission, involving for instance hepatitis virus B and C, is 
theoretically possible during a tattoo application procedure, especially in unsanitary 
settings like prisons. Even though findings are sometimes controversial, the two main 
systematic reviews on the issue assert that tattooing is associated with hepatitis, 
particularly hepatitis C. It has to be considered, however, that any pathogenic 
contamination could be virtually eradicated if strict hygienic measures are duly applied 
by tattoo practitioners.  
The bulk of tattoo/PMU complications consist in hypersensitivity, called also "allergic" 
reactions, including photosensitivity, with unpredictable onset and duration, and 
nonspecific clinical appearance. They may occur either: 1) immediately (acute contact 
eczema by reaction to inks' ingredients , to latex proteins contained in tattooist's gloves, 
or to aftercare topical ointments), affecting mostly the red parts of the tattoos, and 
exceptionally provoke a general flush and cardiovascular collapse; or 2) after a long 
latency (months, years and even decades) in the case of chronic dermatosis and rare 
underlying auto-immune pathologies, such as systemic sarcoidosis, "revealed" rather 
than triggered in predisposed patients. Such reactions, sometimes exacerbated by sun 
exposure, are poorly predictable, and patch tests usually used for detecting allergies are 
mostly inconclusive for detecting the culprit substance (with frequent false negative 
results). Latent cutaneous herpes lesions might be reactivated by tattooing procedures. 
The risk of anaphylactic shock during a laser removal procedure is increased in patients 
with prior allergic reaction at tattoo application stage. 
In the long term sequels to allergic reactions include post-inflammatory dyschromic 
changes and hypertrophic/keloid scars. For laser tattoo removal, further to local or 
systemic allergic responses to inks degradation products, permanent hypertrophic scars 
and pigmentary disorders have also been described (i.e. hypo/hyperpigmentation and 
paradoxical darkening, affecting 5-15% of the individuals treated with QS laser). 
The risk of tattoo-induced tumours cannot be totally excluded, due to the carcinogenic 
properties of many inks' impurities, and of degradation products of ink ingredients, i.a. 
through laser treatment. However, in order to establish a direct cause/effect link, a risk 
assessment of those ingredients is necessary, together with prospective epidemiological 
studies. In any case, tattoos should be avoided in skin areas containing moles or 
pigmentary changes, as they could delay or complicate the diagnostic of potential 
malignant growth.  
Tattoos may also interfere with PET scan and Magnetic Resonance Imaging, provoking in 
rare cases burning complaints, and should be avoided in patients with existing cardiac, 
blood or autoimmune pathologies. Those suffering from diabetes raise their risks of 
complicated tattoo aftermath. Sun exposure is not advised before tattoo laser removal. 
Experience with the CoE ResAP 
According to experts from several Competent Authorities, in order to improve the safety 
of tattoo/PMU inks and practices the recommendations of the CoE ResAP(2008)1 should 
be revised. Practical suggestions ranged from the inclusion of additional substances in 
the negative lists, to the request of adding the period of maximum durability after 
opening and the indication of the ink sterilisation method on the label, to the 
establishment of a compulsory register for complications.  
Furthermore, several members of the CSN-STPM, both stakeholders and representatives 
from Competent Authorities, considered that the recommendations in the CoE 
ResAP(2008)1, in particular on the chemicals listed, should be made binding by an EU 
harmonised measure. 
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The establishment of Good Manufacturing Practices for manufacturing tattoo/PMU inks, 
compulsory training for tattooists, measures to control products sold on-line, as well as 
the ban of “backyard” tattooing were also considered as necessary. 
Risk perception and communication 
Additional information campaigns targeted to tattoo artists, potential clients and general 
public, with a particular emphasis on the young population, were considered as 
necessary both by the experts and papers in the literature.  
These conclusions are supported by a number of studies made on students, which 
pointed out a generally poor knowledge of risks related to body art practices, in 
particular the non-infectious complications. 
Data gaps and research needs 
The following data gaps and research needs were identified: development and 
harmonisation of analytical methods to assess the possible presence of impurities and/or 
banned ingredients, guidelines for risk assessment of tattoo/PMU products, including 
toxicological studies on ingredients, and exposure data from use of tattoo/PMU inks. The 
fate of those colorants in human skin and body (after tattoo application/removal) and 
their toxicokinetics (ADME for absorption, distribution, metabolism, and excretion) 
should be further investigated, including for their degradation products. Prospective 
epidemiological studies would be needed to ascertain the risk of carcinogenicity from 
tattoo inks constituents, including their degradation products.  
Currently, the CoE is developing guidelines, expected for 2016, on the risk assessment 
of tattoo/PMU products. 
Other recommendations 
In addition to addressing the abovementioned research needs, harmonised hygiene 
guidelines for tattoo/PMU professionals should be developed and further enforced. 
Currently, there is an on-going CEN project dealing with this issue. 
A harmonised curriculum and training at EU level for tattooists and a register for 
professional tattooists would be both welcome. Clandestine tattooing, source of most 
post-tattoo infections, must be eradicated and consumers information play a key role to 
reach this objective.  
Risk communication campaigns should be encouraged. 
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List of abbreviations and definitions 
Abbreviations 
ISO two letters country code were used for the abbreviation of country names. 
 
AA  Aromatic Amine 
AAS  Atomic Absorption Spectrometry 
BCC  Basal Cell Carcinoma 
CE-DAD  Capillary Electrophoresis with Diode Array Detector 
CEN  Comité européen de normalisation (European Committee for 
Standardization) 
CI Colour Index 
CoE  Council of Europe 
CSN  Consumer Safety Network 
CVAAS   Cold-Vapour Atomic Absorption Spectrometry 
DG JRC  Directorate General Joint Research Centre  
DG JUST  Directorate General Justice and Consumers 
DG SANCO  ex-Directorate General Health and Consumers 
EC  European Commission 
EDQM  European Directorate for the Quality of Medicines and Health Care 
EFTA  European Free Trade Association 
EU  European Union 
FLAA (or FAAS) Flame Atomic Absorption Analysis 
GC-FID Gas Chromatography coupled with Flame Ionisation Detector 
GC-MS  Gas Chromatography coupled with Mass Spectrometer detector 
GFAAS  Graphite Furnace Atomic Absorption Spectrometry 
GMP  Good Manufacturing Practices 
GPSD  General Product Safety Directive  
HBV  Hepatitis B Virus 
HCV  Hepatitis C Virus 
HGAAS Hydride Generation Atomic Absorption Spectrometry 
HIV  Human Immunodeficiency Virus  
HPLC-DAD High Performance Liquid Chromatography coupled with Diode Array 
Detector 
HPLC-FD High-Performance Liquid Chromatography with Fluorescence Detector 
HPLC-MS High Performance Liquid Chromatography coupled with Mass Spectrometer 
Detector  
HPTLC  High Performance Thin Layer Chromatography  
HPV  Human Papilloma Virus 
ICP-AES Inductively Coupled Plasma Atomic Emission Spectroscopy 
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ICP-MS Inductively Coupled Plasma Mass Spectrometry 
ICP-OES Inductively Coupled Plasma Optical Emission Spectrometry 
INCI  International Nomenclature of Cosmetic Ingredients 
ISO  International Organization for Standardization 
IUPAC  International Union of Pure and Applied Chemistry 
KA  Keratoacanthoma 
MALDI-TOF Matrix-assisted laser desorption/ionization Time of Flight 
MCV  Molluscum Contagiosum Virus 
MRI  Magnetic Resonance Imaging 
MRSA  Methicillin-Resistant Staphylococcus Aureus 
MS  Member States 
NDELA  N-nitrosodiethanolamine 
NTM  Non Tuberculosis Mycobacteriae 
OR  Odds Ratio 
PAA  Primary Aromatic Amines 
PAH  Polycyclic Aromatic Hydrocarbons 
PAO  Period of maximum durability After Opening 
PEH  Pseudoepitheliomatous Hyperplasia 
PET  Positron Emission Tomography 
PG  Pyoderma Gangrenosum 
PMU  Permanent Make-Up 
PPD  Para-phenylendiamine 
OECD  Organisation for Economic Co-operation and Development 
PRISMA  Preferred Reporting Items for Systematic reviews and Meta-Analysis  
RAPEX  Rapid alert system for non-food dangerous products 
REACH  Registration, Evaluation, Authorisation and Restriction of Chemicals  
ResAP  Resolution (Council of Europe) 
STPM  Subgroup Tattoos and Permanent Make-up 
TLC  Thin Layer Chromatography 
QS laser  Quality Switched laser 
SCC  Squamous Cell Carcinoma 
SFA  Spectrometry of Atomic Fluorescence 
TIME  Tattoo Ink Manufacturers in Europe 
 
Definitions 
Basal Cell Carcinoma (BCC) is the most common form of skin cancer. More than two 
million cases of this skin cancer are diagnosed in the United States each year. This skin 
cancer usually develops on skin that gets sun exposure, such as on the head, neck, and 
back of the hands. People who use tanning beds have a much higher risk of getting BCC. 
They also tend to get BCC earlier in life. This type of skin cancer grows slowly, and rarely 
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spreads to other parts of the body, if untreated. (from American Academy of 
Dermatology) 
Eczema (called also atopic dermatitis) is an inflammation causing symptoms such as 
itchy, red, and dry skin. The treatment may require oral or topical corticosteroids and 
light therapy. (from Web MD) 
Granulomatous reactions are sub-classified into about four types. They can be 
tuberculoid, sarcoidal, pallisading or infectious (suppurative). Various diseases present 
as different types of granulomas. Foreign body material can cause any type of 
granuloma but usually it is sarcoidal. The sarcoidal granuloma is sometimes called the 
naked granuloma because there is just a collection of histiocytes without any 
surrounding lymphocytes or neutrophils. The tuberculoid granuloma contains histiocytes 
but also some central caseous necrosis. In the pallisading granuloma the cells are 
surrounding denatured collagen which goes under the name of necrobiosis or sometimes 
there is mucin or foreign body material at the centre of a pallisading granuloma. A 
suppurative granuloma has centrally numerous neutrophils and they are part of an 
infected abscess. The granuloma is the body's immune attempt at isolating this infective 
or inflammatory process. The most common granulomatous diseases encountered by 
dermatologists are ruptured follicular cyst, sarcoidosis, granuloma annulare, actinic 
granuloma, necrobiosis lipoidica, tuberculosis of the skin and leprosy. 
(from"Dermatopathology Made Simple", the teaching website of the Australian Institute 
of Dermatology) 
Keratoacanthoma is a relatively common low-grade tumor that originates in the 
pilosebaceous glands and closely resembles squamous cell carcinoma (SCC). In fact, 
strong arguments support classifying keratoacanthoma as a variant of invasive SCC. In 
most pathology/biopsy reports, dermatopathologists refer to the lesion as "squamous 
cell carcinoma, keratoacanthoma-type." Keratoacanthoma is characterized by rapid 
growth over a few weeks to months, followed by spontaneous resolution over 4-6 
months in most cases. Keratoacanthoma may progress rarely to invasive or metastatic 
carcinoma. Whether these cases were SCC or keratoacanthoma, the reports highlight the 
difficulty of distinctly classifying individual cases. (from Medscape) 
Lichenoid reaction pattern implies histological changes at the dermal/epidermal 
junction due to an immune attack of lymphocytes at the dermal/epidermal junction. 
Classic conditions in this category include lichen planus, lupus erythematosis and 
erythema multiforme. There are variants on this such as fixed drug reaction, graft 
versus host reaction and some of the other collagen diseases that also are associated 
with damage to the dermal/epidermal junction and the greater that degree of damage 
the more it influences the clinical picture. (from "Dermatopathology Made Simple", the 
teaching website of the Australian Institute of Dermatology) 
Molluscum Contagiosum virus (MCV) is a common disease of childhood transmitted 
by skin-to-skin contact or by contact with fomites. Molluscum may represent a sexually 
transmitted disease. It can also present as widespread lesions in the setting of 
immunodeficiency (AIDS) [169].  
Pseudoepitheliomatous Hyperplasia: a benign marked increase and downgrowth of 
epidermal cells, observed in chronic inflammatory dermatoses and over some dermal 
neoplasms and nevi; microscopically, it resembles well-differentiated squamous cell 
carcinoma. (from: Farlex Partner Medical Dictionary © Farlex 2012) 
Sarcoidosis is an idiopathic, multisystemic, granulomatous disease characterised 
histologically by non-caseating epithelioid granulomas. Lung disease, the most common 
systemic manifestation of sarcoidosis, is present in 90% of patients. (Ali [209] citing 
Howard A, White CR. Non-infectious granulomas. In: Bolognia JL, Jorizzo JL, Rapini RP, 
editors. Dermatology. London: Mosby;2003. p. 1455- 69). 
Squamous Cell Carcinoma: a malignant neoplasm derived from stratified squamous 
epithelium, but that may also occur in sites such as bronchial mucosa where glandular or 
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columnar epithelium is normally present; variable amounts of keratin are formed, in 
relationship to the degree of differentiation, and, if the keratin is not on the surface, it 
may accumulate in the neoplasm as a keratin pearl; in instances in which the cells are 
well differentiated, intercellular bridges may be observed between adjacent cells. (from: 
Farlex Partner Medical Dictionary © Farlex 2012) 
Tattoo Complaints: Any unusual condition, sensation or visible reaction in the tattooed 
skin that differs from normal skin of the same person. Usually mild, and treated ”at 
home” [80, 192]. 
Many tattooed individuals described fading of the tattoo colour over time. This was not 
included in the study as a complaint. 
Tattoo Complications: More serious adverse reactions in tattoos associated with 
objective, clinical pathologies of the tattoo in combination with major subjective 
symptoms and significant discomfort, i.e. events that would typically make the patient 
consult a doctor [192].  
Uveitis: eye inflammation affecting the middle layer of tissue in the eye wall (uvea). 
Warning signs often come on suddenly and get worse quickly. They include eye redness, 
pain and blurred vision. The condition can affect one or both eyes, primarily in people 
ages from 20 to 50. Possible causes of uveitis are infection, injury, or an autoimmune or 
inflammatory disease. Many times a cause can't be identified. Uveitis can be serious, 
leading to permanent vision loss. Early diagnosis and treatment are important to prevent 
the complications of uveitis. (Definition by Mayo Clinic Staff) 
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